0001609550-21-000048.txt : 20211102 0001609550-21-000048.hdr.sgml : 20211102 20211102161658 ACCESSION NUMBER: 0001609550-21-000048 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211102 DATE AS OF CHANGE: 20211102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Inspire Medical Systems, Inc. CENTRAL INDEX KEY: 0001609550 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 261377674 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38468 FILM NUMBER: 211371526 BUSINESS ADDRESS: STREET 1: 5500 WAYZATA BLVD STREET 2: SUITE 1600 CITY: GOLDEN VALLEY STATE: MN ZIP: 55416 BUSINESS PHONE: 763-957-5037 MAIL ADDRESS: STREET 1: 5500 WAYZATA BLVD STREET 2: SUITE 1600 CITY: GOLDEN VALLEY STATE: MN ZIP: 55416 10-Q 1 insp-20210930.htm 10-Q insp-20210930
0001609550FALSE--12-312021Q3http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613MemberP3Yhttp://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrentP4YP1YP3YP4YP4Y00016095502021-01-012021-09-30xbrli:shares00016095502021-10-26iso4217:USD00016095502021-09-3000016095502020-12-31iso4217:USDxbrli:shares00016095502021-07-012021-09-3000016095502020-07-012020-09-3000016095502020-01-012020-09-300001609550us-gaap:CommonStockMember2020-12-310001609550us-gaap:AdditionalPaidInCapitalMember2020-12-310001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001609550us-gaap:RetainedEarningsMember2020-12-310001609550us-gaap:CommonStockMember2021-01-012021-03-310001609550us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100016095502021-01-012021-03-310001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001609550us-gaap:RetainedEarningsMember2021-01-012021-03-310001609550us-gaap:CommonStockMember2021-03-310001609550us-gaap:AdditionalPaidInCapitalMember2021-03-310001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001609550us-gaap:RetainedEarningsMember2021-03-3100016095502021-03-310001609550us-gaap:CommonStockMember2021-04-012021-06-300001609550us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-3000016095502021-04-012021-06-300001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001609550us-gaap:RetainedEarningsMember2021-04-012021-06-300001609550us-gaap:CommonStockMember2021-06-300001609550us-gaap:AdditionalPaidInCapitalMember2021-06-300001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001609550us-gaap:RetainedEarningsMember2021-06-3000016095502021-06-300001609550us-gaap:CommonStockMember2021-07-012021-09-300001609550us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300001609550us-gaap:RetainedEarningsMember2021-07-012021-09-300001609550us-gaap:CommonStockMember2021-09-300001609550us-gaap:AdditionalPaidInCapitalMember2021-09-300001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300001609550us-gaap:RetainedEarningsMember2021-09-300001609550us-gaap:CommonStockMember2019-12-310001609550us-gaap:AdditionalPaidInCapitalMember2019-12-310001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001609550us-gaap:RetainedEarningsMember2019-12-3100016095502019-12-310001609550us-gaap:CommonStockMember2020-01-012020-03-310001609550us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100016095502020-01-012020-03-310001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001609550us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001609550srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2019-12-310001609550us-gaap:RetainedEarningsMember2020-01-012020-03-310001609550us-gaap:CommonStockMember2020-03-310001609550us-gaap:AdditionalPaidInCapitalMember2020-03-310001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001609550us-gaap:RetainedEarningsMember2020-03-3100016095502020-03-310001609550us-gaap:CommonStockMember2020-04-012020-06-300001609550us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-3000016095502020-04-012020-06-300001609550insp:FollowOnOfferingMemberus-gaap:CommonStockMember2020-04-012020-06-300001609550us-gaap:AdditionalPaidInCapitalMemberinsp:FollowOnOfferingMember2020-04-012020-06-300001609550insp:FollowOnOfferingMember2020-04-012020-06-300001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001609550us-gaap:RetainedEarningsMember2020-04-012020-06-300001609550us-gaap:CommonStockMember2020-06-300001609550us-gaap:AdditionalPaidInCapitalMember2020-06-300001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001609550us-gaap:RetainedEarningsMember2020-06-3000016095502020-06-300001609550us-gaap:CommonStockMember2020-07-012020-09-300001609550us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001609550us-gaap:RetainedEarningsMember2020-07-012020-09-300001609550us-gaap:CommonStockMember2020-09-300001609550us-gaap:AdditionalPaidInCapitalMember2020-09-300001609550us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001609550us-gaap:RetainedEarningsMember2020-09-3000016095502020-09-300001609550insp:FollowOnOfferingMember2020-04-162020-04-160001609550insp:FollowOnOfferingMember2020-04-1600016095502020-01-012020-12-310001609550us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-09-300001609550us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-09-300001609550us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-09-300001609550us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2021-09-300001609550us-gaap:FairValueMeasurementsRecurringMember2021-09-300001609550us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001609550us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-09-300001609550us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-09-300001609550us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2021-09-300001609550us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2021-09-300001609550us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2021-09-300001609550us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentDebtSecuritiesMember2021-09-300001609550us-gaap:FairValueMeasurementsRecurringMember2020-12-310001609550us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001609550us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001609550us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001609550us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001609550us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001609550us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001609550us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001609550us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001609550us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001609550us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-310001609550us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-12-310001609550us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2020-12-310001609550us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2020-12-310001609550us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2020-12-310001609550us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentDebtSecuritiesMember2020-12-310001609550insp:ComputerEquipmentAndSoftwareMember2021-09-300001609550insp:ComputerEquipmentAndSoftwareMember2020-12-310001609550us-gaap:EquipmentMember2021-09-300001609550us-gaap:EquipmentMember2020-12-310001609550us-gaap:OtherMachineryAndEquipmentMember2021-09-300001609550us-gaap:OtherMachineryAndEquipmentMember2020-12-310001609550us-gaap:LeaseholdImprovementsMember2021-09-300001609550us-gaap:LeaseholdImprovementsMember2020-12-310001609550us-gaap:ConstructionInProgressMember2021-09-300001609550us-gaap:ConstructionInProgressMember2020-12-310001609550srt:MinimumMember2021-01-012021-09-300001609550srt:MaximumMember2021-01-012021-09-30xbrli:pure0001609550us-gaap:LongTermDebtMemberus-gaap:USTreasuryAndGovernmentMember2021-09-300001609550us-gaap:LongTermDebtMember2021-09-300001609550us-gaap:ShortTermDebtMemberus-gaap:CommercialPaperMember2020-12-310001609550us-gaap:ShortTermDebtMemberus-gaap:CorporateDebtSecuritiesMember2020-12-310001609550us-gaap:ShortTermDebtMemberus-gaap:USTreasuryAndGovernmentMember2020-12-310001609550us-gaap:ShortTermDebtMember2020-12-31utr:sqft0001609550insp:OfficeSpaceSubleaseMember2018-09-30insp:renewal_option0001609550insp:OfficeSpaceSubleaseMember2019-05-012019-05-310001609550insp:OfficeSpaceSubleaseMember2019-05-310001609550srt:ScenarioForecastMember2020-12-012022-05-310001609550srt:ScenarioForecastMember2022-05-3100016095502021-08-3100016095502021-08-012021-08-310001609550insp:TermALoanFacilityMember2015-08-310001609550srt:MinimumMemberinsp:TermBLoanFacilityMember2015-08-310001609550insp:TermBLoanFacilityMembersrt:MaximumMember2015-08-310001609550insp:TermALoanFacilityMemberinsp:February2017AmendmentToLoanAndSecurityAgreementMember2017-02-280001609550insp:February2017AmendmentToLoanAndSecurityAgreementMemberinsp:TermLoanFacilityMember2017-02-280001609550insp:February2017AmendmentToLoanAndSecurityAgreementMemberinsp:TermBLoanFacilityMember2017-02-280001609550insp:TermBLoanFacilityMember2018-02-280001609550insp:TermLoanFacilityMember2019-03-260001609550insp:March2019AmendmentToLoanAndSecurityAgreementMemberinsp:TermLoanFacilityMember2019-03-270001609550insp:March2019AmendmentToLoanAndSecurityAgreementMemberinsp:TermLoanFacilityMember2019-03-272019-03-270001609550srt:MinimumMemberinsp:March2019AmendmentToLoanAndSecurityAgreementMemberinsp:TermLoanFacilityMember2019-03-272019-03-270001609550srt:MinimumMemberinsp:March2019AmendmentToLoanAndSecurityAgreementMemberinsp:TermLoanFacilityMember2019-03-270001609550insp:March2019AmendmentToLoanAndSecurityAgreementMemberinsp:TermLoanFacilityMembersrt:MaximumMember2019-03-270001609550insp:TermLoanFacilityMember2021-09-300001609550insp:StockIncentivePlan2018Member2018-12-310001609550insp:StockIncentivePlan2018Member2019-01-010001609550insp:StockIncentivePlan2018Member2021-09-300001609550us-gaap:StockOptionMember2021-07-012021-09-300001609550us-gaap:StockOptionMember2020-07-012020-09-300001609550us-gaap:StockOptionMember2021-01-012021-09-300001609550us-gaap:StockOptionMember2020-01-012020-09-300001609550us-gaap:RestrictedStockUnitsRSUMember2021-07-012021-09-300001609550us-gaap:RestrictedStockUnitsRSUMember2020-07-012020-09-300001609550us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001609550us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001609550us-gaap:EmployeeStockMember2021-07-012021-09-300001609550us-gaap:EmployeeStockMember2020-07-012020-09-300001609550us-gaap:EmployeeStockMember2021-01-012021-09-300001609550us-gaap:EmployeeStockMember2020-01-012020-09-300001609550us-gaap:CostOfGoodsTotalMember2021-07-012021-09-300001609550us-gaap:CostOfGoodsTotalMember2020-07-012020-09-300001609550us-gaap:CostOfGoodsTotalMember2021-01-012021-09-300001609550us-gaap:CostOfGoodsTotalMember2020-01-012020-09-300001609550us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001609550us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300001609550us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001609550us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300001609550us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001609550us-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001609550us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001609550us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-09-300001609550us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:EmployeeStockOptionMember2021-01-012021-09-300001609550us-gaap:ShareBasedCompensationAwardTrancheTwoMemberus-gaap:EmployeeStockOptionMember2021-01-012021-09-300001609550srt:MinimumMemberus-gaap:EmployeeStockOptionMembersrt:DirectorMember2021-01-012021-09-300001609550us-gaap:EmployeeStockOptionMembersrt:MaximumMembersrt:DirectorMember2021-01-012021-09-300001609550us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001609550srt:MinimumMemberus-gaap:EmployeeStockOptionMember2021-01-012021-09-300001609550us-gaap:EmployeeStockOptionMembersrt:MaximumMember2021-01-012021-09-300001609550srt:MinimumMemberus-gaap:EmployeeStockOptionMember2020-01-012020-09-300001609550us-gaap:EmployeeStockOptionMembersrt:MaximumMember2020-01-012020-09-300001609550us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001609550us-gaap:EmployeeStockOptionMember2021-09-300001609550us-gaap:EmployeeStockOptionMember2020-09-300001609550us-gaap:RestrictedStockUnitsRSUMember2020-12-310001609550us-gaap:RestrictedStockUnitsRSUMember2021-09-300001609550insp:EmployeeStockPurchasePlanMember2021-01-012021-09-300001609550insp:EmployeeStockPurchasePlanMember2019-01-010001609550insp:EmployeeStockPurchasePlanMember2021-06-302021-06-300001609550insp:EmployeeStockPurchasePlanMember2020-06-302020-06-300001609550insp:EmployeeStockPurchasePlanMember2021-09-300001609550us-gaap:DomesticCountryMember2020-12-310001609550us-gaap:StateAndLocalJurisdictionMember2020-12-310001609550us-gaap:ResearchMember2020-12-31insp:segment0001609550country:US2021-07-012021-09-300001609550country:US2020-07-012020-09-300001609550country:US2021-01-012021-09-300001609550country:US2020-01-012020-09-300001609550srt:EuropeMember2021-07-012021-09-300001609550srt:EuropeMember2020-07-012020-09-300001609550srt:EuropeMember2021-01-012021-09-300001609550srt:EuropeMember2020-01-012020-09-300001609550us-gaap:StockOptionMember2021-01-012021-09-300001609550us-gaap:StockOptionMember2020-01-012020-09-300001609550us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-09-300001609550us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001609550us-gaap:EmployeeStockMember2021-01-012021-09-300001609550us-gaap:EmployeeStockMember2020-01-012020-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
______________________________
FORM 10-Q
________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021 or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                             to                              
Commission File Number: 001-38468
______________________________
insp-20210930_g1.jpg
Inspire Medical Systems, Inc.
(Exact name of registrant as specified in its charter)
______________________________
Delaware26-1377674
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
5500 Wayzata Blvd., Suite 1600
Golden Valley, MN
55416
(Address of principal executive offices)(Zip Code)
(844672-4357
(Registrant's telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par value per shareINSPNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes     No 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒    No 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer ☐Non-accelerated filer ☐
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 
As of October 26, 2021, the registrant had 27,358,099 shares of common stock, $0.001 par value per share, outstanding.



2

FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements, including statements regarding our future results of operations and financial position, business strategy, the impact of the ongoing and global COVID-19 pandemic on our business, financial results and financial position, prospective products, international product approvals and commercializations, our expectations regarding the new American Medical Association reimbursement codes, our expectations regarding the final reimbursement levels for Inspire therapy procedures, research and development costs, timing and likelihood of success, other insurance providers' plans to begin approving our Inspire therapy, and the plans and objectives of management for future operations.
In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to:
our history of operating losses and dependency on our Inspire system for revenues;
commercial success and market acceptance of our Inspire therapy;
our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize;
competitive companies and technologies in our industry;
the impact on our business, financial condition, and results of operation from the ongoing and global COVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease;
our ability to expand our indications and develop and commercialize additional products and enhancements to our Inspire system;
future results of operations, financial position, research and development costs, capital requirements, and our needs for additional financing;
our ability to forecast customer demand for our Inspire system and manage our inventory;
our dependence on third-party suppliers and contract manufacturers;
risks related to consolidation in the healthcare industry;
our ability to expand, manage, and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the United States;
our ability to manage our growth;
our ability to hire and retain our senior management and other highly qualified personnel;
risks related to product liability claims and warranty claims;
our ability to address quality issues that may arise with our Inspire system;
3

our ability to successfully integrate any acquired business, products or technologies;
changes in global macroeconomic conditions;
any failure of key information technology systems, processes or sites or damage to or inability to access our physical facilities;
our ability to commercialize or obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in commercializing or obtaining regulatory approvals;
any violations of anti-bribery, anti-corruption, and anti-money laundering laws;
risks related to our indebtedness;
our ability to use our net operating losses and research and development carryforwards;
the risk that we may be deemed to be an investment company under the Investment Company Act of 1940;
U.S. Food and Drug Administration ("FDA") or other United States or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets;
our ability to establish and maintain intellectual property protection for our Inspire therapy and system or avoid claims of infringement;
risks related to our common stock; and
other important factors that could cause actual results, performance or achievements to differ materially from those contemplated that are found in "Part I, Item 1. Business," "Part I, Item 1A. Risk Factors," and "Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as updated by “Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report on Form 10-Q.
Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.
You should read this Quarterly Report and the documents that we reference in this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Unless the context requires otherwise, references to “Inspire,” the “Company,” “we,” “us,” and “our,” refer to Inspire Medical Systems, Inc.
4

PART I—FINANCIAL INFORMATION
Item 1.    Financial Statements.
INSPIRE MEDICAL SYSTEMS, INC.
BALANCE SHEETS
(in thousands, except share and per share amounts)
September 30,
2021
December 31, 2020
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$210,200 $190,518 
Investments, short-term 43,844 
Accounts receivable, net of allowance for credit losses of
    $95 and $42, respectively
26,675 25,063 
Inventories15,574 8,479 
Prepaid expenses and other current assets3,046 1,965 
Total current assets255,495 269,869 
Investments, long-term9,984  
Property and equipment, net7,915 5,311 
Operating lease right-of-use asset5,296 5,805 
Other non-current assets204 204 
Total assets$278,894 $281,189 
Liabilities and stockholders' equity
Current liabilities:
Accounts payable$9,989 $7,209 
Accrued expenses17,477 13,516 
Current portion of notes payable6,125  
Total current liabilities33,591 20,725 
Notes payable, non-current portion18,799 24,746 
Operating lease liability, non-current portion6,080 5,886 
Other non-current liability124 85 
Total liabilities58,594 51,442 
Stockholders' equity:
Preferred Stock, $0.001 par value, 10,000,000 shares authorized; no shares
     issued and outstanding
  
Common Stock, $0.001 par value per share; 200,000,000 shares authorized; 27,350,959 and 27,069,276 issued and outstanding at September 30, 2021 and December 31, 2020, respectively
27 27 
Additional paid-in capital497,280 467,038 
Accumulated other comprehensive (loss) income(9)29 
Accumulated deficit(276,998)(237,347)
Total stockholders' equity220,300 229,747 
Total liabilities and stockholders' equity$278,894 $281,189 
The accompanying notes are an integral part of these unaudited financial statements.
5

INSPIRE MEDICAL SYSTEMS, INC.
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)
(in thousands, except share and per share amounts)
Three Months Ended
September 30,
Nine Months Ended
September 30,
2021202020212020
Revenue$61,685 $35,842 $154,996 $69,372 
Cost of goods sold8,624 5,211 22,123 10,462 
Gross profit53,061 30,631 132,873 58,910 
Operating expenses:
Research and development9,614 7,307 27,056 18,807 
Selling, general and administrative53,243 33,216 143,846 89,249 
Total operating expenses62,857 40,523 170,902 108,056 
Operating loss(9,796)(9,892)(38,029)(49,146)
Other expense (income):
Interest income(22)(125)(110)(1,015)
Interest expense537 533 1,590 1,584 
Other expense (income), net33 (2)90 (83)
Total other expense548 406 1,570 486 
Loss before income taxes(10,344)(10,298)(39,599)(49,632)
Income taxes3 87 52 87 
Net loss(10,347)(10,385)(39,651)(49,719)
Other comprehensive loss:
Unrealized gain (loss) on investments3 (81)(38)(29)
Total comprehensive loss$(10,344)$(10,466)$(39,689)$(49,748)
Net loss per share, basic and diluted$(0.38)$(0.39)$(1.46)$(1.93)
Weighted average common shares used to
   compute net loss per share, basic and diluted
27,300,377 26,835,603 27,225,499 25,767,497 

The accompanying notes are an integral part of these unaudited financial statements.
6

INSPIRE MEDICAL SYSTEMS, INC.
STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)
(in thousands, except share amounts)

Nine Months Ended September 30, 2021
Common Stock
SharesAmountAdditional
Paid-In
Capital
Accumulated
Other
Comprehensive
Income (Loss)
Accumulated
Deficit
Total
Stockholders'
Equity
Balance at December 31, 202027,069,276 $27 $467,038 $29 $(237,347)$229,747 
Stock options exercised133,421 — 3,550 — — 3,550 
Issuance of common stock376 — 73 — — 73 
Stock-based compensation expense— — 5,997 — — 5,997 
Other comprehensive loss— — — (20)— (20)
Net loss— — — — (16,216)(16,216)
Balance at March 31, 202127,203,073 27 476,658 9 (253,563)223,131 
Stock options exercised49,318 — 1,719 — — 1,719 
Issuance of common stock329 — 72 — — 72 
Issuance of common stock for employee stock purchase plan11,351 — 1,760 — — 1,760 
Stock-based compensation expense— — 6,341 — — 6,341 
Other comprehensive loss— — — (21)— (21)
Net loss— — — — (13,088)(13,088)
Balance at June 30, 202127,264,071 27 486,550 (12)(266,651)219,914 
Stock options exercised86,473 — 3,843 — — 3,843 
Issuance of common stock415 — 77 — — 77 
Stock-based compensation expense— — 6,810 — — 6,810 
Other comprehensive income— — — 3 — 3 
Net loss— — — — (10,347)(10,347)
Balance at September 30, 202127,350,959 $27 $497,280 $(9)$(276,998)$220,300 

The accompanying notes are an integral part of these unaudited financial statements.
7

INSPIRE MEDICAL SYSTEMS, INC.
STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)
(in thousands, except share amounts)


Nine Months Ended September 30, 2020
Common Stock
SharesAmountAdditional
Paid-In
Capital
Accumulated
Other
Comprehensive
Income
Accumulated
Deficit
Total
Stockholders'
Equity
Balance at December 31, 201924,107,350 $24 $319,865 $102 $(180,156)$139,835 
Stock options exercised254,142 — 787 — — 787 
Issuance of common stock897 — 72 — — 72 
Stock-based compensation expense— — 2,749 — — 2,749 
Other comprehensive income— — — 193 — 193 
Adoption of ASU 2016-13, Financial Instruments - Credit Losses
— — — — 12 12 
Net loss— — — — (16,245)(16,245)
Balance at March 31, 202024,362,389 24 323,473 295 (196,389)127,403 
Stock options exercised70,853 — 732 — — 732 
Issuance of common stock1,119 — 73 — — 73 
Sale of common stock from follow-on public offering, net of offering expenses2,300,000 3 124,651 — — 124,654 
Issuance of common stock for employee stock purchase plan16,730 — 1,059 — — 1,059 
Stock-based compensation expense— — 2,903 — — 2,903 
Other comprehensive loss— — — (141)— (141)
Net loss— — — — (23,089)(23,089)
Balance at June 30, 202026,751,091 27 452,891 154 (219,478)233,594 
Stock options exercised168,970 — 2,312 — — 2,312 
Issuance of common stock784 — 72 — — 72 
Stock-based compensation expense— — 3,311 — — 3,311 
Other comprehensive income— — — (81)— (81)
Net loss— — — — (10,385)(10,385)
Balance at September 30, 202026,920,845 $27 $458,586 $73 $(229,863)$228,823 

The accompanying notes are an integral part of these unaudited financial statements.
8

INSPIRE MEDICAL SYSTEMS, INC.
STATEMENTS OF CASH FLOWS (Unaudited)
(in thousands)
 Nine Months Ended
September 30,
 20212020
Operating activities  
Net loss$(39,651)$(49,719)
Adjustments to reconcile net loss:  
Depreciation and amortization874 587 
Amortization (accretion) of investment premium (discount)15 (66)
Accretion of debt discount178 166 
Non-cash lease expense509 743 
Stock-based compensation expense19,148 8,963 
Non-cash stock issuance for services rendered222 217 
Other, net53 (89)
Changes in operating assets and liabilities:  
Accounts receivable(1,743)(7,921)
Inventories(7,095)(3,132)
Prepaid expenses and other current assets(1,081)(15)
Accounts payable3,490 2,262 
Accrued expenses and other liabilities4,228 (931)
Net cash used in operating activities(20,853)(48,935)
Investing activities  
Purchases of property and equipment(4,135)(1,851)
Purchases of investments(9,993)(52,721)
Proceeds from sales or maturities of investments43,800 129,803 
Net cash provided by investing activities29,672 75,231 
Financing activities  
Proceeds from the exercise of stock options9,112 3,831 
Proceeds from the sale of common stock 124,654 
Proceeds from issuance of common stock from employee stock purchase plan1,760 1,059 
Net cash provided by financing activities10,872 129,544 
Effect of exchange rate on cash(9)5 
Increase in cash and cash equivalents19,682 155,845 
Cash and cash equivalents at beginning of period190,518 22,860 
Cash and cash equivalents at end of period$210,200 $178,705 
Supplemental cash flow information  
Cash paid for interest$1,417 $1,422 
Change in property and equipment acquired but not yet paid657  

The accompanying notes are an integral part of these unaudited financial statements.
9

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)

1. Organization
Description of Business
Inspire Medical Systems, Inc. is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first and only United States ("U.S.") Food and Drug Administration ("FDA") approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. Inspire therapy received premarket approval ("PMA") from the FDA in April 2014 and has been commercially available in certain European markets since November 2011. Japan's Ministry of Health, Labour and Welfare ("MLHW") approved Inspire therapy to treat moderate to severe OSA in June 2018 and was formally added to the Japan National Health Insurance Payment Listing in June 2021. In August 2020, the Australian Therapeutic Goods Administration approved Inspire therapy to treat moderate to severe OSA, and we are currently seeking reimbursement coverage in Australia.

2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, the results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods. For a complete discussion of our significant accounting policies and other information, the unaudited financial statements and notes thereto should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
Follow-On Public Offering
On April 16, 2020, we completed a follow-on offering that included our offer and sale of 2,300,000 shares of common stock at a public offering price of $58.00 per share. We received net proceeds of approximately $124.7 million after deducting underwriting discounts and commissions and offering expenses.
Cash and Cash Equivalents
We consider all highly liquid securities, readily convertible to cash, that mature within 90 days or less from the date of purchase to be cash equivalents. The carrying amount reported in the balance sheets for cash is cost, which approximates fair value.
Foreign Currency
Sales and expenses denominated in foreign currencies are translated at average exchange rates in effect throughout the year. Foreign currency transaction gains and losses are included in other expense (income), net, in the statements of operations and comprehensive loss. Assets and liabilities of foreign operations are remeasured at period-end exchange rates with the impacts of foreign currency remeasurement recognized in other expense (income), net in the statements of operations and comprehensive loss.
10

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
Investments
At December 31, 2020, our short-term investments consisted of commercial paper, corporate bonds, and U.S. government securities, which are classified as available-for-sale and had maturities less than one year. Our long-term investments at September 30, 2021 consisted of U.S. government securities. Investments are reported at their estimated fair market values which are based on quoted, active or inactive market prices when available. Any unrealized gains and losses due to interest rate fluctuations and other external factors are reported as a separate component of accumulated other comprehensive (loss) income. We had less than $0.1 million of unrecognized loss in accumulated other comprehensive (loss) income at September 30, 2021 and less than $0.1 million of unrecognized gain in accumulated other comprehensive (loss) income at December 31, 2020. Any realized gains and losses are calculated on the specific identification method and reported net in other expense (income), net in the statements of operations and comprehensive loss. For both of the three months ended September 30, 2021 and 2020, we recognized $0 of realized gains, net. For the nine months ended September 30, 2021 and 2020, we recognized $0 and $0.1 million of realized gains, net, respectively.
We recognize expected credit losses on investments in accordance with Accounting Standards Update ("ASU"), ASU 2016-13, Financial Instruments - Credit Losses ("ASU 2016-13"), which we adopted effective January 1, 2020 using the modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on the amount and timing of credit losses recognized in our financial statements.
We reassess our estimated credit losses on investments each reporting period. U.S. government securities and cash equivalents are under a "zero-loss exception" for credit losses, meaning no credit loss risk calculation is necessary on those instruments due to the exceptionally low rate of default, which continues to decrease as the securities approach maturity, which for us is no longer than two years. For non-U.S. government securities, we use a discounted cash flow approach to calculate expected credit losses using estimated default rates based upon historical loss data, current conditions, as well as expectations of future economic conditions. We record changes in the allowance for credit losses for available-for-sale debt securities with a corresponding adjustment in credit loss expense on the statement of operations and comprehensive loss. No reversal of a previously recorded allowance for credit losses may be made to an amount below zero. The total allowance for credit losses was $0 at both September 30, 2021 and December 31, 2020.
Fair Value of Financial Instruments
We measure certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and investments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:
Level 1—Observable inputs, such as quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2—Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability.
Level 3—Unobservable inputs that are supported by little or no market activities, which would require us to develop our own assumptions.
We use the methods and assumptions described below in determining the fair value of our financial instruments.
Money market funds: Fair values of money market funds are based on quoted market prices in active markets. These are included as Level 1 measurements in the tables below.
11

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
Commercial paper: Short-term, highly liquid investments are included as a Level 2 measurement in the table below.
Corporate bonds: Consists of short-term notes and bonds with various yields. These are included as a Level 2 measurement in the table below.
U.S. government securities: Consists of U.S. government Treasury bills and notes with original maturities of less than one year to two years. These are included as a Level 1 measurement in the tables below.
The following tables set forth by level within the fair value hierarchy our assets that are measured on a recurring basis and reported at fair value as of September 30, 2021 and December 31, 2020. Assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Fair Value Measurements as of
September 30, 2021
Estimated
Fair Value
Level 1Level 2Level 3
Cash equivalents:
Money market funds$189,355 $189,355 $ $ 
Total cash equivalents189,355 189,355   
Investments:
U.S. government securities$9,984 $9,984 $ $ 
Total investments9,984 9,984   
Total cash equivalents and investments$199,339 $199,339 $ $ 
Fair Value Measurements as of
December 31, 2020
Estimated
Fair Value
Level 1Level 2Level 3
Cash equivalents:
Money market funds$179,389 $179,389 $ $ 
Total cash equivalents179,389 179,389   
Investments:
Commercial paper$13,275 $ $13,275 $ 
Corporate bonds6,540  6,540  
U.S. government securities24,029 24,029   
Total investments43,844 24,029 19,815  
Total cash equivalents and investments$223,233 $203,418 $19,815 $ 

There were no transfers between levels during the periods ended September 30, 2021 and December 31, 2020.
Concentration of Credit Risk
Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable.
Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration
12

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of September 30, 2021 and December 31, 2020, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.
We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.
Accounts Receivable and Allowance for Expected Credit Losses
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the general standard being net 30 days. Collateral or any other security to support payment of these receivables generally is not required.
We recognize expected credit losses on accounts receivable in accordance with Accounting Standards Update ("ASU"), ASU 2016-13, Financial Instruments - Credit Losses ("ASU 2016-13"), which we adopted effective January 1, 2020 using the modified retrospective approach through a cumulative-effect adjustment to retained earnings. The adoption of ASU 2016-13 did not have a material impact on the amount and timing of credit losses recognized in our financial statements.
Each reporting period, we estimate the credit loss related to accounts receivable based on a migration analysis of accounts grouped by individual receivables delinquency status, and apply our historic loss rate adjusted for management's assumption of future market conditions. Any change in the allowance subsequent to the effective date of January 1, 2020 from new receivables acquired, or changes due to credit deterioration on previously existing receivables, is recorded in selling, general and administrative expenses. Write-offs of receivables considered uncollectible are deducted from the allowance. Specific accounts receivable are written-off once a determination is made that the amount is uncollectible. The write-off is recorded in the period in which the account receivable is deemed uncollectible. Recoveries are recognized when received and as a direct credit to earnings or as a reduction to the allowance for credit losses (which would indirectly reduce the loss by decreasing bad debt expense).
Inventories
Inventories are valued at the lower of cost or net realizable value, computed on a first-in, first-out basis and consisted of the following:
September 30, 2021December 31, 2020
Raw materials$1,865 $892 
Finished goods13,709 7,587 
Total inventories, net of reserves$15,574 $8,479 
We regularly review inventory quantities on-hand for excess and obsolete inventory and, when circumstances indicate, incur charges to write down inventories to their net realizable value. The determination of a reserve for excess and obsolete inventory involves management exercising judgment to determine the required reserve, considering future demand, product life cycles, introduction of new products and current market conditions. The reserve for excess and obsolete inventory was $0.3 million and $0.1 million as of September 30, 2021 and December 31, 2020, respectively.
13

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
Property and Equipment
Property and equipment are stated at cost, less accumulated depreciation and amortization and consisted of the following:
September 30, 2021December 31, 2020
Computer equipment and software$1,391 $1,305 
Manufacturing equipment4,322 2,285 
Other equipment249 249 
Leasehold improvements281 192 
Construction in process4,380 3,125 
Property and equipment, cost10,623 7,156 
Less: accumulated depreciation and amortization(2,708)(1,845)
Property and equipment, net$7,915 $5,311 
Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Depreciation and amortization expense was $0.3 million and $0.2 million for the three months ended September 30, 2021 and 2020, respectively, and $0.9 million and $0.6 million for the nine months ended September 30, 2021 and 2020, respectively.
Impairment of Long-lived Assets
Long-lived assets consist primarily of property and equipment and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require that an asset be tested for possible impairment, we compare the undiscounted cash flows expected to be generated by the asset to the carrying amount of the asset. If the carrying amount of the asset is not recoverable on an undiscounted cash flow basis, we determine the fair value of the asset and recognize an impairment loss to the extent the carrying amount of the asset exceeds its fair value. We determine fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. Our cash flow assumptions consider historical and forecasted revenue and operating costs and other relevant factors. We did not record any impairment charges on long-lived assets during either of the nine months ended September 30, 2021 or 2020.
Accrued Expenses
Accrued expenses consisted of the following:
September 30, 2021December 31, 2020
Payroll related$14,876 $11,965 
Interest155 160 
Current operating lease liability27  
Other accrued expenses2,419 1,391 
Total accrued expenses$17,477 $13,516 
Revenue Recognition
We recognize revenue in accordance with Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"). Revenues from product sales are recognized when the customer obtains control of the product, which occurs at a point in time, either upon shipment of the product or receipt of the product,
14

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
depending on shipment terms. Our standard shipping terms are free on board shipping point, unless the customer requests that control of the inventory transfer upon delivery. In those cases where shipping and handling costs are billed to customers, we classify the amounts billed as a component of cost of goods sold.
Revenue is measured as the amount of consideration we expect to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. The majority of our contracts have a single performance obligation and are short term in nature.
Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold.
Variable consideration related to certain customer sales incentives is estimated based on the amounts expected to be paid based on the agreement with the customer using probability assessments.
We offer customers a limited right of return for our product in case of non-conformity or performance issues. We estimate the amount of our product sales that may be returned by our customers based on historical sales and returns. As our historical product returns to date have been immaterial, we have not recorded a reduction in revenue related to variable consideration for product returns.
See Note 9 for disaggregated revenue by geographic area.
Cost of Goods Sold
Cost of goods sold consists primarily of acquisition costs for the components of the Inspire system, overhead costs, scrap and inventory obsolescence, warranty replacement costs, as well as distribution-related expenses such as logistics and shipping costs, net of shipping costs charged to customers. The overhead costs include the cost of material procurement, depreciation expense for production equipment, and operations supervision and management personnel, including employee compensation, stock-based compensation, supplies, and travel.
Research and Development
Research and development expenses consist primarily of product development, clinical and regulatory affairs, quality assurance, consulting services, and other costs associated with products and technologies in development. These expenses include employee compensation, including stock-based compensation, supplies, materials, consulting, and travel expenses related to research and development programs. Clinical expenses include clinical trial design, clinical site reimbursement, data management, travel expenses, and the cost of manufacturing products for clinical trials.
Stock-Based Compensation
We maintain an equity incentive plan to provide long-term incentives for eligible employees, consultants, and members of the board of directors. The plan allows for the issuance of restricted stock units ("RSUs") and non-statutory and incentive stock options to employees and RSUs and non-statutory stock options to consultants and directors. We also offer an employee stock purchase plan which allows participating employees to purchase shares of our common stock at a discount through payroll deductions.
We recognize equity-based compensation expense for awards of equity instruments to employees and directors based on the grant date fair value of those awards in accordance with ASC Topic 718, Stock Compensation ("ASC 718"). ASC 718 requires all equity-based compensation awards to employees and directors, including grants of RSUs and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the fair value of stock options using the Black-Scholes option
15

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
pricing model and the fair value of RSUs is equal to the closing price of our common stock on the grant date. The fair value of each purchase under the employee stock purchase plan is estimated at the beginning of the offering period using the Black-Scholes option pricing model. We have not granted any stock-based awards to our consultants.
The Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i) the expected share price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) the expected dividend yield. Due to our limited operating history and a lack of company specific historical and implied volatility data, we have incorporated our historical stock trading volatility with those of a peer group of public companies for the calculation of volatility. The group of peer companies have characteristics similar to us, including stage of product development and focus on the life science industry. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. We use the simplified method, which is the average of the final vesting tranche date and the contractual term, to calculate the expected term for options granted to employees and directors as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is based on a U.S. government Treasury instrument whose term is consistent with the expected term of the stock options. We use an assumed dividend yield of zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.
We expense the fair value of our equity-based compensation awards granted to employees and directors on a straight-line basis over the associated service period, which is generally the period in which the related services are received. We account for award forfeitures as they occur.
Advertising Expenses
We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $13.4 million and $6.8 million during the three months ended September 30, 2021 and 2020, respectively, and $34.0 million and $18.2 million during the nine months ended September 30, 2021 and 2020, respectively.
Leases
Operating leases are included in operating lease right-of-use ("ROU") asset, accrued expenses, and operating lease liability – non-current portion in our balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of our incremental borrowing rate requires management judgment based on information available at lease commencement. The operating lease ROU assets also include adjustments for prepayments, accrued lease payments and exclude lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise such options. Operating lease cost is recognized on a straight-line basis over the expected lease term. Lease agreements entered into after the adoption of ASC 842 that include lease and non-lease components are accounted for as a single lease component. Lease agreements with a noncancelable term of less than 12 months are not recorded on our balance sheets.
Income Taxes
We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances against deferred tax assets are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized. As we have historically incurred operating losses, we have recorded a full valuation allowance against our net deferred tax assets, and there is no provision for income taxes other than
16

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
minimal state taxes and an accrual for uncertain tax benefits. Our policy is to record interest and penalties expense related to uncertain tax positions as other expense in the statements of operations and comprehensive loss.
Comprehensive Loss
Comprehensive loss consists of net loss and changes in unrealized gains and losses due to interest rate fluctuations and other external factors on investments classified as available-for-sale. Accumulated other comprehensive (loss) income is presented in the accompanying balance sheets as a component of stockholders' equity.
Loss Per Share
Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Because we have reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share as all potentially dilutive shares consisting of outstanding stock options, unvested RSUs, and shares issuable under our employee stock purchase plan were antidilutive in those periods.
Recent Accounting Pronouncements
We have reviewed and considered all recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on our business practices, financial condition, results of operations, or disclosures.

3. Investments
Our investments are classified as available-for-sale and consist of the following:
September 30, 2021
AmortizedUnrealized GrossAggregate
CostGainsLossesFair Value
Long-Term:
U.S. government securities$9,993 $ $(9)$9,984 
Long-term investments$9,993 $ $(9)$9,984 
December 31, 2020
AmortizedUnrealized GrossAggregate
CostGainsLossesFair Value
Short-Term:
Commercial paper$13,275 $ $ $13,275 
Corporate bonds6,543  (3)6,540 
U.S. government securities23,997 32  24,029 
Short-term investments$43,815 $32 $(3)$43,844 
As of September 30, 2021 and December 31, 2020, we had no investments with a contractual maturity of greater than two years. Currently, we do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. We do not consider those investments to be other-than-temporarily impaired as of September 30, 2021. At the end of each reporting period, we evaluate potential credit impairment on available-for-sale securities in an unrealized loss
17

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
position, based on the expected cash flows to be collected and the yield-to-maturity on those securities. Securities with a valuation allowance for expected credit losses and deemed uncollectible are permanently written-down, and a reversal out of the valuation allowance occurs.

4. Leases
In September 2018, we entered into a non-cancelable operating lease agreement to sublease approximately 45,000 square feet of office space for our corporate headquarters, which included real estate taxes and operating expenses in the base rent. This lease commenced January 15, 2019 and expired November 30, 2020.
In May 2019, we entered into a new, non-cancelable operating lease agreement for the same space directly with the landlord. The initial lease term commenced on December 1, 2020 and expires May 31, 2028 with an option to renew for one additional period of five years at the then-prevailing market rate. The exercise of the lease renewal option is at our sole discretion and was not included in the lease term for the calculation of the ROU asset and lease liability when the lease commenced on December 1, 2020 as it is not reasonably certain of exercise.
Beginning December 1, 2020, in addition to base rent, we also pay our proportionate share of the operating expenses, as defined in the lease. These payments are made monthly and adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance. In conjunction with this lease, the landlord agreed to provide a $0.6 million rent abatement and a refurbishment allowance in the amount of the cost of any leasehold improvements, not to exceed approximately $1.1 million upon Inspire providing the necessary documentation evidencing the costs of the leasehold improvements that are completed by May 31, 2022. However, the lease allows us to allocate the refurbishment allowance against base rent instead of taking a tenant improvement reimbursement. At this time, we intend to allocate the full amount of the refurbishment allowance against base rent.
In August 2021, we entered into a new, non-cancelable operating lease agreement for approximately 25,000 square feet of additional corporate office space with our existing landlord. The initial lease term commences on October 1, 2021 and expires May 31, 2028 with an option to renew for one additional period of 5 years at the then-prevailing market rate. The exercise of the lease renewal option is at our sole discretion and will not be included in the lease term for the calculation of the ROU asset and lease liability when the lease commences on October 1, 2021 as it is not reasonably certain of exercise.
Beginning October 1, 2021, in addition to base rent on the additional space, we will also pay our proportionate share of the operating expenses, as defined in the lease. These payments will be made monthly and will be adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance. In conjunction with this lease, the landlord agreed to provide a $0.2 million rent abatement and a refurbishment allowance in the amount of the cost of any leasehold improvements, not to exceed $0.4 million upon Inspire providing the necessary documentation evidencing the costs of the leasehold improvements that are completed by May 31, 2022. However, the lease allows us to allocate the refurbishment allowance against base rent instead of taking a tenant improvement reimbursement. At this time, we intend to allocate the full amount of the refurbishment allowance against base rent. The total minimum lease payments related to this forward-starting lease are $3.6 million.
18

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
The following table presents the lease balances within the balance sheets:
September 30, 2021December 31, 2020
Right-of-use assets:
Operating lease right-of-use asset$5,296 $5,805 
Operating lease liabilities:
Accrued expenses27  
Operating lease liability, non-current portion6,080 5,886 
Total operating lease liabilities$6,107 $5,886 

As of September 30, 2021, the remaining lease term was 6.7 years and the discount rate was 5.2%. The operating cash outflows from our operating leases were $0.1 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively, and $0.1 million and $0.8 million for the nine months ended September 30, 2021 and 2020, respectively.

5. Long-Term Debt
In August 2015, we entered into a loan and security agreement that initially provided for a term A loan facility in the amount of $15.5 million, which was fully funded on the closing date, and a term B loan facility in an amount between $3.5 million and $10.0 million, subject to our achievement of certain revenue milestones. We refer to our term A loan facility and our term loan B facility together as our credit facility.
In February 2017, we amended the loan and security agreement to, among other things, increase borrowings under the term A loan facility by $1.0 million, for a total of $16.5 million outstanding under the credit facility, and reduced borrowings available under the term B loan facility to $9.0 million.
In February 2018, we borrowed an additional $8.0 million under the term B loan facility portion of the credit facility for a total of $24.5 million outstanding under the credit facility.
On March 27, 2019, we amended the loan and security agreement. The amendment modified the terms of the loan and security agreement to: (1) extend the interest-only date from March 1, 2020 to April 1, 2022 and extend the maturity date from February 1, 2022 to March 1, 2024; (2) reduce the final payment percentage from 5.50% to 3.50%; (3) modify the basic rate to be a per annum rate of interest (based on a year of 360 days) equal to the sum of (i) the greater of (A) the 30 day U.S. LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (B) 2.50%, plus (ii) 5.10%; provided, however, under no circumstances will the basic rate be less than 7.60%; (4) provide a mechanism for determining an alternative interest rate to replace the U.S. LIBOR rate upon the occurrence of certain circumstances; and (5) revise the prepayment fee to be between 1.00% and 3.00% of the principal amount, depending on the timing of any prepayment. Upon closing the amendment to the loan and security agreement, payment of the previously accrued final payment under the credit facility was required.
In addition to the principal and interest payments, under the credit facility, we are required to pay a final payment fee of 3.50% on all amounts outstanding, which is being accreted using the effective interest rate method over the term of the loan and security agreement and shall be due at the earlier of maturity or prepayment. Borrowings are prepayable at our option in whole, but not in part, together with all accrued and unpaid interest thereon and, if not previously made, the final payment, subject to a prepayment fee of 1.00%.
The credit facility includes affirmative and restrictive covenants and events of default, including the following events of default: payment defaults, breaches of covenants, judgment defaults, cross defaults to certain other contracts, certain events with respect to governmental approvals if such events could cause a material adverse change, a material impairment in the perfection or priority of the lender's security interest or in the value of the collateral, a
19

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
material adverse change in the business, operations, or condition of us or any of our subsidiaries, and a material impairment of the prospect of repayment of the loans. Upon the occurrence of an event of default, a default increase in the interest rate of an additional 5.00% could be applied to the outstanding loan balance and the lender could declare all outstanding obligations immediately due and payable and take such other actions as set forth in the loan and security agreement.
Our obligations under the credit facility are secured by a first priority security interest in substantially all of our assets, other than our intellectual property. There are no financial covenants contained in the loan and security agreement. We were in compliance with the affirmative and restrictive covenants as of September 30, 2021.
Expected future principal payments for the credit facility are as follows:
Year ending December 31:
2021 (remaining)$ 
20229,188 
202312,250 
20243,062 
Total expected future principal payments$24,500 

6. Employee Retirement Plan
We sponsor an employee retirement plan covering all of our full-time employees. The plan allows for eligible employees to defer a portion of their eligible compensation up to the maximum allowed by IRS Regulations. We may elect to make a voluntary contribution to the plan. We have not made contributions since inception.

7. Stockholders' Equity
Stock-Based Compensation
We adopted the 2007 Stock Incentive Plan (the "2007 Plan") in November 2007, which terminated in accordance with its terms on November 28, 2017; however, the outstanding stock options may continue to be exercised in accordance with their terms. Immediately following the termination of the 2007 Plan, we adopted the 2017 Stock Incentive Plan (the "2017 Plan"), which contains substantially similar terms and conditions as the 2007 Plan. Upon the IPO, no further grants were made under the 2017 Plan and we adopted the 2018 Stock Incentive Plan (the "2018 Plan").
The purpose of the 2018 Plan is to promote the interest of our company and our stockholders by aiding in attracting and retaining employees, officers, consultants, independent contractors, and directors capable of assuring the future success of our business and to afford such persons an opportunity to acquire a proprietary interest in our company. The board of directors may amend, alter, suspend, discontinue, or terminate the 2018 Plan at any time with the approval of our stockholders. A total of 1,386,809 shares of common stock were initially reserved for issuance under the 2018 Plan, and this share reserve will automatically be supplemented each January 1, commencing on January 1, 2019 and ending on and including January 1, 2028, by an amount of shares equal to the lesser of: a) 739,631 shares, b) 4% of the shares outstanding on the final day of the immediately preceding fiscal year and c) such smaller number of shares as determined by the board of directors. As of September 30, 2021, there were 3,284,769 shares reserved for issuance under the 2018 Plan, of which 1,293,557 shares were available for issuance.
The following table presents the components and classification of stock-based compensation expense recognized for stock options and RSUs granted under the 2017 Plan, the 2018 Plan and under our Employee Stock Purchase Plan (the "ESPP"):
20

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
Three Months EndedNine Months Ended
September 30,September 30,
2021202020212020
Stock options$6,405 $2,984 $18,065 $8,303 
Restricted stock units29  77  
Employee stock purchase plan376 327 1,006 660 
Total stock-based compensation expense$6,810 $3,311 $19,148 $8,963 
Cost of goods sold$88 $36 $250 $122 
Research and development1,153 535 3,229 1,252 
Selling, general and administrative5,569 2,740 15,669 7,589 
Total stock-based compensation expense$6,810 $3,311 $19,148 $8,963 
Stock Options
Prior to the IPO, the exercise price of stock options represented fair value of the common stock at the time of issuance and was determined by the board of directors with the assistance of a third-party valuation specialist. Post-IPO, options are granted at the exercise price, which is equal to the closing price of our stock on the date of grant. The stock options granted to employees include a four-year service period and 25% vest after the first year of service and the remainder vest in equal installments over the next 36 months of service. The stock options granted to the board of directors vest in one or three equal annual installments, in each case, subject to the director's continuous service through the applicable vesting date. The stock options have a contractual life of ten years.
A summary of stock option activity and related information is as follows:
OptionsWeighted Average
Exercise Price
Weighted Average
Remaining
Contractual Term
(years)
Aggregate Intrinsic
Value
(in thousands)
Outstanding at December 31, 20202,857,564 $66.09 7.9$351,626
Granted184,845 $208.12 
Exercised(269,212)$33.92 $47,176
Forfeited/expired(93,790)$113.37 
Outstanding at September 30, 20212,679,407 $77.47 7.3$416,515
Exercisable at September 30, 20211,355,413 $28.54 6.1$276,959
The aggregate intrinsic value of options exercised is the difference between the estimated fair market value of our common stock at the date of exercise and the exercise price for those options. The aggregate intrinsic value of outstanding options is the difference between the closing price as of the date outstanding and the exercise price of the underlying stock options.
As of September 30, 2021, the amount of unearned stock-based compensation to be expensed from now through the year 2025 related to unvested employee and non-employee director stock options is $70.0 million, which we expect to recognize over a weighted average period of 2.5 years. If there are any modifications or cancellations of the underlying unvested securities, we may be required to accelerate, increase, or cancel any remaining unearned stock compensation expense. Future stock-based compensation expense and unearned stock-based compensation will increase to the extent that we grant additional stock-based awards.
We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model using the fair market value of our common stock on the date of grant and a number of other assumptions. These
21

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
assumptions include estimates regarding the expected term of the awards, estimates of the stock volatility over a duration that approximates the expected term of the awards, estimates of the risk-free rate, and estimates of expected dividend rates.
The fair value of options granted to employees and non-employee directors was estimated as of the grant date using the Black-Scholes option pricing model using the following assumptions:
Nine Months Ended
September 30,
20212020
Expected term (years)
5.50 - 6.25
5.50 - 6.25
Expected volatility
55.0 - 55.9%
42.3 - 49.3%
Risk-free interest rate
0.79 - 1.40%
0.36 - 1.42%
Expected dividend yield0.0%0.0%
Weighted average fair value$109.81$38.33

Expected Term — Due to our limited amount of historical exercise, forfeiture, and expiration activity, we have opted to use the "simplified method" for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting terms and the original contractual term of the option. We will continue to analyze our expected term assumption as more historical data becomes available.
Expected Volatility — Due to our limited operating history and a lack of company specific historical and implied volatility data, we have incorporated our historical stock trading volatility with those of a group of similar companies that are publicly traded for the calculation of volatility. When selecting this peer group of public companies on which we have based our expected stock price volatility, we generally selected companies with comparable characteristics to it, including enterprise value, stages of clinical development, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. We will continue to analyze the historical stock price volatility assumption as more historical data for our common stock becomes available.
Risk-Free Interest Rate — The risk-free rate assumption is based on the U.S. government Treasury instruments with maturities similar to the expected term of our stock options.
Expected Dividend Yield — The expected dividend assumption is based on our history of not paying dividends and our expectation that we will not declare dividends for the foreseeable future.
The amount of stock-based compensation expense is recognized on a straight-line basis over the vesting term and is reduced by actual forfeitures as they occur.
Restricted Stock Units
RSUs are share awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs include a four-year service period and vest in equal installments on each of the first four anniversaries of the date of grant, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of our common stock on the grant date.
22

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
A summary of RSUs and related information is as follows:
Restricted Stock UnitsWeighted Average
Grant Date Fair Value
Aggregate Intrinsic Value (in thousands)
Unvested at December 31, 2020 $ $ 
Granted2,275 $201.51 
Unvested at September 30, 20212,275 $201.51 $530 
There were no RSUs granted prior to 2021. The aggregate intrinsic value of RSUs outstanding was based on our closing stock price on the last trading day of the period. As of September 30, 2021, there was $0.4 million of unrecognized stock-based compensation expense related to RSUs to be recognized over a period of 3.3 years.
Employee Stock Purchase Plan
Our ESPP allows participating employees to purchase shares of our common stock at a discount through payroll deductions. The plan is available to all of our U.S.-based full-time employees. Participating employees may purchase common stock, on a voluntary after-tax basis, at a price equal to 85% of the lower of the closing market price per share of our common stock on the first or last trading day of each stock purchase period. The plan provides for six-month purchase periods, beginning on January 1 and July 1 of each calendar year.
A total of 277,362 shares of common stock were initially reserved for issuance under the ESPP, and this share reserve will automatically be supplemented each January 1, commencing on January 1, 2019 and ending on and including January 1, 2028, by an amount of shares equal to the lesser of: a) 184,908 shares, b) 1% of the shares outstanding on the final day of the immediately preceding calendar year and c) such smaller number of shares as the board of directors may determine. On June 30, 2021, 11,351 shares were purchased under the ESPP, utilizing $1.8 million of employee contributions. As of September 30, 2021, 754,752 shares were available for future issuance under the ESPP. The current purchase period under the ESPP began on July 1, 2021 and ends December 31, 2021.

8. Income Taxes
At both September 30, 2021 and 2020, a valuation allowance was recorded against all deferred tax assets due to our cumulative net loss position. We recorded income tax expense of $0 and $0.1 million in the three months ended September 30, 2021 and 2020, respectively, and $0.1 million for both of the nine months ended September 30, 2021 and 2020. The nominal Income tax expense in those periods reflects minimal state income tax expense and an accrual for uncertain tax benefits.
We filed our 2020 U.S. federal income tax return during the third quarter of 2021. Considering provision to return true-ups, our gross federal net operating loss carryforward as of December 31, 2020 was $234.8 million, which will expire at various dates beginning in 2028. In addition, net operating loss carryforwards for state income tax purposes of $145.6 million that include net operating losses will begin to expire in 2028. We also have gross research and development credit carryforwards of $4.4 million as of December 31, 2020, which will expire at various dates beginning in 2033.
Utilization of the net operating loss carryforwards may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986 and similar state provisions. We have not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit our utilization of the net operating losses and could be triggered by subsequent sales of securities by us or our stockholders.
23

INSPIRE MEDICAL SYSTEMS, INC. 
NOTES TO FINANCIAL STATEMENTS (Unaudited) 
(Table amounts in thousands, except share and per share amounts)
Realization of the deferred tax assets is dependent upon the generation of future taxable income, if any, the amount and timing of which are uncertain. Based on available objective evidence and cumulative losses, we believe it is more likely than not that the deferred tax assets are not recognizable and will not be recognizable until we have sufficient taxable income. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance.
We had $0.1 million of gross unrecognized tax benefits as of each of September 30, 2021 and December 31, 2020.
We file income tax returns in the applicable jurisdictions. The 2018 to 2020 tax years remain open to examination by the major taxing authorities to which we are subject. We do not expect a significant change to our unrecognized tax benefits over the next 12 months.

9. Segment Reporting and Revenue Disaggregation
We operate our business as one reporting segment. An operating segment is defined as a component of an enterprise for which separate discrete financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance.
We sell our Inspire system to hospitals and ambulatory surgery centers in the U.S. and in select countries in Europe through a direct sales organization. Revenue by geographic region is as follows:
Three Months EndedNine Months Ended
September 30,September 30,
2021202020212020
United States$58,298 $33,121 $145,420 $63,379 
Europe3,387 2,721 9,576 5,993 
Total revenue$61,685 $35,842 $154,996 $69,372 
All of our long-lived assets are located in the U.S.

10. Loss Per Share
Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Because we have reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share as all of the following potentially dilutive shares were antidilutive in those periods:
September 30,
20212020
Common stock options2,679,407 2,514,801 
Restricted stock units2,275  
Employee stock purchase plan6,124  
Total2,687,806 2,514,801 

24

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations.
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes to those statements included elsewhere in this Quarterly Report on Form 10-Q, as well as the audited financial statements and the related notes thereto, and the discussion under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, such as information with respect to our plans and strategy for our business and the impact of the ongoing and global COVID-19 pandemic on our business, financial results and financial condition on our business, financial results and financial condition includes forward-looking statements that involve risks and uncertainties. As a result of many important factors, including those set forth in the "Risk Factors" section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and this Quarterly Report on Form 10-Q, our actual results could differ materially from the results described in, or implied, by these forward-looking statements.

Overview
We are a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with OSA. Our proprietary Inspire system is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. We have developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire therapy is indicated for patients with moderate to severe OSA who do not have significant central sleep apnea and do not have a complete concentric collapse of the airway at the soft palate level. In addition, patients in the U.S. must have been confirmed to fail or be unable to tolerate positive airway pressure treatments, such as CPAP, and be 18 years of age or older, though there are no similar requirements for patients in Europe.
We sell our Inspire system to hospitals and ambulatory surgery centers ("ASCs") in the U.S. and in select countries in Europe through a direct sales organization. Our direct sales force engages in sales efforts and promotional activities focused on ear, nose and throat ("ENT") physicians and sleep centers. In addition, we highlight our compelling clinical data and value proposition to increase awareness and adoption amongst referring physicians. We build upon this top-down approach with strong direct-to-consumer marketing initiatives to create awareness of the benefits of our Inspire system and drive interest through patient empowerment. This outreach helps to educate thousands of patients on our Inspire therapy.
Although our sales and marketing efforts are directed at patients and physicians because they are the primary users of our technology, we consider the hospitals and ASCs where the procedure is performed to be our customers, as they are the purchasing agents of our Inspire system. Our customers are reimbursed the cost required to treat each patient through various third-party payors, such as commercial payors and government agencies. Our Inspire system is currently reimbursed primarily on a per-patient prior authorization basis for patients covered by commercial payors, under Local Coverage Determinations for patients covered by Medicare, and under U.S. government contract for patients who are treated by the Veterans Health Administration. We have secured positive coverage policies with all large national commercial insurers and we estimate that the majority of patients who meet the FDA indication for Inspire therapy are covered by commercial insurance companies or Medicare.
The procedure performed to implant our device is currently described for billing purposes using a Category I Current Procedural Terminology (“CPT”) code (64568), which is used in conjunction with a temporary Category III CPT code (0466T). There are significant changes to the CPT code set for Inspire therapy which will take effect on January 1, 2022. These changes include three new CPT Category I codes, the deletion of the current Category III codes, and the addition of a new CPT code for the Drug Induced Sleep Endoscopy ("DISE") procedure. The three new CPT Category I codes are as follows: 64582 for the insertion of hypoglossal nerve neurostimulator electrode and generator and breathing sensor electrode; 64583 for the revision or replacement of hypoglossal nerve neurostimulator electrode and breathing sensor electrode with connection to existing generator; and 64584 for the removal of hypoglossal nerve neurostimulator electrode and generator and breathing sensor electrode. Temporary
25

Category III codes 0466T, 0467T, and 0468T will be deleted from the 2022 code set. The new CPT code for the DISE procedure is 42975, for the evaluation of sleep-disordered breathing by examination of upper airway using an endoscope. While the Center for Medicare & Medicaid Services ("CMS") has significant discretion over the final reimbursement rates assigned, we believe that these coding changes will have a positive impact on Medicare reimbursement related to our technology.
In July 2021, the proposed 2022 Medicare reimbursement rates were announced for physicians implanting Inspire therapy and performing DISE procedures. The 2022 national average physician payments are expected to be approximately $870 for implantation of a hypoglossal nerve stimulator and approximately $113 for the DISE procedure. Also announced in July 2021 were the 2022 proposed rates of Medicare reimbursement to our hospital and ASC customers under the outpatient prospective payment system. The proposed rate for hospitals increased approximately 3% over the 2021 rate, but the proposed rate for ASCs decreased by approximately 28%. In determining the ASC reimbursement rates under the proposed rules, CMS defaulted to a device offset rate of 31%, rather than retain the existing offset rate of 88.07% that was previously applied prior to the new CPT code. The device offset is generally the device-related portion of the relevant procedure code under the Healthcare Common Procedure Coding System. The result of this proposed change by CMS reduced the payment for the Inspire procedure in ASCs from nearly $25,000 to approximately $17,500. In August 2021, CMS convened the advisory panel on hospital outpatient payment to review several considerations, including ASC classifications for multiple device types. The panel voted unanimously, with no abstentions, to recommend to CMS that it apply the device offset rate of 85.71% and that there be no multiple procedure discounting, which would result in the 2022 rate for ASCs to be approximately consistent with the 2021 rate. We believe that steady or increased Medicare reimbursement rates may positively affect demand for our Inspire system and may have a beneficial impact on our result of operations. The final 2022 reimbursement rates are expected to be announced in late November or early December 2021.
Japan's Ministry of Health, Labour and Welfare ("MLHW") approved Inspire therapy to treat moderate to severe OSA in June 2018 and was formally added to the Japan National Health Insurance Payment Listing in June 2021. We currently plan for the initial implants of Inspire therapy to occur in Japan by the end of 2021. In August 2020, the Australian Therapeutic Goods Administration approved Inspire therapy to treat moderate to severe OSA, and we are currently seeking reimbursement in Australia.
For the nine months ended September 30, 2021, 93.8% of our revenue was derived in the U.S. and 6.2% was derived in Europe. No single customer accounted for more than 10% of our revenue during the nine months ended September 30, 2021.
Our marketing efforts during the first half of 2020 included refocused direct-to-consumer marketing strategies, which initially included a shift from radio and TV in our larger markets that were affected by COVID-19 towards more digital and TV in smaller markets. During the second quarter of 2020, and continuing through today, we resumed radio and TV initiatives in our larger markets as the impact of COVID-19 lessened in those areas. We continue to monitor the impacts of COVID-19 in each advertising market and may again change our advertising strategy on a market-by-market basis if needed. Further, our team has leveraged virtual tools, such as the new Inspire Sleep app released during the second quarter of 2020, to continue physician training and patient education. In January 2021, we began airing four new TV commercials and we expect to continue to increase our digital and social media presence.
In early 2020, we started a call center concept, the Inspire Advisor Care Program ("ACP"). The primary purpose of this program is to assist patients with making a connection with a qualified healthcare provider based on their specific needs. As of November 2, 2021, approximately 450 of our U.S. centers were utilizing the ACP, up from approximately 180 centers at December 31, 2020. We plan to continue to increase the number of our U.S. centers using the ACP during the remainder of 2021.
We rely on third-party suppliers to manufacture our Inspire system and its components. Many of these suppliers are currently single source suppliers. We seek to maintain higher levels of inventory to protect ourselves from supply interruptions, and, as a result, we are subject to the risk of inventory obsolescence and expiration, which could lead to inventory impairment charges. In the U.S., our products are shipped directly to our customers on a purchase order basis, primarily by a third-party vendor with a facility in Tennessee, although we do ship some products from
26

our facility in Minnesota. Warehousing and shipping operations for our European customers are handled by a third-party vendor with a facility located in the Netherlands. Customers do not have the right to return non-defective product, nor do we place product on consignment. Our sales representatives do not maintain trunk stock.
Since our inception in 2007, we have financed our operations primarily through sales of our Inspire system, private placements of our convertible preferred securities, amounts borrowed under our credit facility and registered offerings of our common stock. In April 2020, we sold 2,300,000 shares of common stock at a public offering price of $58.00 per share and received net proceeds of approximately $124.7 million after deducting underwriting discounts, commissions, and offering expenses. We have devoted significant resources to research and development activities related to our Inspire system, including clinical and regulatory initiatives to obtain marketing approval, and sales and marketing activities. For the three months ended September 30, 2021, we generated revenue of $61.7 million with a gross margin of 86.0% and had a net loss of $10.3 million compared to revenue of $35.8 million with a gross margin of 85.5% and a net loss of $10.4 million for the three months ended September 30, 2020. For the nine months ended September 30, 2021, we generated revenue of $155.0 million with a gross margin of 85.7% and had a net loss of $39.7 million compared to revenue of $69.4 million with a gross margin of 84.9% and a net loss of $49.7 million for the nine months ended September 30, 2020. Our accumulated deficit as of September 30, 2021 was $277.0 million.
We have invested heavily in product development. Our research and development activities have been centered on driving continuous improvements to our Inspire therapy. We have also made significant investments in clinical studies to demonstrate the safety and efficacy of our Inspire therapy and to support regulatory submissions. We continue to make investments in research and development efforts to develop our next generation Inspire systems and support our future regulatory submissions for expanded indications and for new markets such as Europe, Japan, and Australia. For example, in March 2021, we received FDA approvals for both a new Inspire physician programmer platform and an improved surgical implant procedure that eliminates one incision with a revised placement of the pressure sensing lead. In May 2021, we received CE Mark approval in Europe for the two-incision implant procedure. In April 2020, we received FDA approval for an expanded age-range for Inspire therapy to include 18 to 21 year old patients. Japan's MLHW approved Inspire therapy to treat moderate to severe OSA in June 2018 and was formally added to the Japan National Health Insurance Payment Listing in June 2021. In August 2020, the Australian Therapeutic Goods Administration approved Inspire therapy to treat moderate to severe OSA.
We also continue to make significant investments to build our sales and marketing organization by increasing the number of U.S. sales representatives and continuing our direct-to-consumer marketing efforts in existing and new markets throughout the U.S. and in Europe. In the three months ended September 30, 2021, we activated 68 centers bringing the total to 603 U.S. medical centers implanting Inspire therapy as of September 30, 2021. At September 30, 2021, ASCs made up 20% of our total U.S. implanting centers, up from 16% at December 31, 2020. Additionally, we created 11 new territories during the three months ended September 30, 2021, bringing the total to 141 U.S. territories as of September 30, 2021.
Because of these and other factors, we may continue to incur net losses for the next several years, and we may require substantial additional funding, which may include future equity and debt financings.
Outlook
We expect the COVID-19 pandemic to continue to adversely impact our revenue due to decreases and delays in the number of Inspire therapy procedures performed and patients screened for eligibility for Inspire therapy. Beginning in the second week of March 2020, substantially all of the scheduled Inspire therapy procedures were postponed and numerous other authorized cases were unable to be scheduled. During April 2020, the widespread shutdown in elective surgical procedures continued, with surgical volumes increasing in May and even further in June, yet still remaining below pre-COVID-19 levels. Surgical volumes continued to increase steadily during the remainder of 2020, with most implanting centers performing procedures by October 2020. A portion of the remaining 2020 procedures performed were those rescheduled from the first half of 2020, and, as a result of which, the initial backlog of postponed cases was largely eliminated by the end of 2020. Resurgences of COVID-19 during 2021 in various U.S. and European regions have, and may in the future, negatively impact our procedure volumes, although surgical volumes generally returned to pre-pandemic levels by the end of the first quarter of 2021. Additionally, while
27

procedural volume rates for elective surgeries generally returned to pre-pandemic levels in the U.S. and Europe by March 31, 2021, the COVID-19 pandemic continues to rapidly evolve and its impact on our business will depend on several factors that are highly uncertain and unpredictable.
In response to the spread of COVID-19 and in line with recommendations from federal and local government and healthcare agencies, in March 2020 we transitioned employees, except for those deemed essential to key aspects of our business, to a remote work environment. Beginning in May 2020, our corporate office re-opened with strict sanitation and physical distancing protocols, although some corporate employees continue to work remotely as a heightened precautionary measure. Additionally, our field staff continues to primarily work remotely and must adhere to applicable COVID-19 protocols when visiting hospitals and ASCs. During the period in which surgical procedures were significantly limited, we identified and implemented innovative solutions to support patients who have Inspire therapy, as well as continued to educate patients who may be struggling with their sleep apnea. Patients continue to reach out to learn more about the therapy and get connected to a healthcare provider, and we are supporting this interaction through the use of several virtual tools, including the Inspire Sleep app that was released in 2020, and other online tools. We are also continuing with our planned expansion in recruiting Territory Managers and sales support roles.
To date, we have not experienced disruptions to our supply chain network as a result of the COVID-19 pandemic. We have also not reduced our capital expenditures and are continuing to invest in research and development, however, we may determine to allocate resources differently due to impacts of the COVID-19 pandemic.
We believe that our existing cash resources will be sufficient to meet our capital requirements and fund our operations for at least the next 12 months. For additional information, see “— Liquidity and Capital Resources.”

Components of Our Results of Operations
Revenue
We derive primarily all of our revenue from the sale of our Inspire system to hospitals and ASCs in the U.S. and select countries in Europe. We recognize revenues from sales of our Inspire system when the customer obtains control of the product, which occurs at a point in time, either upon shipment of the product or receipt of the product, depending on shipment terms.
Our revenue has fluctuated, and may continue to fluctuate, from quarter to quarter due to a variety of factors. For example, we have historically experienced seasonality in our first and fourth quarters and have experienced adverse impacts on our revenue due to the COVID-19 pandemic.
Cost of Goods Sold and Gross Margin
Cost of goods sold consists primarily of acquisition costs for the components of the Inspire system, overhead costs, scrap, and inventory obsolescence, warranty replacement costs, as well as distribution-related expenses such as logistics and shipping costs, net of shipping costs charged to customers. The overhead costs include the cost of material procurement, depreciation expense for production equipment, and operations supervision and management personnel, including employee compensation, stock-based compensation, supplies, and travel. We expect cost of goods sold to increase or decrease in absolute dollars primarily as, and to the extent, our revenue grows or declines, respectively.
We calculate gross margin as gross profit divided by revenue. Our gross margin has been and we expect it will continue to be affected by a variety of factors, including manufacturing costs, the average selling price of our Inspire system, the implementation of cost-reduction strategies, inventory obsolescence costs, which generally occur when new generations of our Inspire system are introduced, and to a lesser extent the sales mix between the U.S. and Europe as our average selling price in the U.S. tends to be higher than in Europe. Our gross margin may increase slightly over the long term to the extent our production volumes increase and we receive discounts on the costs
28

charged by our contract manufacturers, thereby reducing our per unit costs. However, our gross margin may fluctuate from quarter to quarter due to seasonality.
Research and Development Expenses
Research and development expenses consist primarily of product development, engineering, clinical studies to develop and support our products, regulatory expenses, quality assurance, testing, consulting services and other costs associated with the next generation versions of the Inspire system. These expenses include employee compensation, including stock-based compensation, supplies, materials, consulting, and travel expenses related to research and development programs. Additionally, these expenses include clinical trial management, payments to clinical investigators, data management and travel expenses for our various clinical trials.
We expect research and development expenses to increase in the future as we develop next generation versions of our Inspire system and continue to expand our clinical studies to further expand positive coverage policies from private commercial payors in the U.S. and enter into new markets including additional European countries, Japan, and Australia. We expect research and development expenses as a percentage of revenue to vary over time depending on the level and timing of initiating new product development efforts and new clinical development activities.
Selling, General and Administrative Expenses
Selling, general and administrative expenses consist primarily of compensation for personnel, including base salaries, stock-based compensation expense and commissions related to our sales organization, finance, information technology, and human resource functions, as well as spending related to marketing, sales operations, and training and reimbursement personnel. Other selling, general and administrative expenses include training physicians, travel expenses, advertising, direct-to-consumer promotional programs, conferences, trade shows and consulting services, professional services fees, audit fees, insurance costs and general corporate expenses, including facilities-related expenses.
We expect selling, general and administrative expenses to continue to increase as we expand our commercial infrastructure to both drive and support our planned growth in revenue and as we increase our headcount and expand administrative personnel to support our growth and operations as a public company including finance personnel and information technology services. Additionally, we anticipate an increase in our stock-based compensation expense with grants of restricted stock units, stock options, and shares of our common stock purchased pursuant to our employee stock purchase plan.
Other Expense (Income)
Other expense (income) consists primarily of interest expense payable under our credit facility and interest income.
Seasonality
Historically, we have experienced seasonality in our first and fourth quarters, and we expect this trend to continue. In the U.S., we have experienced, and may in the future experience, higher sales in the fourth quarter as a result of patients having paid their annual insurance deductibles in full, thereby reducing their out-of-pocket costs. Historically, in the first quarter of each year in Germany, we have experienced reduced demand for our Inspire therapy as Neue Untersuchungs-und-Behandlungsmethoden ("NUB") coverage status is being determined and as hospitals are establishing their budgets pertaining to allocation of funds to purchase our Inspire therapy. Beginning January 1, 2021, Inspire therapy became fully integrated into the German hospital reimbursement system (“G-DRG”), and we therefore may experience less seasonal fluctuations in Germany.

29

Results of Operations
Three Months EndedNine Months Ended
September 30,September 30,
20212020$ Change% Change20212020$ Change% Change
(in thousands, except percentages)
Revenue$61,685 $35,842 $25,843 72.1 %$154,996 $69,372 $85,624 123.4 %
Cost of goods sold8,624 5,211 3,413 65.5 %22,123 10,462 11,661 111.5 %
Gross profit53,061 30,631 22,430 73.2 %132,873 58,910 73,963 125.6 %
Gross margin86.0%85.5%85.7%84.9%
Operating expenses:
Research and development9,614 7,307 2,307 31.6 %27,056 18,807 8,249 43.9 %
Selling, general and administrative53,243 33,216 20,027 60.3 %143,846 89,249 54,597 61.2 %
Total operating expenses62,857 40,523 22,334 55.1 %170,902 108,056 62,846 58.2 %
Operating loss(9,796)(9,892)96 (1.0)%(38,029)(49,146)11,117 (22.6)%
Other expense, net548 406 142 35.0 %1,570 486 1,084 223.0 %
Loss before income taxes(10,344)(10,298)(46)0.4 %(39,599)(49,632)10,033 (20.2)%
Income taxes87 (84)(96.6)%52 87 (35)(40.2)%
Net loss$(10,347)$(10,385)$38 (0.4)%$(39,651)$(49,719)$10,068 (20.2)%
Comparison of the Three Months Ended September 30, 2021 and 2020
Revenue
Revenue increased $25.8 million, or 72.1%, to $61.7 million for the three months ended September 30, 2021 compared to $35.8 million for the three months ended September 30, 2020. The increase was attributable to a $25.2 million increase in sales of our Inspire system in the U.S. and an increase of $0.7 million in Europe, primarily in Germany. Revenue growth was primarily due to the continued widespread impacts of COVID-19 in the third quarter of 2020, increased market penetration in existing territories, the expansion into new territories, and increased physician and patient awareness of our Inspire system.
Since March 2020, our revenue growth in the U.S. and Europe has been impacted by the COVID-19 pandemic, which disrupted our ability to access our clinician customers and their patients. Specifically, we saw healthcare facilities and clinics restricting access to their clinicians, reducing patient consultations and treatments, or closing temporarily due to COVID-19. As a result, beginning in the second week of March 2020, substantially all of our Inspire therapy procedures were postponed and numerous other cases, which had received prior authorization, were not able to be scheduled and, therefore were also postponed. During April 2020, the widespread shutdown in elective surgical procedures continued, with surgical volumes increasing in May and even further in June, yet still remaining below pre-COVID-19 levels. During the third quarter 2020, surgical volumes increased steadily, but remained negatively impacted by the COVID-19 pandemic, and the backlog of cases from the first half of 2020 was largely eliminated. Revenue during the three months ended September 30, 2021, was also impacted by COVID-19, although to a much lesser extent than in the same prior year period as surgical volumes generally returned to pre-pandemic levels by the end of the first quarter of 2021.
30

Revenue information by region is summarized as follows:
Three Months Ended September 30,
20212020Change
Amount% of RevenueAmount% of Revenue$%
(in thousands, except percentages)
United States$58,298 94.5 %$33,121 92.4 %$25,177 76.0 %
Europe3,387 5.5 %2,721 7.6 %666 24.5 %
Total revenue$61,685 100.0 %$35,842 100.0 %$25,843 72.1 %
Revenue generated in the U.S. was $58.3 million for the three months ended September 30, 2021, an increase of $25.2 million, or 76.0%, compared to the three months ended September 30, 2020. Revenue growth in the U.S. was somewhat due to the continuing impacts from the COVID-19 pandemic in the third quarter of 2020, but was also attributable to increased market penetration in existing territories, the expansion into new territories, increased physician and patient awareness of our Inspire system, and additional positive coverage policies during the three months ended September 30, 2021. As noted above, U.S. revenue during both periods was negatively impacted by the COVID-19 pandemic.
Revenue generated in Europe was $3.4 million in the three months ended September 30, 2021, an increase of $0.7 million, or 24.5%, compared to the three months ended September 30, 2020. Revenue growth in Europe was somewhat due to the continuing impacts from the COVID-19 pandemic in the third quarter of 2020, but was also attributable to increased market penetration in existing territories, the expansion of our European sales representatives into new territories, and increased physician and patient awareness of our Inspire system during the three months ended September 30, 2021. The remainder of our increased revenue from Europe was due to favorable exchange rates. As noted above, European revenue during both periods was negatively impacted by the COVID-19 pandemic.
Cost of Goods Sold and Gross Margin
Cost of goods sold increased $3.4 million, or 65.5%, to $8.6 million for the three months ended September 30, 2021 compared to $5.2 million for the three months ended September 30, 2020. The increase was primarily due to product costs associated with higher sales volume of our Inspire system.
Gross margin increased to 86.0% for the three months ended September 30, 2021 compared to 85.5% for the three months ended September 30, 2020. Gross margin for the three months ended September 30, 2021 was higher primarily due to increased sales volume and manufacturing efficiencies.
Research and Development Expenses
Research and development expenses increased $2.3 million, or 31.6%, to $9.6 million for the three months ended September 30, 2021 compared to $7.3 million for the three months ended September 30, 2020. This change was primarily due to an increase of $1.6 million of compensation and employee-related expenses, mainly as a result of increased headcount and stock-based compensation expense, $0.8 million for ongoing research and development costs, including the Inspire Cloud, the next generation Inspire system, and our physician programmer, partially offset by a decrease of $0.1 million in regulatory submissions and clinical studies expenses.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased $20.0 million, or 60.3%, to $53.2 million for the three months ended September 30, 2021 compared to $33.2 million for the three months ended September 30, 2020. The primary driver of this change was an increase of $11.9 million in compensation, including salaries, commissions, and stock-based compensation, and other employee-related expenses, mainly as a result of increased headcount. In addition, marketing expenses increased $7.1 million, primarily consisting of direct-to-consumer initiatives, including new TV advertisements, which began airing in January 2021, and the expansion of our Advisor Care
31

Program call center. Other drivers of the change to selling, general and administrative expenses included an increase of $1.0 million due to general corporate costs such as office rent, insurance costs, consulting fees, and information technology supplies and equipment.
Other Expense, Net
Other expense, net changed by $0.1 million, or 35.0%, to $0.5 million of expense, net for the three months ended September 30, 2021 compared to $0.4 million of expense for the three months ended September 30, 2020. This change was primarily due to a decrease in interest income of $0.1 million earned on our cash, cash equivalents and investments balances due to lower interest rates.
Income Taxes
We recorded a provision for incomes taxes of less than $0.1 million for the three months ended September 30, 2021 compared to $0.1 million for the three months ended September 30, 2020. This decrease was primarily due to lower state income tax expense.

Comparison of the Nine Months Ended September 30, 2021 and 2020
Revenue
Revenue increased $85.6 million, or 123.4%, to $155.0 million for the nine months ended September 30, 2021 compared to $69.4 million for the nine months ended September 30, 2020. The increase was attributable to a $82.0 million increase in sales of our Inspire system in the U.S and an increase of $3.6 million in Europe, primarily in Germany. Revenue growth was primarily due to the widespread impacts of COVID-19 in the nine months of 2020, increased market penetration in existing territories, the expansion into new territories, and increased physician and patient awareness of our Inspire system.
Beginning in March 2020, our revenue growth in the U.S. and Europe was impacted by the COVID-19 pandemic, which disrupted our ability to access our clinician customers and their patients. Specifically, we saw healthcare facilities and clinics restricting access to their clinicians, reducing patient consultations and treatments, or closing temporarily due to COVID-19. As a result, beginning in the second week of March 2020, substantially all of our Inspire therapy procedures were postponed and numerous other cases, which had received prior authorization, were not able to be scheduled and, therefore were also postponed. During the second quarter 2020, the widespread shutdown in elective surgical procedures continued, with surgical volumes increasing in May and even further in June, yet still remaining below pre-COVID-19 levels. During the third quarter 2020, surgical volumes increased steadily, but remained negatively impacted by the COVID-19 pandemic, and the backlog of postponed cases from the first half of 2020 was largely eliminated. During the nine months ended September 30, 2021, resurgences of COVID-19 in various U.S. and European regions disrupted our ability to access our clinician customers and their patients, although to a lesser extent than in the same prior year period as surgical volumes generally returned to pre-pandemic levels by the end of the first quarter of 2021.
Revenue information by region is summarized as follows:
Nine Months Ended September 30,
20212020Change
Amount% of RevenueAmount% of Revenue$%
(in thousands, except percentages)
United States$145,420 93.8 %$63,379 91.4 %$82,041 129.4 %
Europe9,576 6.2 %5,993 8.6 %3,583 59.8 %
Total revenue$154,996 100.0 %$69,372 100.0 %$85,624 123.4 %
32

Revenue generated in the U.S. was $145.4 million for the nine months ended September 30, 2021, an increase of $82.0 million, or 129.4%, compared to the nine months ended September 30, 2020. Revenue growth in the U.S. was primarily due to the widespread shutdown of elective surgical procedures in the first nine months of 2020, but was also attributable to increased market penetration in existing territories, the expansion into new territories, increased physician and patient awareness of our Inspire system, and additional positive coverage policies during the nine months ended September 30, 2021. As noted above, U.S. revenue during both periods was negatively impacted by the COVID-19 pandemic.
Revenue generated in Europe was $9.6 million in the nine months ended September 30, 2021, an increase of $3.6 million, or 59.8%, compared to the nine months ended September 30, 2020. Revenue growth in Europe was primarily due to the widespread shutdown of elective surgical procedures in the first nine months of 2020, but was also attributable to increased market penetration in existing territories, the expansion of our European sales representatives into new territories, and increased physician and patient awareness of our Inspire system during the nine months ended September 30, 2021. The remainder of our increased revenue from Europe was due to favorable exchange rates. As noted above, European revenue during both periods was negatively impacted by the COVID-19 pandemic.
Cost of Goods Sold and Gross Margin
Cost of goods sold increased $11.7 million, or 111.5%, to $22.1 million for the nine months ended September 30, 2021 compared to $10.5 million for the nine months ended September 30, 2020. The increase was primarily due to product costs associated with higher sales volume of our Inspire system.
Gross margin increased to 85.7% for the nine months ended September 30, 2021 compared to 84.9% for the nine months ended September 30, 2020. Gross margin for the nine months ended September 30, 2021 was higher primarily due to higher sales volumes and manufacturing efficiencies.
Research and Development Expenses
Research and development expenses increased $8.2 million, or 43.9%, to $27.1 million for the nine months ended September 30, 2021 compared to $18.8 million for the nine months ended September 30, 2020. This change was primarily due to an increase of $4.8 million of compensation and employee-related expenses, mainly as a result of increased headcount and stock-based compensation expense, $3.8 million for ongoing research and development costs, including ongoing development of the Inspire Cloud and the next generation Inspire system, somewhat offset by a $0.3 million decrease in regulatory submissions and clinical studies expenses.
Selling, General and Administrative Expenses
Selling, general and administrative expenses increased $54.6 million, or 61.2%, to $143.8 million for the nine months ended September 30, 2021 compared to $89.2 million for the nine months ended September 30, 2020. The primary driver of this change was an increase of $33.8 million in compensation, including salaries, commissions, and stock-based compensation, and other employee-related expenses, mainly as a result of increased headcount. In addition, marketing expenses increased $18.4 million, primarily consisting of direct-to-consumer initiatives, including new TV advertisements which began airing in January 2021 and the expansion of our Advisor Care Program call center. During the nine months ended September 30, 2020, we initially refocused our direct-to-consumer marketing strategies by shifting from radio and TV in our larger markets that were affected by COVID-19 towards more digital and TV in smaller markets. During the second quarter of 2020, we resumed radio and TV initiatives in our larger markets as the impact of COVID-19 lessened in those areas. Further, our team leveraged virtual tools, including the new Inspire Sleep app released in the second quarter of 2020, and telemedicine to continue physician training and patient education. Other drivers of the change to selling, general and administrative expenses included an increase of $2.4 million primarily due to office rent, insurance costs, and banking fees.
33

Other Expense, Net
Other expense, net increased by $1.1 million, or 223.0%, to $1.6 million of expense, net for the nine months ended September 30, 2021 compared to $0.5 million of expense for the nine months ended September 30, 2020. This change was primarily due to a decrease of $0.9 million in interest income due to lower interest rates on our cash, cash equivalents and investments balances and a $0.2 million decrease in gains on investments and foreign currency translation.
Income Taxes
We recorded a provision for income taxes of $0.1 million for the both of the nine months ended September 30, 2021 and 2020.

Liquidity and Capital Resources
As of September 30, 2021, we had cash, cash equivalents and investments of $220.2 million and an accumulated deficit of $277.0 million, compared to cash, cash equivalents and investments of $234.4 million and an accumulated deficit of $237.3 million as of December 31, 2020.
Our sources of capital have historically been from private placements of our convertible preferred securities, sales of our Inspire system, borrowings under credit facilities and registered offerings of our common stock. In April 2020, we completed a follow-on offering that included our offer and sale of 2,300,000 shares of common stock at a public offering price of $58.00 per share. We received net proceeds of approximately $124.7 million after deducting underwriting discounts, commissions, and offering expenses.
The COVID-19 pandemic has negatively impacted the global economy, disrupted global supply chains and created significant volatility and disruption of financial markets. An extended period of global supply chain and economic disruption could materially affect our business, results of operations, access to sources of liquidity and financial condition. However, we believe that our existing cash resources will be sufficient to meet our capital requirements and fund our operations for at least the next 12 months. We may also seek liquidity through additional securities offerings or through borrowings under a new credit facility. We cannot ensure investors that we will be able to obtain such financing on commercially reasonable terms if at all.
Cash Flows
The following table presents a summary of our cash flow for the periods indicated:
Nine Months Ended
September 30,
20212020
(in thousands)
Net cash provided by (used in):
Operating activities$(20,853)$(48,935)
Investing activities29,672 75,231 
Financing activities10,872 129,544 
Effect of exchange rate on cash(9)
Net increase in cash and cash equivalents$19,682 $155,845 
Operating Activities
The net cash used in operating activities was $20.9 million for the nine months ended September 30, 2021 and consisted of a net loss of $39.7 million, non-cash charges of $21.0 million, and a decrease in net operating assets of $2.2 million. The non-cash charges consisted of stock-based compensation, depreciation and amortization, non-
34

cash lease expense, stock issued for services rendered, accretion of the debt discount, and amortization of the investment premium, and other, net. Operating assets includes inventories, which increased due to manufacturing of systems inventory to meet increased sales, accounts receivable which increased due to higher sales, and prepaid expenses and other current assets which increased primarily due to prepaid insurance. Operating liabilities includes accrued expenses, which increased primarily due to accrued compensation, and accounts payable, which increased generally due to our increased business volume year-over-year and the costs to support the growth of our operations, including compensation and personnel-related costs.
The net cash used in operating activities was $48.9 million for the nine months ended September 30, 2020 and consisted of a net loss of $49.7 million, a decrease in net operating assets of $9.7 million and an increase in non-cash charges of $10.5 million. The non-cash charges consisted of stock-based compensation, non-cash lease expense, depreciation and amortization, stock issued for services rendered, and accretion of the debt discount, offset by the non-cash income related to the accretion of the investment discount, and other, net. Operating assets includes accounts receivable, which increased due to higher sales, and inventories, which increased due to continued manufacturing of systems inventory. Operating liabilities includes accrued expenses, which decreased primarily due to the payment of accrued compensation as annual bonuses were paid during the first quarter of 2020. Operating liabilities also includes accounts payable, which increased generally due to the costs to support the growth of our operations, including compensation and personnel-related costs.
Investing Activities
Net cash provided by investing activities for the nine months ended September 30, 2021 was $29.7 million and consisted of proceeds from sales or maturities of investments of $43.8 million, partially offset by purchases of investments of $10.0 million and purchases of property and equipment of $4.1 million.
Net cash provided by investing activities for the nine months ended September 30, 2020 was $75.2 million and consisted primarily of proceeds from sales or maturities of investments of $129.8 million, partially offset by purchases of investments of $52.7 million and purchases of property and equipment of $1.9 million.
Financing Activities
Net cash provided by financing activities was $10.9 million for the nine months ended September 30, 2021 and consisted of proceeds from the exercise of stock options of $9.1 million and proceeds from the issuance of common stock from our ESPP of $1.8 million.
Net cash provided by financing activities was $129.5 million for the nine months ended September 30, 2020 and consisted primarily of $124.7 million in proceeds from our follow-on offering in April 2020. Proceeds from the exercise of stock options of $3.8 million and proceeds from the issuance of common stock from our ESPP of $1.1 million made up the remainder of the cash provided by financing activities.
Indebtedness
In August 2015, we entered into a loan and security agreement with Oxford Finance, as lender and collateral agent. The loan and security agreement initially provided for a term A loan facility in the amount of $15.5 million, which was fully funded on the closing date, and a term B loan facility in an amount of at least $3.5 million but no more than $10.0 million, to be available in the future subject to our achievement of certain revenue milestones. We refer to our term A loan facility and our term loan B facility together as our credit facility. In February 2017, we amended the loan and security agreement to, among other things, increase borrowings under the term A loan facility by $1.0 million, increase the minimum amount of the term B loan facility to $5.0 million and reduce the maximum amount of the term B loan facility to $9.0 million. In February 2018, we borrowed an additional $8.0 million under the term B loan facility portion of the credit facility. As of September 30, 2021, we had $24.5 million of outstanding borrowings under our credit facility. No borrowings remain available under this credit facility.
In March 2019, we amended the loan and security agreement. Following such amendment, outstanding borrowings under the credit facility bear interest at an annual rate equal to the sum of (i) the greater of (A) the 30 day U.S.
35

LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (B) 2.50%, plus (ii) 5.10%; provided, however, under no circumstances will the basic rate be less than 7.60%. We are required to make monthly payments of interest only through April 1, 2022. Following the interest-only period, we will be required to make monthly payments of interest and principal in 24 consecutive monthly installments. Outstanding borrowings under the credit facility mature on March 1, 2024. On the maturity date, in addition to our regular monthly payments of principal and accrued interest, we will be required to make a payment of 3.50% of the total amount borrowed under the credit facility, which we refer to as the Final Payment, unless we have already made such payment in connection with an acceleration or prepayment of borrowings under the credit facility.
Borrowings under the facility are pre-payable at our option in whole, but not in part, together with all accrued and unpaid interest thereon and, if not previously made, the Final Payment (as defined in the loan and security agreement), subject to a prepayment fee of 1.0%. We are also required to prepay the amounts outstanding under the credit facility upon the occurrence of certain customary events of default, as well as the occurrence of certain material adverse events. The credit facility also includes certain customary affirmative and negative covenants, but does not include any financial covenants. The credit facility is secured by substantially all of our personal property other than our intellectual property. We were in compliance with all covenants under the credit facility as of September 30, 2021.

Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements, as defined by applicable regulations of the SEC, that are reasonably likely to have a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.
Contractual Obligations and Commitments
There have been no material changes to our contractual obligations and commitments from those described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
Critical Accounting Policies and Estimates
Our critical accounting policies and estimates are described in "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. We have reviewed and determined that those critical accounting policies and estimates remain our critical accounting policies and estimates as of and for the three and nine months ended September 30, 2021.
Recent Accounting Pronouncements
We have reviewed all recently issued standards and have determined that such standards will not have a significant impact on our financial statements or do not otherwise apply to our operations.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk.
Interest Rate Risk
The risk associated with fluctuating interest rates is primarily limited to our cash equivalents which are carried at quoted market prices and our short-term investments. We do not currently use or plan to use financial derivatives in our investment portfolio. The interest rate for our outstanding debt is variable. A hypothetical 1% change in interest rates during any of the periods presented would not have had a material impact on our consolidated financial statements.
36

Credit Risk, Foreign Currency Risk, and Inflation Risk
For market risks related to changes in credit, foreign currency and inflation, reference is made to Item 7A “Quantitative and Qualitative Disclosures About Market Risk” contained in Part II of our Annual Report on Form 10-K for the year ended December 31, 2020. Our exposure to these risks has not materially changed from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Item 4.    Controls and Procedures.
Evaluation of disclosure controls and procedures
The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and other procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our management, with the participation of our chief executive officer and our chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures were effective, at the reasonable assurance level, as of the end of the period covered by this Quarterly Report on Form 10-Q.
Changes in internal control over financial reporting.
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

37

PART II—OTHER INFORMATION

Item 1.    Legal Proceedings.
From time to time we may be involved in claims and proceedings arising in the course of our business. The outcome of any such claims or proceedings, regardless of the merits, is inherently uncertain. We are not party to any material legal proceedings.

Item 1A.    Risk Factors.
For a discussion of our potential risks and uncertainties, see the information in "Part I, Item IA. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020. There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.
None.

Item 3.    Defaults Upon Senior Securities.
None.

Item 4.    Mine Safety Disclosures.
Not applicable.

Item 5.    Other Information.
None.
38

Item 6.    Exhibits.
Exhibit
Number
DescriptionFormFile No.ExhibitFiling
Date
Filed/
Furnished
Herewith
3.1 8-K001-384683.15/7/2018
3.2 8-K001-384683.25/7/2018
31.1 *
31.2 *
32.1 **
32.2 **
101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document*
101.SCHInline XBRL Taxonomy Extension Schema Document*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*
_______________________________________________________________________________
*    Filed herewith.
**    Furnished herewith.

39

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Inspire Medical Systems, Inc.
Date:November 2, 2021By:/s/ TIMOTHY P. HERBERT
Timothy P. Herbert
President, Chief Executive Officer and Director
(principal executive officer)
Date:November 2, 2021By:/s/ RICHARD J. BUCHHOLZ
Richard J. Buchholz
Chief Financial Officer
(principal financial officer and principal accounting officer)

40
EX-31.1 2 a2021-q3ex31x1.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION
I, Timothy P. Herbert, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Inspire Medical Systems, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:November 2, 2021By: /s/ TIMOTHY P. HERBERT
Timothy P. Herbert
 President, Chief Executive Officer and Director
(principal executive officer)


EX-31.2 3 a2021-q3ex31x2.htm EX-31.2 Document

Exhibit 31.2

CERTIFICATION
I, Richard J. Buchholz, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Inspire Medical Systems, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date:November 2, 2021By: /s/ RICHARD J. BUCHHOLZ
Richard J. Buchholz
 Chief Financial Officer
(principal financial officer and principal
accounting officer)


EX-32.1 4 a2021-q3ex32x1.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Inspire Medical Systems, Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:November 2, 2021By: /s/ TIMOTHY P. HERBERT
Timothy P. Herbert
 President, Chief Executive Officer and Director
(principal executive officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

EX-32.2 5 a2021-q3ex32x2.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Inspire Medical Systems, Inc. (the "Company") on Form 10-Q for the quarterly period ended September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date:November 2, 2021By: /s/ RICHARD J. BUCHHOLZ
Richard J. Buchholz
 Chief Financial Officer
(principal financial officer)
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


EX-101.SCH 6 insp-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 2102102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2203201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Summary of Significant Accounting Policies - Follow-On Public Offering (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Summary of Significant Accounting Policies - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Summary of Significant Accounting Policies - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2409405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2410406 - Disclosure - Summary of Significant Accounting Policies - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2411407 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2412408 - Disclosure - Summary of Significant Accounting Policies - Advertising Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2113103 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 2314302 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2415409 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2116104 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2317303 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2418410 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2419411 - Disclosure - Leases - Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2120105 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2321304 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2123106 - Disclosure - Employee Retirement Plan link:presentationLink link:calculationLink link:definitionLink 2124107 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2325305 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2426413 - Disclosure - Stockholders' Equity - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2427414 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense Recognized (Details) link:presentationLink link:calculationLink link:definitionLink 2428415 - Disclosure - Stockholders' Equity - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2429416 - Disclosure - Stockholders' Equity - Assumptions Used to Calculate Fair Value of Options (Details) link:presentationLink link:calculationLink link:definitionLink 2430417 - Disclosure - Stockholders' Equity - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 2431418 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2132108 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2433419 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2134109 - Disclosure - Segment Reporting and Revenue Disaggregation link:presentationLink link:calculationLink link:definitionLink 2335306 - Disclosure - Segment Reporting and Revenue Disaggregation (Tables) link:presentationLink link:calculationLink link:definitionLink 2436420 - Disclosure - Segment Reporting and Revenue Disaggregation (Details) link:presentationLink link:calculationLink link:definitionLink 2137110 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2338307 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2439421 - Disclosure - Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 insp-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 insp-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 insp-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Loss Per Share Earnings Per Share, Policy [Policy Text Block] Leasehold improvements Leasehold Improvements [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net loss Net Income (Loss) Attributable to Parent Entity Emerging Growth Company Entity Emerging Growth Company Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Preferred stock, outstanding (in shares) Preferred Stock, Shares Outstanding Income Statement Location [Axis] Income Statement Location [Axis] Range [Domain] Statistical Measurement [Domain] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Advertising Expenses Marketing and Advertising Expense [Abstract] Schedule of expected future principal payments for the credit facility Schedule of Maturities of Long-term Debt [Table Text Block] Leasehold improvements Leasehold Improvements, Gross Entity Filer Category Entity Filer Category Forfeited /expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Other non-current assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Number of shares available for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Dividend yield Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Retirement Benefits [Abstract] Increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 2023 Long-Term Debt, Maturity, Year Two 2021 (remaining) Long-Term Debt, Maturity, Remainder of Fiscal Year Document Fiscal Year Focus Document Fiscal Year Focus Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Antidilutive securities excluded from computation of diluted weighted average shares outstanding (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of inventory Schedule of Inventory, Current [Table Text Block] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Research and development Research and Development Expense [Member] Sale of Stock [Axis] Sale of Stock [Axis] Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Relationship to Entity [Domain] Title of Individual [Domain] Outstanding, beginning of period Outstanding, end of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Award Type [Domain] Award Type [Domain] Notes payable, non-current portion Notes Payable, Noncurrent Stock options Common stock options Equity Option [Member] Credit Facility [Domain] Credit Facility [Domain] Assets Assets [Abstract] Weighted Average Remaining Contractual Term Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] 2024 Long-Term Debt, Maturity, Year Three Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Exercisable (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Preferred Stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding Preferred Stock, Value, Issued Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Outstanding at beginning of the year (in shares) Outstanding at ending of the year (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Entity Address, City or Town Entity Address, City or Town Accumulated Deficit Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Operating lease sublease land agreement (square feet) Area of Real Estate Property Advertising Expenses Advertising Cost [Policy Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Change in property and equipment acquired but not yet paid Capital Expenditures Incurred but Not yet Paid Property and Equipment Property, Plant and Equipment [Line Items] Percentage of shares to vest Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Short-term Debt Short-term Debt [Member] Entity Interactive Data Current Entity Interactive Data Current Stock-Based Compensation Compensation Related Costs, Policy [Policy Text Block] Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Non-cash lease expense Operating Lease, Expense U.S. government securities US Treasury and Government [Member] Additional borrowing amount under credit facility Line of Credit Facility, Additional Borrowing Capacity The amount of additional borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Unvested at December 31, 2020 (in shares) Unvested at June 30, 2021 (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Document Type Document Type March 2019 Amendment to Loan and Security Agreement March 2019 Amendment To Loan And Security Agreement [Member] March 2019 Amendment To Loan And Security Agreement 2022 Long-Term Debt, Maturity, Year One Prepaid expenses and other current assets Prepaid Expense, Current Restricted Stock Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Entity Current Reporting Status Entity Current Reporting Status Cumulative Effect, Period of Adoption, Adjustment Cumulative Effect, Period of Adoption, Adjustment [Member] Commercial paper Commercial Paper [Member] Operating lease payments Operating Lease, Payments Other, net Other Noncash Income (Expense) Cash equivalents: Cash Equivalents, at Carrying Value [Abstract] Research and Development Research and Development Expense, Policy [Policy Text Block] Plan Name [Axis] Plan Name [Axis] Assets Assets, Fair Value Disclosure [Abstract] Total expected future principal payments Long-term Debt Total cash equivalents and investments Assets, Fair Value Disclosure Level 1 Fair Value, Inputs, Level 1 [Member] Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Document Transition Report Document Transition Report Income Tax Disclosure [Abstract] Computer equipment and software Computer Equipment And Software [Member] Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and Purchased software applications for licensing or long-term internal use. Term A loan facility Term A Loan Facility [Member] Term A Loan Facility Total liabilities and stockholders' equity Liabilities and Equity Other accrued expenses Other Accrued Liabilities, Current Investments, Debt and Equity Securities [Abstract] Vesting after first year of service Share-based Payment Arrangement, Tranche One [Member] Scenario [Axis] Scenario [Axis] Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Additional paid-in capital Additional Paid in Capital Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Supplemental cash flow information Supplemental Cash Flow Elements [Abstract] Liabilities and stockholders' equity Liabilities and Equity [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Loss Per Share Earnings Per Share [Text Block] Operating expenses: Operating Expenses [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Stock options exercised Stock Issued During Period, Value, Stock Options Exercised Minimum Minimum [Member] Realized gains Debt Securities, Available-for-sale, Realized Gain Organization Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Gross profit Gross Profit Outstanding credit facility amount Long-term Line of Credit Effect of exchange rate on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Preferred shares, authorized (in shares) Preferred Stock, Shares Authorized Unrecognized tax benefits Unrecognized Tax Benefits Income Tax Authority [Domain] Income Tax Authority [Domain] Unrealized Gross Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Trading Symbol Trading Symbol Current liabilities: Liabilities, Current [Abstract] Issuance and sale of common stock Stock Issued During Period, Value, New Issues Selling, general and administrative General and Administrative Expense Exercisable (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Stockholders' Equity Share-based Payment Arrangement [Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Accounting Policies [Abstract] Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Issuance and sale of common stock (in shares) Stock Issued During Period, Shares, New Issues Number of reporting segments Number of Reportable Segments Amortization (accretion) of investment premium (discount) Investment Income, Amortization of Discount Operating lease liability Operating lease liability Operating Lease, Liability Common Stock, $0.001 par value per share; 200,000,000 shares authorized; 27,350,959 and 27,069,276 issued and outstanding at September 30, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Amortization (accretion) of investment premium (discount) Investment Income, Amortization of Premium Total other expense Nonoperating Income (Expense) Office Space Sublease Office Space Sublease [Member] Office Space Sublease [Member] Weighted average recognition period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unvested at December 31, 2020 (in dollars per share) Unvested at March 31, 2021 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Expected future principal payments Long-term Debt, Fiscal Year Maturity [Abstract] Leases Lessee, Operating Leases [Text Block] Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Allowance for credit loss Accounts Receivable, Allowance for Credit Loss, Current Summary of weighted average assumptions for fair value of options granted Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Document Period End Date Document Period End Date Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Segment Reporting and Significant Customers Revenues from External Customers and Long-Lived Assets [Line Items] Schedule of revenue by geographic region Revenue from External Customers by Geographic Areas [Table Text Block] Investments Marketable Securities, Policy [Policy Text Block] Entity Registrant Name Entity Registrant Name Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] February 2017 Amendment to Loan and Security Agreement February 2017 Amendment To Loan And Security Agreement [Member] February 2017 Amendment To Loan And Security Agreement Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Proceeds from sale of stock Sale of Stock, Consideration Received on Transaction Increase in interest rate in default Percentage of Increase in Interest Rate In Event of Default The percentage of increase in interest rate, upon the occurrence of an event of default. Financial Instrument [Axis] Financial Instrument [Axis] Accrued expenses Total accrued expenses Accrued Liabilities, Current Revenue Revenue from Contract with Customer, Excluding Assessed Tax Employee Retirement Plan Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block] Significant change to unrecognized tax benefits over the next 12 months Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit Finished goods Inventory, Finished Goods, Net of Reserves Final payment percentage Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage Number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Options Share-based Payment Arrangement, Option [Member] Stock Incentive Plan 2018 Stock Incentive Plan2018 [Member] Represents information pertaining to the 2018 Stock Incentive Plan ("the 2018 Plan"). Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Common Stock Common Stock [Member] Interest income Investment Income, Interest Segment Reporting and Revenue Disaggregation Segment Reporting Disclosure [Text Block] Operating loss Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Current operating lease liability Operating Lease, Liability, Current Unrealized Gross Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Long-term Debt Long-term Debt [Member] Additional Paid-In Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Investments: Short-term Investments [Abstract] Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Schedule of restricted stock units activity Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Other expense (income), net Other Nonoperating Income (Expense) Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] U.S. government securities US Government Debt Securities [Member] Total liabilities Liabilities Raw materials Inventory, Raw Materials, Net of Reserves Follow-on Offering Follow-on Offering [Member] Follow-on Offering Schedule of accrued expenses Schedule of Accrued Liabilities [Table Text Block] Accounts receivable Increase (Decrease) in Receivables Award Type [Axis] Award Type [Axis] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Total stockholders' equity Stockholders' Equity Attributable to Parent Net operating loss carryforwards Operating Loss Carryforwards Common stock, issued (in shares) Common Stock, Shares, Issued Preferred shares, issued (in shares) Preferred Stock, Shares Issued Employee Stock Purchase Plan Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan Estimated useful lives Property, Plant and Equipment, Useful Life Current portion of notes payable Notes Payable, Current Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Operating lease liability, non-current portion Operating Lease, Liability, Noncurrent Fair Value, Measurement Frequency [Domain] Measurement Frequency [Domain] Interest expense Interest Expense Variable interest rate Debt Instrument, Interest Rate, Variable Rate Debt Instrument, Interest Rate, Variable Rate City Area Code City Area Code Weighted average fair value (in dollars per share) Share Price Accumulated deficit Retained Earnings (Accumulated Deficit) Contractual life of stock options Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Restricted stock units Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Issuance of common stock for employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Remaining lease term Lessee, Operating Lease, Remaining Lease Term Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Vesting in years two through four Share-based Payment Arrangement, Tranche Two [Member] Income Statement [Abstract] Amendment Flag Amendment Flag Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Investments, short-term Short-term Investments Forfeited/expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Beginning balance Ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Income taxes Income tax expense Income Tax Expense (Benefit) Accounts receivable, net of allowance for credit losses of $95 and $42, respectively Accounts Receivable, after Allowance for Credit Loss, Current Equity Components [Axis] Equity Components [Axis] Term loan facility Term Loan Facility [Member] Represents the information pertaining to term A loan facility. Short-term investments available-for-sale Cash, Cash Equivalents and Investments [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Investment Type [Axis] Investment Type [Axis] Total current assets Assets, Current Sale of Stock [Domain] Sale of Stock [Domain] Inventories Total inventories, net of reserves Inventory, Net Operating lease income Operating Lease, Lease Income, Lease Payments Entity File Number Entity File Number Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Unvested at December 31, 2020 Unvested at June 30, 2021 Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Unearned stock-based compensation Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Proceeds from issuance of common stock from employee stock purchase plan Proceeds from Issuance of Common Stock from Employee Stock Purchase Plan Proceeds from Issuance of Common Stock from Employee Stock Purchase Plan Entity Small Business Entity Small Business Lease Balances within the Balance Sheets Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Preferred shares, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Equity Component [Domain] Equity Component [Domain] Statement [Line Items] Statement [Line Items] Right-of-use assets: Right-of-Use Assets [Abstract] Right-of-Use Assets Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Investments with maturity greater than one year Debt Securities, Available-for-sale, Noncurrent Purchases of investments Payments to Acquire Investments Federal Domestic Tax Authority [Member] Total investments Fair Value Debt Securities, Available-for-sale Proceeds from sales or maturities of investments Proceeds from Sale, Maturity and Collection of Investments Entity Address, State or Province Entity Address, State or Province Employee stock purchase plan, percent Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Accounts Receivable and Allowance for Expected Credit Losses Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Level 2 Fair Value, Inputs, Level 2 [Member] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Segment Reporting [Abstract] Cost Debt Securities, Available-for-sale, Amortized Cost Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Entity Shell Company Entity Shell Company Local Phone Number Local Phone Number Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of stock-based compensation expense recognized Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Forecast Forecast [Member] Vesting [Axis] Vesting [Axis] Proceeds from the sale of common stock Proceeds from Issuance of Common Stock Total assets Assets Directors Director [Member] Plan Name [Domain] Plan Name [Domain] Common stock, authorized (in shares) Common Stock, Shares Authorized Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Geographical [Domain] Geographical [Domain] Title of Individual [Axis] Title of Individual [Axis] Research and development Research and Development Expense Depreciation and amortization expenses Depreciation, Depletion and Amortization, Nonproduction Renewal term Lessee, Operating Lease, Renewal Term Stock Options Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Prepayment fee Percentage of Prepayment Fee The percentage of prepayment on borrowings. Other equipment Other Machinery and Equipment [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Credit carryforwards Tax Credit Carryforward, Amount Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Tax Identification Number Entity Tax Identification Number Corporate bonds Corporate Bond Securities [Member] Geographical [Axis] Geographical [Axis] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Weighted average common shares used to compute net loss per share, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted State State and Local Jurisdiction [Member] Sale of stock, price per share (in dollars per share) Sale of Stock, Price Per Share Vesting [Domain] Vesting [Domain] Accounting Standards Update [Extensible List] Accounting Standards Update [Extensible Enumeration] Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Unrealized gain (loss) on investments Unrealized Gain (Loss) on Investments Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Number of additional shares reserved for issuance, maximum (in shares) Common Stock, Capital Shares Reserved for Future Issuance, Additional Shares Reserved, Maximum Common Stock, Capital Shares Reserved for Future Issuance, Additional Shares Reserved, Maximum Corporate bonds Corporate Debt Securities [Member] Depreciation and amortization Depreciation, Depletion and Amortization Payroll related Accrued Salaries, Current Schedule of assets and liabilities measured at fair value on a recurring basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Long-term Debt, by Current and Noncurrent [Abstract] Cost of goods sold Cost of Goods and Service Benchmark [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Inventories Increase (Decrease) in Inventories Common stock, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Investments, long-term Long-term Investments Financial Instruments [Domain] Financial Instruments [Domain] Cost of goods sold Cost of Goods and Services Sold Loss Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Unrecognized loss (gain) in accumulated other comprehensive loss (income), less than OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Schedule of property and equipment Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Stockholders' equity: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Total operating expenses Operating Expenses Other non-current liability Other Liabilities, Noncurrent Earnings Per Share [Abstract] Property and equipment, cost Property, Plant and Equipment, Gross Document Quarterly Report Document Quarterly Report Manufacturing equipment Equipment [Member] Operating lease liabilities: Operating Lease, Liability [Abstract] Line of Credit Facility [Table] Line of Credit Facility [Table] Outstanding, beginning of the period (in dollars per share) Outstanding, end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Total stock-based compensation expense Share-based Payment Arrangement, Expense Cost of Goods Sold Cost of Goods and Service [Policy Text Block] Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Europe Europe [Member] R&D credit Research Tax Credit Carryforward [Member] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Non-cash stock issuance for services rendered Share-based Compensation, Noncash, Services Share-based Compensation, Noncash, Services Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Investments [Domain] Investments [Domain] Accretion of debt discount Amortization of Debt Issuance Costs Reserve for excess and obsolete inventory Inventory Valuation Reserves Construction in process Construction in Progress [Member] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] United States UNITED STATES Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Current assets: Assets, Current [Abstract] Number of shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Leases [Abstract] Entity Central Index Key Entity Central Index Key Income Taxes Income Tax, Policy [Policy Text Block] Impairment of Long-lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Security Exchange Name Security Exchange Name Total cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Stock options exercised (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Weighted average common shares used to compute net loss per share, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Recurring basis Fair Value, Recurring [Member] Income Taxes Income Tax Disclosure [Text Block] Service period Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period Interest Interest Payable, Current Current Fiscal Year End Date Current Fiscal Year End Date Summary of the company's stock option activity and related information Share-based Payment Arrangement, Option, Activity [Table Text Block] Variable interest rate on credit facility Debt Instrument, Basis Spread on Variable Rate Term B loan facility Term B Loan Facility [Member] Represents the information pertaining to term B loan facility. Schedule of dilutive securities excluded from computations of diluted weighted average shares outstanding Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Statement of Cash Flows [Abstract] Other expense (income): Nonoperating Income (Expense) [Abstract] Discount rate Lessee, Operating Lease, Discount Rate Incentive from landlord, rent abatement Incentive from Lessor, Rent Abatement Incentive from Lessor, Rent Abatement Credit Facility [Axis] Credit Facility [Axis] Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Issuance of common stock for employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Basic interest rate Debt Instrument, Interest Rate During Period Selling, general and administrative General and Administrative Expense [Member] Expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Employee stock purchase plan Employee Stock [Member] Allowance for credit loss Investments, Allowance for Credit Loss Investments, Allowance for Credit Loss Stock-based compensation expense APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Maximum borrowing amount under credit facility Line of Credit Facility, Maximum Borrowing Capacity Money market funds Money Market Funds [Member] Accounts payable Accounts Payable, Trade, Current Entity Address, Postal Zip Code Entity Address, Postal Zip Code Credit Facility Line of Credit Facility [Line Items] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Title of 12(b) Security Title of 12(b) Security Statement [Table] Statement [Table] Advertising expenses Advertising Expense Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Weighted average assumptions Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Range [Axis] Statistical Measurement [Axis] Cover [Abstract] Incentive from landlord, refurbishment allowance, maximum Incentive from Lessor, Refurbishment Allowance, Maximum Incentive from Lessor, Refurbishment Allowance, Maximum Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercisable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercisable Inventories Inventory, Policy [Policy Text Block] Scenario [Domain] Scenario [Domain] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Number of additional shares reserved for issuance, percentage, maximum Common Stock, Capital Shares Reserved for Future Issuance, Additional Shares Reserved, Percentage, Maximum Common Stock, Capital Shares Reserved for Future Issuance, Additional Shares Reserved, Percentage, Maximum Long-Term Debt Long-term Debt [Text Block] Adjustments to reconcile net loss: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Accounting Standards Update 2016-13 [Member] EX-101.PRE 10 insp-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 insp-20210930_g1.jpg begin 644 insp-20210930_g1.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_X1#X17AI9@ 34T *@ @ ! $[ ( M / (2H=I 0 ! (6IR= $ > 0TNH< < @, /@ M &UL;G,Z9&,] M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT'!A8VME="!E;F0])W7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C) MRM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! 0$! M 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" Q$$ M!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF)R@I M*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#Z1HHHH **** " MBBB@ HHHH **** "BBB@ HJ"ZO;6QC\R]N8;=/[TT@0?F:P;KXC^"K-BMSXK MT=&'4?;8R?T--)O8#I:*Y)?BKX#9L#Q;I.?>Z45JV/B[PYJ9 T[7],NF/18; MR-C^0-/EDN@&Q10#D9'(HJ0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **:[K'&SR$*J@EB>PKD_\ A:_@+_H;=)_\"5II-[ ==17(_P#"U_ 7 M_0VZ3_X$K1_PM?P%_P!#;I/_ ($K3Y)=@.NHKD?^%K^ O^AMTG_P)6M[1=>T MKQ%8&]T*_@O[4.8S-;N&7<,9&1WY%)Q:W0&A1112 **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH *R=6\5>']";;K6MZ?8/_6> M1I9'.6=V)9CZDGK773PSDKRT)(--O)3TCAND9C^ .: MVZ_.,$JP*D@@Y!':O:_A#\=]3\/ZE;:+XNO)+W1IF$:W,S;I+0G@'<>2GJ#T M'3T-5,*TKQ=P4CZQHI%8.H92&4C((/!%+7$4%%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !4%[?6NFV)_#KAM$UZ_LPO\ !'.VP_53P?RKU7PM^U!XCTYDA\46%OJ\'1IH MAY,P]^/E/Y#ZUX=16);.QFFC_ -Y4)'ZXK:K)\5:0=?\ M"&KZ0N U]9RP*3V+(0/U-.-KZ@?GT[O+(TDC%G8EF8G))/4TE27%O+:74MO< MQM'-"YCD1A@JP."#^-1U[AD%%%%,#[@^"FM3:[\']"N;ER\T436S,3DGRV*# M_P = KO*XGX/Z!-X;^$VAV%VACN# 9Y4/53(Q?!]P& _"NVKQ)VYW8U"BBBH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ KQSXT_&N/P5$^@^&W2;7I%_>2<,MFI'4CNY[#MU/8'<^ M,OQ/B^'?A?;9,CZW? I9QGGRQWE8>@[>I_&OB^ZNI[Z[ENKR9Y[B9S))+(V6 M=B'H\_O2V);%N[NXO[R6[OIY+BXFM0T45Z9 4444 M %%%% !1110 4444 %%%% '<_#'XIZO\.-8#V[-=:5,P^UV#-\KC^\O]UQZ] M^AK[/\.>(],\5Z#;:QH=RMQ9W"Y5AP5/=6'9@>"*_/>O1?@[\4+CX=^)0ET[ MR:'>N%O(1SL["51ZCOZCCTKDKT>=\_ZX/_ .@FOSLK M]$]4_P"0/>?]<'_]!-?G97?@^I,A:***[R KZ[_9C_Y)))_V$IO_ $%*^1*^ MN_V8_P#DDDG_ &$IO_04KEQ7\,J.Y[#1117EEA1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% '@GQI^!$_B/4)O$W@U$.H2_-=V)(43M M_?0G@-Z@]>O7K\TZGI&HZ+>-:ZO8W%E.AP8[B(HP_ U^B-17%I;W<>R[MXIT M_NRH&'ZUU4\3*"L]26C\[[.RNM0N5M["VFNIF.%CAC+L?H!S7OOPA_9]OCJ= MMK_CNW^S6\#"2#37Y>5AR#(/X5']WJ>^!U^D;:QM+)2+.UAMP>HBC"_RJ>G4 MQ4I*RT#E"BBBN0H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ JIJFIVNC:3=:EJ,HAM;2)II7/\*J,F MK=>"_M0>,C8>'['PK9R;9=1;[1=8/(A0_*OXMS_P"KIPYY*(F?/_ (\\8WGC MKQC>ZY?$J)FVP1$\0Q#[J#\.OJ237.T45[222LB HHHIB"BBB@ HHHH **** M "BBB@ HHHH **** /IO]F?XAM>V,O@O5)MTUJIFT]F/+1_Q1_\ 2 ZJ?8C(/UKZ%?]K#3@WR>%+HKZF\4? M^RUYU>A)SO!%IGT'17@]E^U7X=E<#4- U*W!ZM$\U9G_ DV@_\ 0;T[_P "X_\ &K6J?\@B\_ZX/_Z":_.R MN.C1]K?4INQ^A/\ PDV@_P#0;T[_ ,"X_P#&C_A)M!_Z#>G?^!9(H-7L))'(5$2Y0EB>P /-:-?!/PU_P"2I>&?^PI;_P#H MP5]TZQK&GZ!I,^IZQ=1VEG;KNDED. !_4^@')KFK4O9M):C3N7:P]?\ &GAO MPLF?$&M6=@<9$>6YG>:YE>:5SEY)&+,Q]23UK6GA6]9:"YCZ^U#]I7P!9N5MY=0O ML?Q6]K@'_OLK6:O[4W@XM@Z5K('KY47_ ,77RA171]5IBYF?96E?M%?#W4I% M274+G3V;I]KMF _-=P%>B:3K>EZ]9B[T74+:_MS_ ,M+:57 ]CCH:_/&M#1= M?U;PYJ*7^A:A<6%RG22!RN?8CH1['BHEA(_98*?"+X]P>+IX="\6" M*TUAOE@N%^6*[/IC^%_;H>V.E>UUPSA*#LRPHHHJ "BHYYX;6WDGN94AAB4N M\DC!511U))Z"OGOXB_M,+;S2Z;\/XDF925;4YURN?^F:'K_O-Q['K6D*:0S))X@CNI%_ALXGF_\ M> V_K7QQKOB76O$UX;K7]4NM0F)R#/(6"_0=%'L *S*[(X1?:8N8^M+C]J+P M3$V(++6)_<0(H/YO4-F1U.0RG!!J)82/1AS'Z-T5\:>!OC[XM\)2QP:A<-KFFJ0&@NW)D M4?[$G4?0Y'M7U-X(\>Z'X_T4:AH-QN*X$]M)Q+ WHP_D1P:Y*E&5/?8I.YTM M%%%8C*UYJ5CIRHVH7EO:JYPIGE5-Q]LGFJG_ DV@_\ 0;T[_P "X_\ &O$O MVK_^0#X<_P"OF;_T%:^8ZZZ6'4X\UR6['Z$_\)-H/_0;T[_P+C_QH_X2;0?^ M@WIW_@7'_C7Y[45K]37<.8_12SU&RU%6;3[RWNE0X8P2JX4^^#5FO ?V4?\ MD6_$/_7W%_Z :]*^(OQ1T+X<::)-2PB8>9)[G^ZON?PS7)*FU/D6 MH[Z'9DA5)8X &23VKBM?^,7@3PW(T6H>(;:2=>##:9G8'T.P$#\2*^4O'/Q> M\5^.YI$O[YK33R?EL+5BD8'^UW<_7\ *X:NJ&$_F8N8^M+G]J+P3%)M@L=8N M!_>6!%'ZO3[7]J#P1.P6XM=7MO\ ::W1@/\ OER:^2**U^JTQ<_#/XS:'\1(EM#C3M:5C5Q2BXNS*"BBBI SI?$.BP3/%/J]A'(A*NCW* J?0@GB MF?\ "3:#_P!!O3O_ +C_P :^'OB7_R5/Q-_V%+C_P!&&N7KNCA$U>Y/,?H3 M_P )-H/_ $&]._\ N/_ !I?^$FT'_H-Z=_X%Q_XU^>M.3_6+]:KZFNX]N(K>)2 9)7"*,^YI;3_ (\X?^N:_P J\S_:+_Y(MJ7_ M %WM_P#T:M<,8\TE$H[W_A)M!_Z#>G?^!N3RV/@TOI&FY*_:N,C[3.J$_0$Y-<=>?'KX<6;%6\1+,1_SPMI M7'YA<5\6W-U<7EP]Q>3R7$SG+R2N69C[D\FHJ[(X2/5D\Q^B.DZG:ZUH]IJ> MGN7M;R%9H692I*L,@X/3@U;KF/AI_P DM\,_]@NW_P#18KIZ\^2LVBPHHKSC MXB_&SPYX WV>[^T]8 XLK=A^[/\ TT;HOTY/M3C%R=D!Z/7.Z[\0/"?AIBNN M>(+"TD7K$9@T@_X N6_2OD7QC\:_&?C%Y(Y]2;3K%N!9V!,2X]&;[S?B<>U> M?DDDDG)/4GO79'"/[3)YC[#OOVD_A]:,5@N-0O<=[>T(!_[[*UEG]J;P>&P- M*UDCU\J+_P"+KY0HK986F+F9]>6?[37@.X8"==4M/4RVH8#_ +Y8FNOT7XL^ M!?$#JFG>);+S6Z1SN8&/MAP,U\*45+PD'LPYF?HVK*ZAD(92,@@Y!I:^"_"G MQ)\5^"YE.@ZQ/' IR;65O,A;_@!X'U&#[U]'?#G]HG1?%,L6F^)XX]%U-R%2 M0M_H\S>@8_/>N:IAYPU6I29[-11UZ45S#"BBB@ HHHH **** "OAGXP^ M(SXH^*VM7BOO@AF-K!Z!(_EX^I!/XU]J>)-3&B^%M4U,G'V.SEG'U5"1_*O@ M+3=,U+Q#J\=EI=K-?7UR_P L42[F8GJ?ZD]!7;A$KN3)D4J ,G Y-?2O@;]F M"VCBCO/'EZTLIY_L^S?:J^SR=3_P''U->TZ'X'\,>&HU30]"L;,K_P M$A!< M_5SEC^)K:>*A'1:BY3X2MO#NMWB[K31]0G7UBM78?H*DE\*^(8%)GT'4XP.I M>SD']*_0>BLOKC[#Y3\YI8)8'VSQ/$WHZD']:97Z*7>GV=_&8[ZT@N4/59H@ MX/X$5QVM?!CP!KH8W7ANU@D;_EI9@P,#Z_)@?F*I8M=4+E/ARBOICQ%^RK92 MAY/"NO36[=5@OT#K]-ZX(_(UXSXT^%'BSP'%]HUW3P;(OL%Y;N)(LGH">JY] MP*Z(5H3V8K,XVBBBMA!1110 4444 %%%% !1110 4444 =7X.^)?BGP-<*VA M:G(MN#EK.8^9 _\ P ]/J,'WKZ@^&?QST/QX8].O@NE:V1@6TCYCG/\ TS8] M3_LGGZ]:^-*5':.17C8JZG*LIP0?45A4HQJ>HT['Z-T5X)\#?C<^NO!X6\7W M&=1QMLKUS_Q\_P"PY_O^A_B^O7WNO+G!P=F:;A1114 %%%% %75/^0/>?]<' M_P#037YV5^B>J?\ ('O/^N#_ /H)K\[*[\'U)D+1117>0%?7?[,?_)))/^PE M-_Z"E?(E?7?[,?\ R223_L)3?^@I7+BOX94=SU?5/^01>?\ 7!__ $$U^=E? MHGJG_((O/^N#_P#H)K\[*RP?4Y->9JS(P9"5(Z$'%)6;@ MG+F8PHJ[I>C:GK=T+;1M/NK^<_\ +.VA:1OR KLK;X&_$:ZC#IX9G0'H)9HD M/Y%LU3G%;L#@**Z[5_A3XZT.!IM1\,7ZQ*,M)$@E51ZDH3BN1((.",$=10I) M[, HHHJA"H[1R*\;%74Y5E."#ZBOLWX&?$=O'G@TP:G+OUC3-L5R2>9E(^23 M\<$'W!]:^,:]$^!?BA_#'Q7TS=)MM=1;[#.">"'/RG\'"_K7/7I\\/-%)GVQ M117!?&CQ7)X0^%NI7EJ_EWER!:6S \J\G!(]PNX_A7EQBY.R+/"?CS\7)O$^ ML3^&=!N&31;.39.\;?\ 'W(#SSW0'H.Y&?2O%J**]F$%"-D9A117H/PP^$.L M?$FXDGAD6PTF!]DU[(F[+?W47^)L>X _2G*2BKL#SZBOL'2OV;/ -A JWT-[ MJ4H'S23W)3)^B;:MW?[.WPZNHBL>E7%JQZ/#>29'_?1(_2N;ZU3'RL^,Z*]K M^)G[.]]X3TV?6?"]W)JFG0*7G@E4">%1U;CAP.^ "/0UXI71"<9J\1!6]X,\ M8ZIX&\2V^LZ-*5DC.)8B?DGC[HP]#^AP:P:*II-68'Z"^%?$MCXO\,66N:4^ MZWNX]P4GF-NC(?<$$?A6O7S3^RSXL>/4-4\*7,F8I4^VVH)Z,,*X'U!4_P# M37TM7C58)=2E59KV:\CBLK8G_62>6>3_ +(Z MG\NXKR/6];U'Q'K-QJNLW+W5Y+8$N;#2&M;1QE;F^;R58>H!^8CW -=S#^RIXE:,&?7M*C?NJ MB1@/QVBE*M3CHV%F>%45[!K/[,_CC386EL&T_50HSLMYRCG\' 'ZUY7JNCZC MH6H/8ZS8W%C=1_>AGC*,/?GJ/>JC4C+X6!3HHHJQ$MK=3V5W%=6H_B'OGOQ\=5I>'=?O MO"_B*RUG29?+NK.42(>S>JGV(R#[&L:U)5(^8T['Z%45D>%?$5IXM\+6&N:< M?W%Y"'"YR4;HRGW!!'X5KUY#5G9FA\%?$O\ Y*GXF_["EQ_Z,-IH] MCXTHHHKVC,*]L_9;D2+XB:M)*RHB:0[,S' $L>237B=:^A^)+SP_9ZO#I[; M&U2S-E)(#@K&75F ^H7'T)K.I%RBXH:.V^-'Q3G\?^(VM-/E9-!L7*VT8.!. MPX,K?7MZ#W)KS*BBJC%05D 44450C[U^&G_)+?#/_8+M_P#T6*Z>N8^&G_)+ M?#/_ &"[?_T6*XGX^?$]O!?AU=&T:;9K6IH<.IYMX>A?V)Z#\3VKQ>5SGRHT MZ'-?&OX[/I]6[=!SR/F:21Y9&DE9G=R69F M.2Q/4DTA)8DL7+\D+PJ M+_>9CPH]S6C:2NP,FBOICPO^RO91P)+XOUJ::8C+6^G@(B^V]@2?R%=BG[.7 MPZ6/:VF73G'WVO9,_H<5S/%4TQ\K/C:BOJW6_P!ESPK>0L=#U+4--FQ\OF,) MX_Q! /\ X]7@WC_X5^(_AWZM['\,UI"M";LA69Q M=%%%;"/>?@A\<)M)N;?PQXPN3+ITA$=G>RMDVQZ!&/=.P/\ #].GU'G/2OSC MKZU_9V^([^)_#3^'=6F+ZEI*#RGALXVEN+B!;>.-!DNTCJ@ ^NZJ?PF^%U MA\.O#R>9''-K5R@-Y=8R0>OEJ>RC]3SZ8Y2[^)FNW8421V05760+Y).&4Y!Y M/8@&IXOBOKZ']Y%92#T,;#^35Z7]BXQ0Y5;[R/:1N>R45Y=:?&"4$"_TE&'= MH)'=0(22Y>SD/\ #&]\_ZX M/_Z":_.ROT3U3_D#WG_7!_\ T$U^=E=^#ZDR%HHHKO("OKO]F/\ Y)))_P!A M*;_T%*^1*^N_V8_^222?]A*;_P!!2N7%?PRH[GJ^J?\ ((O/^N#_ /H)K\[* M_1/5/^01>?\ 7!__ $$U^=E98/J.0M%%%=Y 5ZA\&OA#-\1=1>^U-I+;0;1P MLLB<-1@JJ.Y/ %??O@GPS;^#_ 7IFAVJ M@"U@ D8#[\AY=OQ8DUS8BJX1LMV4ETG=7,PJ2V MN)+2[AN83MDA=9$([$'(_E4=% C]$]-O%U#2K2]3[MS"DH^C*#_6O"?VK[MT M\.^';0$[);J64CW1 !_Z&:]<^'DQN/AGX;D;JVEV^?\ OVM>1?M7VS/X?\.W M0'RQ74T9/NR*1_Z :\JBK5DC1['S'1117K&85]V?";3[;3/A-X=QO8_FQKX3KWSX,_'JR\-:+!X:\8"1;.W)6UOHU+^4I.=CJ.<#)P1GTQ M7+B82E'W2D?4%%9.B^*M!\1PB70M8LK]2,X@F5F'U7J/Q%:U>8TUN6(RAU*N M RL,$$<$5\1?$KX>:EH'Q&UBPTC2+V:P$_F6S06SNH1P&"@@8XSC\*^WJ*UI M573=T)JY^?'_ BWB#_H!:G_ . (/\ H!:G_P" T+XMZ!>2Z1J,,+7'DRN]JZJ%D4H06!ZOWY^[]: M\D^ G@U/%WQ,MWO(Q)8Z6GVR92.'8$!%/U8@X]%-?:%<.)JM>XBXH****\\H M*YSQKX$T/Q[HCZ?KMJKD ^1O?#PZU!&#?:*WF[@.6A8@.OX M<-_P$^M?(=>O1J>TA%;F3/EXO;4$] 2%D _'8 M?Q-?15?$'P2UIM#^,&A2[ML=S,;23W$@*C_QXJ?PK[?KRL3'EJ7[FD=CX*^) M?_)4_$W_ &%+C_T8:YBNG^)?_)4_$W_84N/_ $8:YBO2A\*("E3_ %B_44E* MG^L7ZBK$?HM:?\>+2_B+U-'L?&E%%%>T9A1110 %B HR3P .]>H> M$/V?_&GBF&.ZN+>/1K-QE9;\E78>HC'S?GBO7O@9\&K30-*MO$WB6U6;6+E1 M+;0RKD6:'D'!_C(YSVZ=!Z7^RGHD2*=9\17UR_P#$+:)( M5_7<:WXOV9_ $:X==3E/J]WC^2BO7:*Y76J/J.R,RTMM/\*>%XK>-C#IVEVH M4-(V2D<:]2>_ KX5\<>*KGQIXSU'7;LL/M,I\I"?]7$.$7\!C\X5TWPZ\52>"_'^EZTC$113!+@#^*%N''Y'/U KF:*T:35F!^C:.LD:O M&P96 *D="*6N+^$.MGQ!\)= O9'WRK;"WD/?=&2G/_?.?QKM*\.2L[&@5PWC MCQ\NB%M.TDK)?X^>0\K!_BWMVK6\;^)!X;T%I(2/MDY\NW!['NWX#^E>$N[R MR-)*Q=W)9F8Y))ZDU]#D^6QK_OZJ]U;+O_P#*I.VB'W-U/>7+W%W,\TTARTC MMDFHJ**^U225D&IEB8M3\UNQ^[[H>Q]NAKVC2]5L]9T^.\T^82PR# MJ.JGN".QKXG'9=5POVLM KEK>< M_9UR^Z-_9'/*G_>R/<5\W7UC=:9?SV.H6\EM= M6[F.6&1<,C#J"*[J=6-1>Z3:Q!1116H@HHHH **** "BBB@#[R^&6NMXE^&6 M@ZI(VZ66T5)6SU=/D8_FIKJJ\B_9HNVN/A"L3'/V:_FC'L#M?^;&O7:\2HN6 M;1HM@HHHJ!E75/\ D#WG_7!__037YV5^B>J?\@>\_P"N#_\ H)K\[*[\'U)D M+1117>0%?7?[,?\ R223_L)3?^@I7R)7UW^S'_R223_L)3?^@I7+BOX94=SU M?5/^01>?]<'_ /037YV5^B>J?\@B\_ZX/_Z":_.RLL'U'(6BBBN\@Z#P!;+= M_$?PY!(,K)J=N&![CS%K[\KX*^&O_)4O#/\ V%+?_P!&"OO6O.Q?Q(N(4445 MQ%!1110!\2_'A0OQL\08&,O$?_(*5Y[7H?QY_P"2VZ__ +\/_HE*\\KVJ?P+ MT,PHHHK01]Z_#3_DEOAG_L%V_P#Z+%<_\>/#,GB;X3:@MLADN=/9;V)0,D[, M[A_WP6KH/AI_R2WPS_V"[?\ ]%BNF90RE6 92,$$=:\7F<9W7"M9FUG1;=I?#UTY8%!G[&Q/W&]%S]T_AUZ^2UZ\)J:NB HHHJQ#HY' MBD#Q.R.O(93@C\:Z33?B1XST@!=/\3ZI$@Z(;EG4?\!8D5S-%2XI[C/4],_: M+^(6G[1/J%KJ"CM=6J\_BFTUW&B_M72!E3Q%X:4C^*6QGQ_XX_\ \57SI16< MJ%-] NS[<\,?&[P+XI=(;;6%L;E^!;Z@ODL3Z!C\I_ UWX(905(((R".]?G) M7?\ @#XQ^)_ 4\<5OA8=9+V=C]<@?TKUJO&K.]1FBV"BBBLA MA1110!2UK3H]7T&_TV8 QWEM) P/HRD?UK\\I8VAF>)QAD8JP]Q7Z-5^>WB: M,0^+=7C7HE],H_"0UW8-ZM$R,RBBBO0(+NBW;:?KVGWB'#6]S'*#[JP/]*_0 MX$,H(Y!&17YR X((K]%;(DZ?;D]3$O\ *N#&="XGPC\2_P#DJ?B;_L*7'_HP MUS%=/\2_^2I^)O\ L*7'_HPUS%=D/A1(4J?ZQ?J*2E3_ %B_458C]%K3_CSA M_P"N:_RKS/\ :+_Y(MJ7_7>W_P#1JUZ9:?\ 'G#_ -BZ6F/QEDKQ*O7H*U- M&;W"BBBMQ'?_ _^,.N?#C2;FPT2QT^9+F;SI)+F-V;.T#'##CC]376?\-2^ M,_\ H&:+_P!^9?\ XY7BE%9.E"3NT.[/:_\ AJ7QG_T#-%_[\R__ !RC_AJ7 MQG_T#-%_[\R__'*\4HI>PI]@NSVO_AJ7QG_T#-%_[\R__'*/^&I?&?\ T#-% M_P"_,O\ \A>/_C+KWQ%T.#2]:LM/AA@N!<(]M&ZMN"LN.6/ M&&->>T45I&*BK( HHHJA'UO^S!>FX^%MS;L<_9=2D4>P*(W\R:]EKPC]E,G_ M (0O6QV&H*?_ "&*]WKQZVE1FBV/$OB3JS:CXOE@#9ALE$*C_:ZL?SX_"N1J MSJ4YNM5NYW.3+.[G\6)JM7Z3AJ2HT8TUT1QMW=PHHHKH$%%%% !1110 4444 M %;GA;Q1=>&-3$T.9+:0@3P9X<>H]".QK#HK.I3A5@X35TQIM.Z/I+3[^VU2 MPAO+*0203+N5A_+ZU9KQGX<^*CH^J#3;R3_0KML*2>(I#T/T/0_A7LU?G>/P M*M'UFWC5)M0@>.? M'\;1E<,??#X_ 5]25\H_M1ZXE]X^T_28FR--L\R>SR'./^^50_C73AK^T5A/ M8\1HHHKU3,**** "BBB@ HHHH ^N/V8(F3X43NW234Y2/^^$']*]DKS[X&:0 MVC_!O0XY%VR7,;739_Z:,67_ ,=*UZ#7BU7>;9HM@HHHK,95U3_D#WG_ %P? M_P!!-?G97Z)ZI_R![S_K@_\ Z":_.RN_!]29"T445WD!7UW^S'_R223_ +"4 MW_H*5\B5]=_LQ_\ )))/^PE-_P"@I7+BOX94=SU?5/\ D$7G_7!__037YV5^ MB>J?\@B\_P"N#_\ H)K\[*RP?4?^2VZ_\ [\/_ M *)2O/*]#^//_);=?_WX?_1*5YY7M4_@7H9A1116@C[U^&G_ "2WPS_V"[?_ M -%BNGKF/AI_R2WPS_V"[?\ ]%BNGKPY?$S4CG@BNK>2"YB2:&12KQR*&5@> MH(/45X?XX_9ET?5Y)+WP==C1[AN3:2@O;L?;^)/U'L*]THIPG*#O%@?#?B/X M-^.O##.;W09[F!?^7BR'GH1Z_+R/Q KB)(WBD*2HR.IP588(_"OT;K,U7PUH M>N*5UG1[&_!_Y^;='/YD5UQQ;^TB>4_/:BOM;4O@)\.M2R3H(M7/\5K/)'C\ M,X_2N/U?]E;P[J^+?V>/&?AJ M&2ZL8H=;M$&2UEGS /4QGD_\!S7E;*R,5<%64X((P0:WC.,U>+$)1115B.X^ M$GCV?P#X[M;QI&&G73""_CSP8R?O8]5)R/Q'>ON-6#J&4AE(R"#U%?G)7W;\ M*-7?7/A/X>O9FWR&S6)V/OZ$[8=7CO(USU!&QS^&$_.OHFO'K*U1FBV"BBB ML1A1110 5^>>OSBZ\2ZG<*J[OM-]#$1[%P#^E?H)7GXQZI%Q/@KXE_P#)4_$W_84N/_1A MKF*Z?XE_\E3\3?\ 84N/_1AKF*[8?"B0I4_UB_44E*G^L7ZBK$?HM:?\>9_M%_\D6U+_KO;_\ HU:],M/^/.'_ *YK_*O,_P!HO_DBVI?]=[?_ M -&K7BTOXB]31['QI1117M&85[=^RQ_R4C5/^P4__HV.O$:]N_98_P"2D:I_ MV"G_ /1L=8U_X;&MSZNHHHKQS0**** /E']J>)E^(^F2G[KZ6H'X2R?XUXC7 MT9^U?IC>9X&?A5XP\8:/_ M &IX>TH7=GYC1>9]HC3YAC(PS ]Q6O\ \*!^)'_0O_\ DW#_ /%UZ_\ LK:J ML_@K6-++#?:7PF _V9$ _FAKW:N"IB)PFXEI(^*O^% _$C_H7_\ R;A_^+H_ MX4#\2/\ H7__ ";A_P#BZ^U:*S^MS[(.5'Q5_P *!^)'_0O_ /DW#_\ %T?\ M*!^)'_0O_P#DW#_\77VK11];GV0);'['-<78DC7S4?,KLA<171^T1G'7=U_\ M>S7,5^GX>HJM&-1=4CB:L[!1116P@HHHH **** "BBB@ HHHH *]T\ ^(#KW MAJ,SONNK4^3-GJ<#AOQ'Z@UX778?#/5SIWBQ+9VQ#?+Y1'^T.5/\Q^->1F^% M5?"MK>.J_4TIRM(]KHHHK\_.H**** "BBB@"*ZN8K*SFNKEQ'#!&TDCGHJ@9 M)_(5\ >+=?E\4^+]4UNXSNO;EI0#_"N<*OX* /PKZ]^/>NMH?P>U4Q-MEOBE MFA!_OGYO_' U?%5>AA(Z.1,@HHHKN("BBB@ HHHH *UO"OA^X\4^+--T2T!\ MR]N%BR!]U<_,WX+D_A637TO^S-\/7M;:;QIJD)5[A3!IZL.0F?GD_'&T>P/K M656?)!L:U/?[.TAL+&"TM5V0V\:Q1J/X548 _(5-117C&@4444 5=4_Y ]Y_ MUP?_ -!-?G97Z)ZI_P @>\_ZX/\ ^@FOSLKOP?4F0M%%%=Y 5]=_LQ_\DDD_ M["4W_H*5\B5]=_LQ_P#)))/^PE-_Z"EJ?\@B\_ZX/_ .@FOSLK+!]1R%HHHKO(.G^&O_)4O#/_ &%+?_T8*^]: M^"OAK_R5+PS_ -A2W_\ 1@K[UKSL7\2+B%%%%<104444 ?$WQY_Y+;K_ /OP M_P#HE*\\KT/X\_\ );=?_P!^'_T2E>>5[5/X%Z&84445H(^]?AI_R2WPS_V" M[?\ ]%BO-OB1\?[_ ,!>.KS0(_#]O=QVZQNDSW+(7#(&Z!3W)'X5Z3\-/^26 M^&?^P7;_ /HL5\]_M2Z(]IXZTW6%4^5?V?EEL?QQL<_^.LM>52C&55J1H]C1 M_P"&L-2_Z%6U_P# QO\ XFC_ (:PU+_H5;7_ ,#&_P#B:^?:*[OJ]+L3=GT; MI7[4]W>ZQ9VMWX;MH()YTCEE%VQ,:E@"V-O8'-?1]?G'TZ5]K_!KXCVGCOP; M;Q33J-:L(EBO("?F; P)0.X;U['(KEQ%%12<4-,]%HHHKB*"OEG]J#PC9:3X MATSQ!I\*PMJ@D2Z5!@-(FTA\>I#<_2OJ:OD[]I;QK9>(?%=EHFES+/#HZN)Y M$.5,SD94'OM"@?4D=JZ<-?VF@GL>*4445ZIF%?:'[/98_!/1]_0//M^GG/7Q M?7W3\(=+?1_A'X=M)5VN;03,".AD)D_]FKCQ;]Q(J.YYC^U?_P @'PY_U\S? M^@K7S)7TW^U?_P @'PY_U\S?^@K7S)5X;^&@>X4445TDG6_#'QF_@/Q]8:R= MQM03#=HO5H6X;\1PP]P*^Z;2[M[^RAN[*9)[>=!)%*ARKJ1D$'Z5^=->N?"/ MXY7G@-$T?7(Y+_0BV4"G,MKD\E,]5[[?R]^3$47/WH[E)GV!16!X;\<^&O%U MLLWA_6+6[+#)B#[95^J'##\JWZ\UIK1EA14<]Q#:PM-=31PQ*,L\C!5 ]R:\ M?^(O[0^@>'+6:R\*31ZSJQ!59(SFWA/J6_B^B_B151A*;M% 8G[3GCN*UT6# MP=8R@W-VRSWH4_3B)\U0T6Q\%?$O_DJ? MB;_L*7'_ *,-W_\ 1JUZ9:?\>9_M%_ M\D6U+_KO;_\ HU:\6E_$7J:/8^-****]HS"O;OV6/^2D:I_V"G_]&QUXC7MW M[+'_ "4C5/\ L%/_ .C8ZQK_ ,-C6Y]74445XYH%%%% 'F?Q_P##;>(OA+?O M"F^XTUEO8P!SA,A__'&8_A7Q?7Z,S0QW%O)#.@DBD4HZ,,A@1@@U\(_$KP9/ MX$\=W^CR*WV8-YMI(?\ EI"QRI^HZ'W!KT,)/1Q)DG_ !\9Q^$ MOB5##>RB.QU9/LDK,'$TF_?B6F>^44BL&4,I!!&00>M+7GE!11 M6?KFO:7X;TF74M7;_ &FP/H !7!5Z=+#QY??6I#9[S_PU;K__ $+NF_\ ?V3_ !H_ MX:MU_P#Z%W3?^_LG^->#4J(TDBI&I9F.%4#))]*T]A3["NS[B^$OCC4?B%X. MDUO5+&"R)NGAB2!F(95"_-S[DC\*[FN9^'/AK_A$?AWH^BNH6:WMP9\?\]6^ M9_\ QYB/PKIJ\J=N9VV-#DOB%X9;7]#\ZT3=>V>7C ZNO\2_U'N*\2^O\J^F MJ\V\=?#YKF635M!BS*V6GM5_C/\ >7W]1WKZ3)LRC27U>J[+H^WD8U(7U1Y; M12LI1BK@JRG!!X(-)7V)SA1110 4444 %%%% !1110 5+;7#VEU##[$U\+:GIE[HVJ7&G:I;R6UW; M.8Y8I!@J1_GK7I862<.4B15HHHKL)"BBB@ HH +, HR2< #O7M/PP_9[U7Q+ M+#J?B])=*TGAEMV&V>X'T_@4^IY]!WJ)SC!7D,P?@[\)KOXAZXMU?(\.@6CC M[3-T\XCGRD/J>Y[#WQ7V9:VT%E:16MI$D,$*"..-!A44# 'IBH=+TNQT72X M-.TFUCM+.W39%#$N%4?Y[]ZMUY56JZCN6E8****Q&%%%% %75/\ D#WG_7!_ M_037YV5^B>J?\@>\_P"N#_\ H)K\[*[\'U)D+1117>0%?7?[,?\ R223_L)3 M?^@I7R)7UW^S'_R223_L)3?^@I7+BOX94=SU?5/^01>?]<'_ /037YV5^B>J M?\@B\_ZX/_Z":_.RLL'U'(6BBBN\@Z?X:_\ )4O#/_84M_\ T8*^]:^"OAK_ M ,E2\,_]A2W_ /1@K[UKSL7\2+B%%%%<104444 ?$WQY_P"2VZ__ +\/_HE* M\\KT/X\_\EMU_P#WX?\ T2E>>5[5/X%Z&84445H(^]?AI_R2WPS_ -@NW_\ M18K#^-O@9_''PZN(;*/S-2L&^U6@ Y<@?,G_ )<_B!6Y\-/^26^&?\ L%V_ M_HL5T]>+S.,[HTZ'YQD%6(8$$'!![45]&?'/X'SO=7/BSP;:F42$R7]A$OS! MN\D8[YZE1]1[?.9!!P>#7K4ZBJ1NB'H%6M-U2_T;4(K[2;R:SNHCE)H'*,OX MBJM%7N(]>T?]I?QUIL*Q7PT_5 HQON8"KG\4*C]*V'_:K\2F/$>@:4K^K-(1 M^6X5X3163H4WT'=GHWB?X[>._%%L]K-J2:?:R AXM/C\K<]:**T MC&,59( HHJ[H^C:CX@U:#3-&M);R\G;;'%$N2??V [D\"GL!M_#GPA/XX\=Z M=HT2MY+R"2Z>_"#X6V_PW\/ M-]H*3ZS> ->3KR%](U/]T>O<\^F/1*\JO4]I+39%I6/G[]J__D ^'/\ KYF_ M]!6OF2OIO]J__D ^'/\ KYF_]!6OF2NW#?PT2]PHHHKI))OL=Q]@^V^2WV;S M?)\W'R[\9V_7'-0U] ? 3PAIWCGX8^*]#U93Y4UU$TX%N^U?4M3.=2U"ZO#_T\3M) M_,U4HHHV$%%%%, KLOA=X N?B'XS@TU%9+&$B6^G _U<0/3/]YN@_/L:SO!? M@C6O'FNIIF@VQ<\&:=AB.!?[SGM].I[5]I^ / >E_#WPS'I6E+OD8[[FZ88> MXDQ]X^@[ =A^)KFKUE!66Y25SH[6U@L;.&UM(EA@@C6.*-1@(H& !] *EHHK MRBSX*^)?_)4_$W_84N/_ $8:YBNG^)?_ "5/Q-_V%+C_ -&&N8KVX?"C,*5/ M]8OU%)2I_K%^HJQ'Z+6G_'G#_P!W_P#1JUXM+^(O4T>Q\:4445[1F%>W?LL?\E(U M3_L%/_Z-CKQ&O;OV6/\ DI&J?]@I_P#T;'6-?^&QK<^KJ***\%LV2HFM6 +VPO!<0.8Y8I%PR,#@@CUJ*OL7XN_!.Q\?1/JNCF.QU]%_P!81B.Z Z*^.A]& M_ Y'3Y+UW0-5\,ZM+INNV,UE=Q'YHY5QD>H/0CW'%>M2K1J+S,VK&=1116PC MK/#/Q1\9>$8UAT37;F.W7I;2XEB'L%;('X8KMX/VGO'44866WTB<_P!Y[9P3 M^3@5XY16;I0EJT.[/6=0_:3^(%[&R6\^GV.?XK>T!(_[[+5YUKOB;6_$]Y]J M\0:I=:A*/NF>0L%_W1T7\!6713C3A'9 %%%%6(*]D_9Y^&\GB;Q4GB/4H#_9 M.DR!H]PXGG'*J/4+PQ_ =ZQ/A;\&]8^(5['=W*26&A(W[V\9<&7'58P>I]^@ M_2OL31-%T_P[HMMI6CVRVUG:ILCC7L/4GN2>2>YKCQ%917+'&/U['\:\_U+X4:Q;,3IT\%['V!/EO^1X_6 MO8:*]+#9GBL,N6$KKL]2'"+/ I?!'B6%B&TBX/NF&_D:C_X0[Q'_ - :[_[X MKZ!HKTEQ#7ZP7X_YD>R1\_?\(=XC_P"@-=_]\4?\(=XC_P"@-=_]\5] T4?Z MPU_Y%^(>R1\_?\(=XC_Z UW_ -\4?\(=XC_Z UW_ -\5] T4?ZPU_P"1?B'L MD?/W_"'>(_\ H#7?_?%'_"'>(_\ H#7?_?%?0-%'^L-?^1?B'LD?/W_"'>(_ M^@-=_P#?%'_"'>(_^@-=_P#?%?0-%'^L-?\ D7XA[)'-^ ;.[L/!]M;7\#P3 M([YC<8(!8D?SKI***\"M4=:I*H^KN:I65@HHHK(84444 %Q_ BNXHIQDXNZ ^2?$'[,GC'396;1)[+6(/X=LG MDR?BK,+^ %=W117-*3D[LH****0!1110 M4444 5]01I=,NHXU+.T+JH'H_\ ?L?XT?\ "G_B#_T*>H_]^Q_C7W316WUN?87*?"W_ M I_X@_]"GJ/_?L?XU]-?L_^']6\-?#5['7K":PNC?RR"*88;:53!_0UZ?16 M=2O*I&S&E8KZ@C2:9=)&I9FA<*!W)4U\-_\ "I/'_P#T*6J?]^#7W914TJSI MWL#5SX3_ .%2>/\ _H4M4_[\&C_A4GC_ /Z%+5/^_!K[LHK;ZW/L+E/C/P%\ M,?&VG?$3P_>7WAC48+:WU&&265X2%10X))/IBOLRBBL*E5U'=C2L%%%%9#"B MBB@#Y+^,GPZ\8:Y\6M:U#2/#M_>6*+*OB) <'Z@BN'_P"%2>/_ /H4 MM4_[\&ONRBNN.*E%)6)Y3X3_ .%2>/\ _H4M4_[\&C_A4GC_ /Z%+5/^_!K[ MLHI_6Y]@Y3G_ #9W.G?#OP_9WT+P7-OIT$ M9>/_ ($^%_&\DM["ATC57Y-U:J-LA]73HWU&#[UZ;13C)Q=T!\;>)?V=_'6@ MN[V-I%K5L.DED_SX]XVPV?IFO.M1T/5=(E,>JZ9>63CJMQ T9_45^AU-DC25 M"DJ*ZGJK#(-=4<7);HGE/SDHK]!KCPGX.W;;^+8P/SK M[PM?#VBV)S9:186Q'>&V1/Y"M'ITJ7C'T0$_P!F+Q)J*;N#1[;J MT49$TQ'IQ\H^N3]*^AO!7P\\.> ; V_AZQ$PP/:NGHK MFG6G/<=K!11160SY^_:O_P"0#X<_Z^9O_05KYDKZ;_:O_P"0#X<_Z^9O_05K MYDKU<-_#1#W"BBBNDD^GOV4?^1;\0_\ 7W%_Z :]E\3^$]%\8Z.^F>(;&.[M MVY7/#1M_>5ARI]Q7C7[*/_(M^(?^ON+_ - ->_5Y%9M56T:+8^5?&O[,NNZ7 M))<^#KA=7M.2+>5A'<(/3G"M]>#[5X]JWA[6=!G,.MZ5>6$@.,7$#)GZ$CFO MT+IDL4<\9CFC61#U5U!!_"M(8J2WU%RGYRT5^@4_@OPMDRMZO8QD_ M^@T^V\(^&[)@UGX?TN!AT:.SC4C\0*U^MKL'*?">B>$?$/B.58]"T6^OB3C= M# Q4?5N@_$U[)X*_9@U2\DCNO&]ZNGV^039VK!YF]B_W5_#=^%?3ZJJ*%10J MCH , 4M93Q4WMH'*97AWPSH_A/2$TWP_8165JG.U!RY_O,QY8^YK5HHKE;;U M904444@/C3Q]\,?&VH_$3Q!>V/AC49[:XU&:2*5(25=2Y((/IBN>_P"%2>/_ M /H4M4_[\&ONRBNM8J25K$\I\)_\*D\?_P#0I:I_WX-*OPE\?!USX2U3K_SP M-?==%/ZW+L'*1VRE;6)6&"$ (].*X#XYZ+J6O_"B_P!/T6RFO;N2:$K#"NYB M!(">/I7H=%4^$_^%2>/_\ H4M4_P"_!KUO]G3P1XF\,^/-0N_$&B7FGV\FFM&D MD\>T,WF1G'UP#^5?2-%3/$RG'E:"P4445RE!1110 4444 %8GBCP?H/C+339 M>(]-AO(AG8S##QGU5ARI^E;=%--IW0'S1XN_9:NXG>X\%:LEQ'U%I?\ RN/8 M2 8/X@?6O(]<^&7C3PXS?VKX%I"?P K[Z@\(>&K4@VWA[2HB.A M2RC&/R%:L4,4"!(8TC4=%10!2>,[(.4^+O#WP$\?:^ZEM)_LN!NLVH/Y6/\ M@'+?I7MG@G]FOPYH$D=YXFF;7;M>1$R[+=3_ +O5OQ./:O:**PGB*DM-AV0R M**."%(H(UCC10J(BX50.@ '04^BBN<84444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% 'S]^U?_ ,@'PY_U\S?^@K7S M)7TW^U?_ ,@'PY_U\S?^@K7S)7JX;^&B'N%%%%=))]/?LH_\BWXA_P"ON+_T M U[]7@/[*/\ R+?B'_K[B_\ 0#7OU>/7_B,T6P4445B,**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@#Y^_:O_P"0#X<_Z^9O_05KYDK[5^,/PPNO MB;I^F6UGJ4-@;*5Y&:6,ONW # P?:O*?^&4-6_Z&BR_\!G_QKT*%:$8)-D-. MYX!17O\ _P ,H:M_T-%E_P" S_XT?\,H:M_T-%E_X#/_ (UO]8I]Q69O_LH_ M\BWXA_Z^XO\ T U[]7G/P?\ AC=?#+2]2M+S48;\WLR2*T493;A<8.37HU>; M6DI3;1:V"BBBLAA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !115+5-7L-&M#>/<["BD5@ZAE(*D9!!ZUQWQ$\1ZCX=M+&32Y$C::1 ME?>@;( 'K7/AZ$\155*&[&W97.RHKD_A]K]_XAT:YN=4D222.X**40+QM![? M6NLI5Z,J%1TI[H$[JX4445B,**** "BBB@ HHHH **** "BBB@ HHHH **S] M;UJTT#2WO[\OY2L%P@RQ). *YG_ (6OX?\ ^>=[_P!^1_\ %5U4L'B*T>:G M!M$N26YVU%-BE2:%)8CN1U#*1W!Z4ZN78H**** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **PO$7B[3O##VZZBL[&X#%/*0-TQG.2/6I_#WB M2R\2VDMQIRS*D3[&\U0ISC/J?6MWAZRI>V<7R]Q75[&M1116 PHHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\VU'XL-::[+;P: MFA04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X' MXKU:Y\1>+)\L619C!;QD\* V!^9Y->^5X!XJTJYT+Q1=1R*R!I3-!)_>4G(( M/MT_"OH^'^3VT[_%;3]3&K>QZ1IWPLT."T1=0\ZZN,?._F%%S[ =OK7+>.O M4&@6::CI3R-;;PDL4AW%,]"#Z=N:U-*^+B+ D>LZ?(9 ,-+;L"&]]IQC\ZZ* MQ^(OAK4&$;W1MV;HMS&5'Y\C]:M3S7#5O:5$Y+JMU^&P>XU9&/\ "C6IKK3[ MG2KEF;[+AX2W9#U7\#_.HOC!_P @_2_^NS_^@BO1(O*=!)!L96&0R8P1]17G M?Q@_Y!^E_P#79_\ T$5SX.M&OFD:D8\MV]/DQR5H6+/PC_Y%N\_Z^S_Z M=] M7 _"/_D7+S_K[/\ Z M.^(GC.;1572]*?9>2INDE'6)3TQ[G]*SQ>'J8G,9T MJ>[8XM*%V=G=:E8V) O;RWMR>@EE5?YFEM=0L[T$V=W!<8Z^5(&Q^5>/>'OA M_J7B>W_M*]N_L\,I)624&227WZ]/(O!.I^#T34K2\\V%6 \^',;QGMD9 MZ>^:V_LS".?L57]_TTOV%SRM>Q[917(_#_Q7)XCTR2"^(-]:X#L!CS%/1L>O M+XB>,YM$5-,TM]EY,FZ24=8E[8]S^E>=' 5WB?JUO>_#U]"^96N=E=:E8 MV) O;RWMR>GFRJO\S2VNH6=Z#]CNX+C'7RI V/RKQ[P]X U+Q1;_ -I7MW]G MAE)*R2@R22^_7I[DTWQ%X(U/PA&FI6EYYL*, 9H08WC/;(ST]\UZ/]F81S]B MJ_O^FE^Q'/*U['M=1R7,$+ 331QDC(#,!FN4^'_BR3Q%ILD%^0;ZUQO8#'F* M>C8]>QKDOBZ,^(;'_KU_]G-<=#+I3Q?U6H[/[RG/W>9'K*RQO'YB2*R?W@E--Y2ZG9F3.-@G7/Y9KQ_0K3Q!XLTJ'1=.<6^G6>?-P/6NS^R\-3J.G6K)2Z+\K]B>=M72/9, MYZ45XWX \97.F:I!IE],TEA<,(TWG/DL>F#Z9XQ7LE>;CL%/!U.26JZ,N,E) M7"BB@G R:X2CR[XN:KNFLM)C;A0;B4 ]SPO_ +-7"ZCH\^G:?IUW-]R_A,J< M=,-C'Y8/XU>UFXD\5>.)3 2WVJY$,/LF=H_3FO1/B1HB/X)B:V3_ )!A4KCL MF-I_H?PK[BC56 CA\,]Y;_/_ (+_ .9KFNR_P##G5?[3\'6Z.V9;0F!^>P^ M[^A'Y5U5>0_"?5/LVO7&G.V$NX]R#_;7G^1/Y5Z]7S6:T/88N26SU7S_ ."; M0=XD4EU;Q.5EGB1AU#. :UCUB'6=,N)?*M]1M)9/[B3J3^0-7:\2\0?#G5-!L6O4EBO((^9#$"K(/7![ M?2MWX;>,;F2^71-4F:9)%/V:1SEE(&=A/<8Z?2HK97!T'7PU3G2W&IN]FCTZ M26.%=TKJBYQEC@4V*>&;/DRI)CKL8'%<=\5O^1-7_KZC_DU>;^&I-9N!?RJ<+E:Q&&=?GMKUV];A*=I6/<)M9TNWF\JXU&TB MDZ;'G4'\B:MQR)+&'B=71AD,IR#^->.7WPKUNTL7N$FM;ET7S:1C97CB)XB>%8\!AZ'.*VEE5*=&53#5>9QWT%SM.S1[=37D M2)"\C*BCDLQP!5;5-1@TG2[B_NSB*!"[8ZGT ]R>*\6N+[7?B#KZVR,<,24@ MW8BA3U/^/6N'!8"6*3FWRPCNRI2Y3V5==TEY/+35+-GSC:+A<_SJ^"" 0<@] M#7E4OP?N1:YAU6)Y\9V-"0I/IG/]*R?"_BC4?"6N_P!FZHTAM%E\J>!SGR3G M&Y?3U]"*Z_[,HUH2EA*O,UTM8GG:^)'M=1S3PV\9DN)4B0=6=@H_,U6U;4HM M)T:ZU"7YHX(C)@'[WH/Q->)0+K/Q \1>5)<;Y6!<[V/EP(/0=AT'O7+@) MC*I.7+".[*E*VA[7'KFDRR;(M3LW<]%6X4G^=7\YZ5X]K/PLO=,TJ6\M[V*[ M\E"[Q>64.!UQR*Z:F64I4)5L- M4YE'?2PE-WLT>LT445X9H>7?&'_CYTG_ ')?YK6C\(O^0!??]?7_ +(*SOC# M_P ?.D_[DO\ -:T?A%_R ;[_ *^O_9!7U-3_ )$L?Z^TS%?Q#O)9X8<>=*D> M>F]@,TJ312H7CD1U'5E8$5YI\81DZ3_VU_\ 9:YGP]::]XBTO^PM(/E6<]^BO8;G:5K'LW]N:3YWE?VG9^9G&SSU MS^6:O @@$'(/2O$-=^'.K:%IKWSO;W4$8S)Y).4'K@CD5M?"SQ%<#46T2YE: M2"2,O &.=C#J![$9./:JK973^KNOAZG,EN"F[V:/4Y)4B7=*ZHOJQP*;%<0S M$B&:.0CKL8'%7^&IM7::XTSP^&%Q?JJ.Z'!5%R3SV M'/)K/"97]9PSK<]K/KMTUN.4[.Q[I/K&F6LOE7.HVL,G]R2=5/Y$U:BECFC$ MD+K(C=&0Y!_&O'KKX4ZY#:/.D]K<2@;C$C-N;Z$C!-9_@7Q#7(^(+-&PJCU;U..I-<&!P$\6V[\L5 MNRI2Y3V;^WM($GEG5++?TV_:$S_.KR.KJ&1@RGD$'(->2CX0ZG]FW'4+038_ MU>UL?3=_]:L33]8USP)K;6LN]1&P\VU=LHX]1_0BN]950KIK"U>:2Z;$\[7Q M(]SDFCA4--(D8)P"S 4D5Q#-GR94DQUV,#BN:\26\'B_X?R3V7[S?$+F#U#+ MSCZ]17G7PUU7^S?%T4+'$5ZIA;_>ZK^HQ^-I54O>ANK?UYC<[-(] MNJ*2Y@A;;--'&V,X9P*EKP?Q7>2>)/'4ZVWS[IA:P#V!V_JXY2Y4>[HZR('C8,IZ%3D&HKB\MK--]W<10+ZRN%'ZU@ZYJ$?@KP0#:JI M:WC2" $<%SQD_J:\LT30]6\>:M/))=[B@#37$Y+;<] !^?' XK;"Y=&O"5:< M^6FNHI3L[+<]J@UG3+J01VVHVDSGHLIR,UT_PN\2W6H+/I-_*TS0()(9'.6VYP5)[XR,5=?+::P[Q&'J M)K&IR31 MK "@GD& =PZ57^(_A*Z6\OO$9N(?L[&,>5@[^BK].M*% MH8_,)E!P1G':O5PN%PLLNE>2UW=MGIH1*4N<]]CECF7=#(L@SC*L#7(7_@3P MO=ZT][<2E'=]\L"SA49N^1U&?3-7_!/ANX\,:-+9W4T4SO.9 T0.,$ 8Y^E> M/^+ /^$TU7C_ )>W_G7GY=A74Q%2%"JTDMUU*G*R3:/H)%5$"H % P .@%*3 MCK42R+%:"21@J(FYF/0 #K7B_B?QAJ7BK5/L6FM*EFS^7#;Q<&;G@MZY].@K M@P6!J8R;2=DMV5*2BCU^37-)BD\N74[-'Z;6N%!_G5N*6.>,20R+(AZ,C9!_ M&O);;X1ZI+:A[B^M8)2,^5M+8]B1_3-89;7_ !KGE!S"X^;:&W13K].X_45 MZ$)KRHS?*XK];%2G971[K+<0P0^; M-+'''UWNP"_G5>VU?3;R3R[34+6=_P"[',K'\@:\HM?#GB3QU;Q7DTT=O8QH M([=9F.W"C'RJ/IU-8?B'PIJ7A6XA-X49)#^ZG@8XR.W8@UW4LIH2E[*59<_9 M$NH]['O]%^&?$R&?>9K"X&Y"Q^;!_D1_.O5R[!2Q7 M,X3Y91V_JY$Y?";19B3:7%U:D] &#J/S&?UKC_ !/\.[WP]9/?0W"7 MEHA&\A=KH#QDCG(_&O4=-\6Z)JEJLUOJ-NN1DQRR!'7V(-N= M-LKF.ZNKI=A$3!A&,\DD-=5:0DE9R@]@H '\J] ^$?_(MWG_7V?_0%KD/B5I$FG^+)KG:? M(O@)4;MNQAA]<\_C6F$E&.:U4]VM/P%+X$7[7X@>)K2SAMX-'B$4,:H@^S2= M ,#O4.J^-O$FL:5<:?=:2@AG7:Q6VDR.^1S7?^#_ !58ZWHENK7$:7L482:% MV ;(&,CU!ZU-XH\5V?AW2Y)O-BENB,0V^_ES[XZ#WKB^L1CB/9K#+GOW>_?8 MJVE[GG_PN@O+7Q<_FV\T49Y_&VJ-(D2:?XKENMI\B^ D1NVX### MZ]_QKT,+6E+,I*M%1DX[7OY_D1)>YH7K3Q_XFL[*&VM]'B$4,:HG^C2= ,#O M4.J^-O$FKZ7<6%UI*"*X3:Q6VDR/<M6/$_BNS\.Z7)-YL4MUC$-OOY<^^.0/>O/\ K$8XCV:PRY[]WOWV+MI> MYYY\+X;RU\7GS;>:*.2V=6+QE1U!'7Z5+\7?^1AL?^O7_P!G-=1X+\:ZAXJU M&>*6PA@MX(]S2(Q/S$\#G\?RKE_B[_R,-C_UZ_\ LYKJHSJ3S9.K'E=MKWZ" M=N30[+X;6\<'@:T9!AIF>1SZG<1_("NJKS3X:^+;&WTO^QM2N$MY(W+0/(V% M92M]%+'Q;J4=N-JQW3% /X>*?%@4+^]O MKDNX'\*DY)^@%?0BJ$0*O P*]//7RPHTY?$EK^'^1%+JQ:P?&VJ_P!C^$;V M=6VRR)Y,7^\W'Z#)_"MZO+/BYJN^ZLM*C;B-3/*!ZGA?TS^=>3EM#ZQBH0>V M[]$:3=HG*^#=2T[1O$<5_JOF&.!&,8C3<2Y&!^A->A7WQ)\,W^GW%I,+PQSQ MM&W[CL1CUK)\'_#S3M8\-PW^JFX$L[,R".3: F<#M[$UN?\ "JO#OK>?]_O_ M *U>[CL1EU3$-U7+FCIIMH914TM#R;2;]M)UFTOHB2;>4/\ [P!Y'XC-?1<4 MJ30I+$=R2*&4CN#R*\,\<^&XO#6N)!9^8;6:(/&9&R<]&&?\]:],^'.J_P!I M^#K=';,MH3 _T'W?T(_*ISJ,<1AZ>*I[;??_ ,$*>C<6>=?$S_D>KK_KE'_Z M"*]9\*VT=IX3TR*( +]F1N.Y(R3^9->3?$S_ )'JZ_ZYQ_\ H(KM_ /C#3[K M0;?3KVZCM[RU3RP)6"B11T()]N,>U+'TJE3+:+@KI)7^X(M*;.VEC2:%XI%# M(ZE6![@U\]:2QLO%EGY).8;U0OX/BO9_$?B_3=#TN6074,MT5(AAC<,S-VX' M0>]>2^"-,EU?QC9C!989!<3-Z!3G]3@?C2R>$J6'K5:BM&WY7"IJTD>B_%;_ M )$U?^OJ/^35B?!^)3/JLN/G"QJ#['5]#5\]6O_(YQ?]A$?^C: M>1;5O1?J%7H>G?%>=X_",<:D@372*WN "?Y@5YUX6U_4] FN)M)LDN7E4*[- M$S[1UQ\IXS_2O5OB!I$FL>$;B.W4O- PG11U;;U'Y$UYY\-_$EMH>LS0W\@B MMKQ0OF-T1QTS[26(7"J>!P21]-V*YSX3IIK:G>->>4;Q57[.),=.=Q7/?I7/AG]?H.3=U%#KGXD^(+JSEC_L2,121LI81R' (ZYKGO 7'CC2_^NA_] M ->N^*]>L='T&Z-S.GFR1,D4(8;G8C P/ZUY#X"&/'&EC_IH?_0#7HX.<*F# MK2A3Y%9_/1DRNI+4][HHHKXPZ#R[XP_\?.D_[DO\UK1^$7_(!OO^OK_V05G? M&'_CYTG_ ')?YK6C\(O^0!??]?7_ +(*^IJ?\B6/]?:9BOXA1^,/72?^VO\ M[+6O\*(U7PC*X4!GNGW'UP%Q61\8>ND_]M?_ &6MGX4_\B:W_7U)_):SJ_\ M(FAZ_JP7\0Z77U#>&]2##(^R2\'_ '#7C7PY/_%=Z?\ 23_T6U>S:]_R+FI? M]>DO_H!KQGX<_P#(]Z=_VT_]%M1E?^XXCT?Y,)_$CT7XH?\ (D2_]=X__0JY MCX01J=6U*0CYE@0 ^@+'/\A73_%#_D2)?^N\?_H5 M'_Y$]3U_R!_Q$>JU\]WBA/&DZJ, :B<#T_>5]"5\^7W_ ".]Q_V$6_\ 1E+( M/BJ^@5>AZE\49WA\%.J' EGC1O<9S_05S/PAMHWU;4;A@#)%"JJ<= Q.?_01 M7<>-M'DUOPG=VMNNZ=0)8E]64YQ^(R/QKRSP%XBB\.>(&-\2EK<)Y4K8_P!6 MQX/UJL"G6RNK2I_%?\ R_R"6DTV>Y5Y9\7[:-;S3+H "1TDC8^H!!'\ MS7HXUC33:_:!?VODXSYGG+MQ]+4K:*]_N'4:Y3N?A3,\O@]XWY6*Y=5SZ$ _S)KS?Q1ITGAWQAD;[6S MU>->8F\B4C^Z>5/YY'XUUX/%069U(KX9MK^OZZBE'W$=+JGB6.+P"^MPL 9; M8&/GH[# 'X$_I7GGPOTG[?XH-Y*-T=BF_)'5VX7^I_"L*;Q!--X1MM#.=D-R MTN[/52.!^!+'\J]5^&ND_P!F^$HYW7$MZWG-Z[>BC\N?QK2M1_LW!5$MYNR] M/^&O]XD^>2.@UFZTZRTV2YUGROLT?)\U0PSVP.YKSR?XI6UK*T>@:'&JL?O/ MA"__ %1_6K'Q@DE%KI<8)\EI)"P[%@!C]":D^$R:;_95S(/*.H^<0Y;&\)@ M8Q[=:Y,/AJ%+ _6JL7.[VO9;V*;;ERHP=;\>:YJVB7-G=Z0D-O,F&D$C_P#H2UV/Q'UZQM?"]SI_GH]W= (L2MD@9!+'T'%<;\*? M^1PD_P"O5_\ T):]"G*,\LJRA3Y%K\]M2'I-:G=_$K_D1+S_ 'H__0Q7'_"' M_D/7_P#U[#_T(5V/Q(1G\"7VT9VF,GZ;Q7"?"W4K33_$-RM[<1P":WVHTC;0 M2&!QD^US8X M_7%>*^&-6?PKXLCGO(W41,T-S'CYE!X/'L>?PJLL7M,%7I0^+7\@GI)-GOM> M??%VVC;0K&Y('F1W.P'V922/_'179VVM:9=VHN+>_MGA(SO$HX^OI^->6_$O MQ3:ZS<6^GZ;*)H+9B\DJGY6?&, ]P!GGWKS\IH57C(M)Z;E5&N4V/@_,YLM4 M@)^1)(W ]"00?_017'?$#_D>M3_WE_\ 0%KT7X8:-+IOAI[JX4I)?/Y@4]0@ M&%_/D_C7G7Q _P"1ZU/_ 'E_] 6O;P4XSS6LX[6_R,Y? CVO0XUB\/Z>D:A5 M6VC _W17*?%E0?"9_![_ %>K?[T7_LU>F4\X_P!^ MG\OR04_A"BBBO*+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG/$W@K3?$V)9]UO=J, M+<1#DCT8=Q71T5K2K5*,^>F[,32>C/)+CX0ZFKG[-J-I*O8R*RG^1JUIWPAE M\T'5=201CJELA)/XGI^5>HT5Z;SK&N-N;\$1[.)3TO2K/1K!+/3H5AA3L.I/ MJ3W-8GC7PG-XJMK2*"Z2W-N[,2Z%LY&.U=/17G4\15I5?;1?O=]RVDU8YWP9 MX9E\+:7/:SW*7!EF\P,BE<< 8Y^E:>L:-8Z[I[6>I0^9&>01PR'U![&K]%$\ M14G5]LW[W<+)*QY7??"&Z68G3-2B>// N%*L/Q&<_I3;+X0WC2@ZCJ<*)W$" M%F/XG%>K45Z/]M8WEY>;\$1[.)GZ)H=CH&G+9Z='L0'+,QRSMZD]S3M7T:RU MW3VL]2A\V)N0>C*?4'L:O45Y?M:G/[2_O;WZEV5K'E=_\(;I9B=,U*)X\\+< M*58?B,Y_(4VS^$-ZTH.H:G!&G?R$+,?SQ7JU%>I_;6-Y>7F_!$>SB9VB:'8^ M']/6STZ/8FM6DVEV37$ M<=OL9@RC!W$XY-/*:R^NJI5EWU;":]VR*FB>!;/Q/X%L+A9#:WJ^8OFJN0XW MM@,._P!:JI\(=5\[#:A9K'_> 8G\L?UKO/ ^GW6E^$;2TOX3#/&7W(2#C+DC MI[&N@K2KFV)HUJD:O02IQ:5SG?"W@RP\+QL\1-Q=R##W#C!QZ*.PK MHJ**\>K6J5IN=1W;-$DM$%>=^(/AM?Z[KUUJ+ZI"@F?Y4,1.U0, =?05Z)16 MN&Q57"RBBN9MMW91S/C3PE_PE5G M;)%.EO-;R$AV7.5(Y'Z#\JK^"O!]YX5FNO.OH[B&X5?D5"I##OU]":ZZBNM8 MVNJ'U>_N]OQ)Y5>YXA\3/^1ZNO\ KE'_ .@BNE;XJ7COPEKFK>+;B[T_3WF@>- KAU&2%P>IKT;P_;2V?AS3[:Y3R MYHK=$=2?ND*,BO=Q.-='"4'0G[R2OMVZHSC&\G<\U@^$.IF8"XU&TCCSRT89 MC^1 _G7H?ASPQ8>&;(PV*EI'P99G^](?Z#VK8HKQL3F6)Q4>2I+3ML6H);&# MXP\/2>)M#%A#.L#"99-[J2.,\?K5+P3X/F\*?;//NX[G[1LQL0KMVY]?K75T M5BL76C0>'3]UCY5>X5YK#\+;N+7$OSJ<)5;D3[/*.<;]V.M>E448?%UL-S>R M=K[@XI[A7#^(_AE8:ML;]IO[+9ZY?^6*ZOPS\-['0[I+V\F-]=Q\IE=J1GU [GW-=G1796 MS;%UH)"_#$OA;3KBVGN4N#-+Y@9%* MXX QS]*Z.BNMXRLZ"P[?N_TR>57N*_L?D7<=M]GWYWH6W;L>GTJ[ MX/\ #TGAG0S837"W#&9I-Z*0.0./TK>HI/%UI4%AV_=0(;;49=1AF6'=E%C()RI'7/O7H-%%'%UJ-.5. M#TEN#BF[LQ/%N@R>(]!?3X9U@9I%?>RY'!S67X*\%3^%;J[EGO([@3HJ@(A7 M&"3W^M=?11'%UHT'AT_=?]?H'*KW"O-KCX77,J&QG:W4'\#BK]% M>9&3A)2CNBSRM/A!=>8OFZK"4R-P$1R1W[UZC#$D$*11+M2-0J@=@.!3Z*ZL M5C:^*M[5WL3&*CL9FOZ#9^(]+:RO@P&=R2+]Z-NQ%><3?"/5$F/V34K5TSPS MAD;'T /\Z]:HJ\-F&(PL>6G+3L$H*6YYQ9_":.+3KG[7>K->RQE8F"'RXC_> M]2:O^#_ -QX9UIKZ:^BN%:%H]B1D'D@YZ^U=Q15U,TQ=2,H3E=2WT0N2*(;R MTAO[.:UND$D,R%'4]P:\PO\ X0W8N&_LS486@)^47"D,!Z9 .?TKU6BLL+CJ M^$O[)[CE%2W.;\$^&9_"VDS6MS/',\LWF9C! ' &.?I7-ZQ\+[O4]G>))# M<[FM+W&#-&,A_P#>'?Z]:ZBBN:C7J4)\]-V8VDU9GD4GPAU828CO[)DS]YMP M/Y8-;^@?"NRL+A+C6+C[BL2J<4 MP!T%>>>(_AK=:YX@N]1BU&&%9R"$:,DC"@>OM7H=%<6&Q57"S XML 12 insp-20210930_htm.xml IDEA: XBRL DOCUMENT 0001609550 2021-01-01 2021-09-30 0001609550 2021-10-26 0001609550 2021-09-30 0001609550 2020-12-31 0001609550 2021-07-01 2021-09-30 0001609550 2020-07-01 2020-09-30 0001609550 2020-01-01 2020-09-30 0001609550 us-gaap:CommonStockMember 2020-12-31 0001609550 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001609550 us-gaap:RetainedEarningsMember 2020-12-31 0001609550 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001609550 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001609550 2021-01-01 2021-03-31 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001609550 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001609550 us-gaap:CommonStockMember 2021-03-31 0001609550 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001609550 us-gaap:RetainedEarningsMember 2021-03-31 0001609550 2021-03-31 0001609550 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001609550 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001609550 2021-04-01 2021-06-30 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001609550 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001609550 us-gaap:CommonStockMember 2021-06-30 0001609550 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001609550 us-gaap:RetainedEarningsMember 2021-06-30 0001609550 2021-06-30 0001609550 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001609550 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0001609550 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001609550 us-gaap:CommonStockMember 2021-09-30 0001609550 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0001609550 us-gaap:RetainedEarningsMember 2021-09-30 0001609550 us-gaap:CommonStockMember 2019-12-31 0001609550 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001609550 us-gaap:RetainedEarningsMember 2019-12-31 0001609550 2019-12-31 0001609550 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001609550 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001609550 2020-01-01 2020-03-31 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001609550 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2019-12-31 0001609550 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0001609550 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001609550 us-gaap:CommonStockMember 2020-03-31 0001609550 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001609550 us-gaap:RetainedEarningsMember 2020-03-31 0001609550 2020-03-31 0001609550 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001609550 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001609550 2020-04-01 2020-06-30 0001609550 us-gaap:CommonStockMember insp:FollowOnOfferingMember 2020-04-01 2020-06-30 0001609550 us-gaap:AdditionalPaidInCapitalMember insp:FollowOnOfferingMember 2020-04-01 2020-06-30 0001609550 insp:FollowOnOfferingMember 2020-04-01 2020-06-30 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001609550 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001609550 us-gaap:CommonStockMember 2020-06-30 0001609550 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001609550 us-gaap:RetainedEarningsMember 2020-06-30 0001609550 2020-06-30 0001609550 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001609550 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001609550 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001609550 us-gaap:CommonStockMember 2020-09-30 0001609550 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001609550 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001609550 us-gaap:RetainedEarningsMember 2020-09-30 0001609550 2020-09-30 0001609550 insp:FollowOnOfferingMember 2020-04-16 2020-04-16 0001609550 insp:FollowOnOfferingMember 2020-04-16 0001609550 2020-01-01 2020-12-31 0001609550 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001609550 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001609550 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001609550 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001609550 us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001609550 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001609550 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001609550 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-09-30 0001609550 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2021-09-30 0001609550 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2021-09-30 0001609550 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2021-09-30 0001609550 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2021-09-30 0001609550 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001609550 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2020-12-31 0001609550 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001609550 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2020-12-31 0001609550 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2020-12-31 0001609550 insp:ComputerEquipmentAndSoftwareMember 2021-09-30 0001609550 insp:ComputerEquipmentAndSoftwareMember 2020-12-31 0001609550 us-gaap:EquipmentMember 2021-09-30 0001609550 us-gaap:EquipmentMember 2020-12-31 0001609550 us-gaap:OtherMachineryAndEquipmentMember 2021-09-30 0001609550 us-gaap:OtherMachineryAndEquipmentMember 2020-12-31 0001609550 us-gaap:LeaseholdImprovementsMember 2021-09-30 0001609550 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001609550 us-gaap:ConstructionInProgressMember 2021-09-30 0001609550 us-gaap:ConstructionInProgressMember 2020-12-31 0001609550 srt:MinimumMember 2021-01-01 2021-09-30 0001609550 srt:MaximumMember 2021-01-01 2021-09-30 0001609550 us-gaap:USTreasuryAndGovernmentMember us-gaap:LongTermDebtMember 2021-09-30 0001609550 us-gaap:LongTermDebtMember 2021-09-30 0001609550 us-gaap:CommercialPaperMember us-gaap:ShortTermDebtMember 2020-12-31 0001609550 us-gaap:CorporateDebtSecuritiesMember us-gaap:ShortTermDebtMember 2020-12-31 0001609550 us-gaap:USTreasuryAndGovernmentMember us-gaap:ShortTermDebtMember 2020-12-31 0001609550 us-gaap:ShortTermDebtMember 2020-12-31 0001609550 insp:OfficeSpaceSubleaseMember 2018-09-30 0001609550 insp:OfficeSpaceSubleaseMember 2019-05-01 2019-05-31 0001609550 insp:OfficeSpaceSubleaseMember 2019-05-31 0001609550 srt:ScenarioForecastMember 2020-12-01 2022-05-31 0001609550 srt:ScenarioForecastMember 2022-05-31 0001609550 2021-08-31 0001609550 2021-08-01 2021-08-31 0001609550 insp:TermALoanFacilityMember 2015-08-31 0001609550 srt:MinimumMember insp:TermBLoanFacilityMember 2015-08-31 0001609550 srt:MaximumMember insp:TermBLoanFacilityMember 2015-08-31 0001609550 insp:TermALoanFacilityMember insp:February2017AmendmentToLoanAndSecurityAgreementMember 2017-02-28 0001609550 insp:TermLoanFacilityMember insp:February2017AmendmentToLoanAndSecurityAgreementMember 2017-02-28 0001609550 insp:TermBLoanFacilityMember insp:February2017AmendmentToLoanAndSecurityAgreementMember 2017-02-28 0001609550 insp:TermBLoanFacilityMember 2018-02-28 0001609550 insp:TermLoanFacilityMember 2019-03-26 0001609550 insp:TermLoanFacilityMember insp:March2019AmendmentToLoanAndSecurityAgreementMember 2019-03-27 0001609550 insp:TermLoanFacilityMember insp:March2019AmendmentToLoanAndSecurityAgreementMember 2019-03-27 2019-03-27 0001609550 srt:MinimumMember insp:TermLoanFacilityMember insp:March2019AmendmentToLoanAndSecurityAgreementMember 2019-03-27 2019-03-27 0001609550 srt:MinimumMember insp:TermLoanFacilityMember insp:March2019AmendmentToLoanAndSecurityAgreementMember 2019-03-27 0001609550 srt:MaximumMember insp:TermLoanFacilityMember insp:March2019AmendmentToLoanAndSecurityAgreementMember 2019-03-27 0001609550 insp:TermLoanFacilityMember 2021-09-30 0001609550 insp:StockIncentivePlan2018Member 2018-12-31 0001609550 insp:StockIncentivePlan2018Member 2019-01-01 0001609550 insp:StockIncentivePlan2018Member 2021-09-30 0001609550 us-gaap:StockOptionMember 2021-07-01 2021-09-30 0001609550 us-gaap:StockOptionMember 2020-07-01 2020-09-30 0001609550 us-gaap:StockOptionMember 2021-01-01 2021-09-30 0001609550 us-gaap:StockOptionMember 2020-01-01 2020-09-30 0001609550 us-gaap:RestrictedStockUnitsRSUMember 2021-07-01 2021-09-30 0001609550 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001609550 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001609550 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001609550 us-gaap:EmployeeStockMember 2021-07-01 2021-09-30 0001609550 us-gaap:EmployeeStockMember 2020-07-01 2020-09-30 0001609550 us-gaap:EmployeeStockMember 2021-01-01 2021-09-30 0001609550 us-gaap:EmployeeStockMember 2020-01-01 2020-09-30 0001609550 us-gaap:CostOfGoodsTotalMember 2021-07-01 2021-09-30 0001609550 us-gaap:CostOfGoodsTotalMember 2020-07-01 2020-09-30 0001609550 us-gaap:CostOfGoodsTotalMember 2021-01-01 2021-09-30 0001609550 us-gaap:CostOfGoodsTotalMember 2020-01-01 2020-09-30 0001609550 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0001609550 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001609550 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0001609550 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001609550 us-gaap:GeneralAndAdministrativeExpenseMember 2021-07-01 2021-09-30 0001609550 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001609550 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-09-30 0001609550 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001609550 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-09-30 0001609550 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-09-30 0001609550 srt:MinimumMember srt:DirectorMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001609550 srt:MaximumMember srt:DirectorMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001609550 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001609550 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001609550 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-09-30 0001609550 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001609550 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001609550 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001609550 us-gaap:EmployeeStockOptionMember 2021-09-30 0001609550 us-gaap:EmployeeStockOptionMember 2020-09-30 0001609550 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001609550 us-gaap:RestrictedStockUnitsRSUMember 2021-09-30 0001609550 insp:EmployeeStockPurchasePlanMember 2021-01-01 2021-09-30 0001609550 insp:EmployeeStockPurchasePlanMember 2019-01-01 0001609550 insp:EmployeeStockPurchasePlanMember 2021-06-30 2021-06-30 0001609550 insp:EmployeeStockPurchasePlanMember 2020-06-30 2020-06-30 0001609550 insp:EmployeeStockPurchasePlanMember 2021-09-30 0001609550 us-gaap:DomesticCountryMember 2020-12-31 0001609550 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001609550 us-gaap:ResearchMember 2020-12-31 0001609550 country:US 2021-07-01 2021-09-30 0001609550 country:US 2020-07-01 2020-09-30 0001609550 country:US 2021-01-01 2021-09-30 0001609550 country:US 2020-01-01 2020-09-30 0001609550 srt:EuropeMember 2021-07-01 2021-09-30 0001609550 srt:EuropeMember 2020-07-01 2020-09-30 0001609550 srt:EuropeMember 2021-01-01 2021-09-30 0001609550 srt:EuropeMember 2020-01-01 2020-09-30 0001609550 us-gaap:StockOptionMember 2021-01-01 2021-09-30 0001609550 us-gaap:StockOptionMember 2020-01-01 2020-09-30 0001609550 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-09-30 0001609550 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001609550 us-gaap:EmployeeStockMember 2021-01-01 2021-09-30 0001609550 us-gaap:EmployeeStockMember 2020-01-01 2020-09-30 shares iso4217:USD iso4217:USD shares pure utr:sqft insp:renewal_option insp:segment 0001609550 false --12-31 2021 Q3 http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member P3Y http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent P4Y P1Y P3Y P4Y P4Y 10-Q true 2021-09-30 false 001-38468 Inspire Medical Systems, Inc. DE 26-1377674 5500 Wayzata Blvd. Suite 1600 Golden Valley MN 55416 844 672-4357 Common Stock, $0.001 par value per share INSP NYSE Yes Yes Large Accelerated Filer false false false 27358099 210200000 190518000 0 43844000 95000 42000 26675000 25063000 15574000 8479000 3046000 1965000 255495000 269869000 9984000 0 7915000 5311000 5296000 5805000 204000 204000 278894000 281189000 9989000 7209000 17477000 13516000 6125000 0 33591000 20725000 18799000 24746000 6080000 5886000 124000 85000 58594000 51442000 0.001 0.001 10000000 10000000 0 0 0 0 0 0 0.001 0.001 200000000 200000000 27350959 27350959 27069276 27069276 27000 27000 497280000 467038000 -9000 29000 -276998000 -237347000 220300000 229747000 278894000 281189000 61685000 35842000 154996000 69372000 8624000 5211000 22123000 10462000 53061000 30631000 132873000 58910000 9614000 7307000 27056000 18807000 53243000 33216000 143846000 89249000 62857000 40523000 170902000 108056000 -9796000 -9892000 -38029000 -49146000 22000 125000 110000 1015000 537000 533000 1590000 1584000 -33000 2000 -90000 83000 -548000 -406000 -1570000 -486000 -10344000 -10298000 -39599000 -49632000 3000 87000 52000 87000 -10347000 -10385000 -39651000 -49719000 3000 -81000 -38000 -29000 -10344000 -10466000 -39689000 -49748000 -0.38 -0.38 -0.39 -0.39 -1.46 -1.46 -1.93 -1.93 27300377 27300377 26835603 26835603 27225499 27225499 25767497 25767497 27069276 27000 467038000 29000 -237347000 229747000 133421 3550000 3550000 376 73000 73000 5997000 5997000 -20000 -20000 -16216000 -16216000 27203073 27000 476658000 9000 -253563000 223131000 49318 1719000 1719000 329 72000 72000 11351 1760000 1760000 6341000 6341000 -21000 -21000 -13088000 -13088000 27264071 27000 486550000 -12000 -266651000 219914000 86473 3843000 3843000 415 77000 77000 6810000 6810000 3000 3000 -10347000 -10347000 27350959 27000 497280000 -9000 -276998000 220300000 24107350 24000 319865000 102000 -180156000 139835000 254142 787000 787000 897 72000 72000 2749000 2749000 193000 193000 12000 12000 -16245000 -16245000 24362389 24000 323473000 295000 -196389000 127403000 70853 732000 732000 1119 73000 73000 2300000 3000 124651000 124654000 16730 1059000 1059000 2903000 2903000 -141000 -141000 -23089000 -23089000 26751091 27000 452891000 154000 -219478000 233594000 168970 2312000 2312000 784 72000 72000 3311000 3311000 -81000 -81000 -10385000 -10385000 26920845 27000 458586000 73000 -229863000 228823000 -39651000 -49719000 874000 587000 15000 66000 178000 166000 509000 743000 19148000 8963000 222000 217000 -53000 89000 1743000 7921000 7095000 3132000 1081000 15000 3490000 2262000 4228000 -931000 -20853000 -48935000 4135000 1851000 9993000 52721000 43800000 129803000 29672000 75231000 9112000 3831000 0 124654000 1760000 1059000 10872000 129544000 -9000 5000 19682000 155845000 190518000 22860000 210200000 178705000 1417000 1422000 657000 0 Organization<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inspire Medical Systems, Inc. is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first and only United States ("U.S.") Food and Drug Administration ("FDA") approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. Inspire therapy received premarket approval ("PMA") from the FDA in April 2014 and has been commercially available in certain European markets since November 2011. Japan's Ministry of Health, Labour and Welfare ("MLHW") approved Inspire therapy to treat moderate to severe OSA in June 2018 and was formally added to the Japan National Health Insurance Payment Listing in June 2021. In August 2020, the Australian Therapeutic Goods Administration approved Inspire therapy to treat moderate to severe OSA, and we are currently seeking reimbursement coverage in Australia.</span></div> Summary of Significant Accounting Policies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, the results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods. For a complete discussion of our significant accounting policies and other information, the unaudited financial statements and notes thereto should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Follow-On Public Offering</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 16, 2020, we completed a follow-on offering that included our offer and sale of 2,300,000 shares of common stock at a public offering price of $58.00 per share. We received net proceeds of approximately $124.7 million after deducting underwriting discounts and commissions and offering expenses.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid securities, readily convertible to cash, that mature within 90 days or less from the date of purchase to be cash equivalents. The carrying amount reported in the balance sheets for cash is cost, which approximates fair value.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales and expenses denominated in foreign currencies are translated at average exchange rates in effect throughout the year. Foreign currency transaction gains and losses are included in other expense (income), net, in the statements of operations and comprehensive loss. Assets and liabilities of foreign operations are remeasured at period-end exchange rates with the impacts of foreign currency remeasurement recognized in other expense (income), net in the statements of operations and comprehensive loss. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2020, our short-term investments consisted of commercial paper, corporate bonds, and U.S. government securities, which are classified as available-for-sale and had maturities less than one year. Our long-term investments at September 30, 2021 consisted of U.S. government securities. Investments are reported at their estimated fair market values which are based on quoted, active or inactive market prices when available. Any unrealized gains and losses due to interest rate fluctuations and other external factors are reported as a separate component of accumulated other comprehensive (loss) income. We had less than $0.1 million of unrecognized loss in accumulated other comprehensive (loss) income at September 30, 2021 and less than $0.1 million of unrecognized gain in accumulated other comprehensive (loss) income at December 31, 2020. Any realized gains and losses are calculated on the specific identification method and reported net in other expense (income), net in the statements of operations and comprehensive loss. For both of the three months ended September 30, 2021 and 2020, we recognized $0 of realized gains, net. For the nine months ended September 30, 2021 and 2020, we recognized $0 and $0.1 million of realized gains, net, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize expected credit losses on investments in accordance with Accounting Standards Update ("ASU"), ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2016-13"), which we adopted effective January 1, 2020 using the modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on the amount and timing of credit losses recognized in our financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reassess our estimated credit losses on investments each reporting period. U.S. government securities and cash equivalents are under a "zero-loss exception" for credit losses, meaning no credit loss risk calculation is necessary on those instruments due to the exceptionally low rate of default, which continues to decrease as the securities approach maturity, which for us is no longer than two years. For non-U.S. government securities, we use a discounted cash flow approach to calculate expected credit losses using estimated default rates based upon historical loss data, current conditions, as well as expectations of future economic conditions. We record changes in the allowance for credit losses for available-for-sale debt securities with a corresponding adjustment in credit loss expense on the statement of operations and comprehensive loss. No reversal of a previously recorded allowance for credit losses may be made to an amount below zero. The total allowance for credit losses was $0 at both September 30, 2021 and December 31, 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and investments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Observable inputs, such as quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs that are supported by little or no market activities, which would require us to develop our own assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the methods and assumptions described below in determining the fair value of our financial instruments.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money market funds: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values of money market funds are based on quoted market prices in active markets. These are included as Level 1 measurements in the tables below.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial paper:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term, highly liquid investments are included as a Level 2 measurement in the table below.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate bonds:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consists of short-term notes and bonds with various yields. These are included as a Level 2 measurement in the table below.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. government securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of U.S. government Treasury bills and notes with original maturities of less than one year to two years. These are included as a Level 1 measurement in the tables below.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth by level within the fair value hierarchy our assets that are measured on a recurring basis and reported at fair value as of September 30, 2021 and December 31, 2020. Assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,029 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,815 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,418 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,815 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods ended September 30, 2021 and December 31, 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of September 30, 2021 and December 31, 2020, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Expected Credit Losses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the general standard being net 30 days. Collateral or any other security to support payment of these receivables generally is not required. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize expected credit losses on accounts receivable in accordance with Accounting Standards Update ("ASU"), ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2016-13"), which we adopted effective January 1, 2020 using the modified retrospective approach through a cumulative-effect adjustment to retained earnings. The adoption of ASU 2016-13 did not have a material impact on the amount and timing of credit losses recognized in our financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, we estimate the credit loss related to accounts receivable based on a migration analysis of accounts grouped by individual receivables delinquency status, and apply our historic loss rate adjusted for management's assumption of future market conditions. Any change in the allowance subsequent to the effective date of January 1, 2020 from new receivables acquired, or changes due to credit deterioration on previously existing receivables, is recorded in selling, general and administrative expenses. Write-offs of receivables considered uncollectible are deducted from the allowance. Specific accounts receivable are written-off once a determination is made that the amount is uncollectible. The write-off is recorded in the period in which the account receivable is deemed uncollectible. Recoveries are recognized when received and as a direct credit to earnings or as a reduction to the allowance for credit losses (which would indirectly reduce the loss by decreasing bad debt expense).</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value, computed on a first-in, first-out basis and consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,865 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,709 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,587 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net of reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,574 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,479 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review inventory quantities on-hand for excess and obsolete inventory and, when circumstances indicate, incur charges to write down inventories to their net realizable value. The determination of a reserve for excess and obsolete inventory involves management exercising judgment to determine the required reserve, considering future demand, product life cycles, introduction of new products and current market conditions. The reserve for excess and obsolete inventory was $0.3 million and $0.1 million as of September 30, 2021 and December 31, 2020, respectively. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation and amortization and consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,623 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,156 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,915 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,311 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgwMGEyZmY2ZDgxMzQ3ZDdhMTkzMDllNzBkNDRlMDEwL3NlYzo4MDBhMmZmNmQ4MTM0N2Q3YTE5MzA5ZTcwZDQ0ZTAxMF8zNy9mcmFnOmEwZTYzYjhjN2NjNTQxNGU4Y2I3OWM4ZDRjOGVkMWU5L3RleHRyZWdpb246YTBlNjNiOGM3Y2M1NDE0ZThjYjc5YzhkNGM4ZWQxZTlfMTE1ODU_3e9d8a07-df91-49c3-bae9-e7b8723ccad4">three</span> to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Depreciation and amortization expense was $0.3 million and $0.2 million for the three months ended September 30, 2021 and 2020, respectively, and $0.9 million and $0.6 million for the nine months ended September 30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-lived Assets</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist primarily of property and equipment and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require that an asset be tested for possible impairment, we compare the undiscounted cash flows expected to be generated by the asset to the carrying amount of the asset. If the carrying amount of the asset is not recoverable on an undiscounted cash flow basis, we determine the fair value of the asset and recognize an impairment loss to the extent the carrying amount of the asset exceeds its fair value. We determine fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. Our cash flow assumptions consider historical and forecasted revenue and operating costs and other relevant factors. We did not record any impairment charges on long-lived assets during either of the nine months ended September 30, 2021 or 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accrued Expenses</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,965 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,477 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,516 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 606"). Revenues from product sales are recognized when the customer obtains control of the product, which occurs at a point in time, either upon shipment of the product or receipt of the product, </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depending on shipment terms. Our standard shipping terms are free on board shipping point, unless the customer requests that control of the inventory transfer upon delivery. In those cases where shipping and handling costs are billed to customers, we classify the amounts billed as a component of cost of goods sold.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. The majority of our contracts have a single performance obligation and are short term in nature.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable consideration related to certain customer sales incentives is estimated based on the amounts expected to be paid based on the agreement with the customer using probability assessments. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer customers a limited right of return for our product in case of non-conformity or performance issues. We estimate the amount of our product sales that may be returned by our customers based on historical sales and returns. As our historical product returns to date have been immaterial, we have not recorded a reduction in revenue related to variable consideration for product returns.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 9 for disaggregated revenue by geographic area.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold consists primarily of acquisition costs for the components of the Inspire system, overhead costs, scrap and inventory obsolescence, warranty replacement costs, as well as distribution-related expenses such as logistics and shipping costs, net of shipping costs charged to customers. The overhead costs include the cost of material procurement, depreciation expense for production equipment, and operations supervision and management personnel, including employee compensation, stock-based compensation, supplies, and travel.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of product development, clinical and regulatory affairs, quality assurance, consulting services, and other costs associated with products and technologies in development. These expenses include employee compensation, including stock-based compensation, supplies, materials, consulting, and travel expenses related to research and development programs. Clinical expenses include clinical trial design, clinical site reimbursement, data management, travel expenses, and the cost of manufacturing products for clinical trials.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an equity incentive plan to provide lon</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g-term incentives for eligible employees, consultants, and members of the board of directors. The plan allows for the issuance of restricted stock units ("RSUs") and non-statutory and incentive stock options to employees and RSUs and non-statutory stock options to consultants and directors. We also offer an employee stock purchase plan which</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allows participating employees to purchase shares of our common stock at a discount through payroll deductions. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize equity-based compensation expense for awards of equity instruments to employees and directors based on the grant date fair value of those awards in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"). ASC 718 requires all equity-based compensation awards to employees and directors, including grants of RSUs and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the fair value of stock options using the Black-Scholes option </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pricing model and the fair value of RSUs is equal to the closing price of our common stock on the grant date. The fair value of each purchase under the employee stock purchase plan is estimated at the beginning of the offering period using the Black-Scholes option pricing model. We have not granted any stock-based awards to our consultants.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i) the expected share price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) the expected dividend yield. Due to our limited operating history and a lack of company specific historical and implied volatility data, we have incorporated our historical stock trading volatility with those of a peer group of public companies for the calculation of volatility. The group of peer companies have characteristics similar to us, including stage of product development and focus on the life science industry. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. We use the simplified method, which is the average of the final vesting tranche date and the contractual term, to calculate the expected term for options granted to employees and directors as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is based on a U.S. government Treasury instrument whose term is consistent with the expected term of the stock options. We use an assumed dividend yield of zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense the fair value of our equity-based compensation awards granted to employees and directors on a straight-line basis over the associated service period, which is generally the period in which the related services are received. We account for award forfeitures as they occur.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Expenses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $13.4 million and $6.8 million during the three months ended September 30, 2021 and 2020, respectively, and $34.0 million and $18.2 million during the nine months ended September 30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in operating lease right-of-use ("ROU") asset, accrued expenses, and operating lease liability – non-current portion in our balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of our incremental borrowing rate requires management judgment based on information available at lease commencement. The operating lease ROU assets also include adjustments for prepayments, accrued lease payments and exclude lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise such options. Operating lease cost is recognized on a straight-line basis over the expected lease term. Lease agreements entered into after the adoption of ASC 842 that include lease and non-lease components are accounted for as a single lease component. Lease agreements with a noncancelable term of less than 12 months are not recorded on our balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances against deferred tax assets are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized. As we have historically incurred operating losses, we have recorded a full valuation allowance against our net deferred tax assets, and there is no provision for income taxes other than </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">minimal state taxes and an accrual for uncertain tax benefits. Our policy is to record interest and penalties expense related to uncertain tax positions as other expense in the statements of operations and comprehensive loss.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss consists of net loss and changes in unrealized gains and losses due to interest rate fluctuations and other external factors on investments classified as available-for-sale. Accumulated other comprehensive (loss) income is presented in the accompanying balance sheets as a component of stockholders' equity.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Because we have reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share as all potentially dilutive shares consisting of outstanding stock options, unvested RSUs, and shares issuable under our employee stock purchase plan were antidilutive in those periods.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed and considered all recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on our business practices, financial condition, results of operations, or disclosures.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, the results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods. For a complete discussion of our significant accounting policies and other information, the unaudited financial statements and notes thereto should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.</span></div> 2300000 58.00 124700000 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid securities, readily convertible to cash, that mature within 90 days or less from the date of purchase to be cash equivalents. The carrying amount reported in the balance sheets for cash is cost, which approximates fair value.</span></div> Foreign CurrencySales and expenses denominated in foreign currencies are translated at average exchange rates in effect throughout the year. Foreign currency transaction gains and losses are included in other expense (income), net, in the statements of operations and comprehensive loss. Assets and liabilities of foreign operations are remeasured at period-end exchange rates with the impacts of foreign currency remeasurement recognized in other expense (income), net in the statements of operations and comprehensive loss. InvestmentsAt December 31, 2020, our short-term investments consisted of commercial paper, corporate bonds, and U.S. government securities, which are classified as available-for-sale and had maturities less than one year. Our long-term investments at September 30, 2021 consisted of U.S. government securities. Investments are reported at their estimated fair market values which are based on quoted, active or inactive market prices when available. Any unrealized gains and losses due to interest rate fluctuations and other external factors are reported as a separate component of accumulated other comprehensive (loss) income. 100000 100000 0 0 100000 100000 0 0 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and investments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1—Observable inputs, such as quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2—Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3—Unobservable inputs that are supported by little or no market activities, which would require us to develop our own assumptions.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the methods and assumptions described below in determining the fair value of our financial instruments.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money market funds: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values of money market funds are based on quoted market prices in active markets. These are included as Level 1 measurements in the tables below.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial paper:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Short-term, highly liquid investments are included as a Level 2 measurement in the table below.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate bonds:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consists of short-term notes and bonds with various yields. These are included as a Level 2 measurement in the table below.</span></div><div style="margin-bottom:12pt;padding-left:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. government securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consists of U.S. government Treasury bills and notes with original maturities of less than one year to two years. These are included as a Level 1 measurement in the tables below.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth by level within the fair value hierarchy our assets that are measured on a recurring basis and reported at fair value as of September 30, 2021 and December 31, 2020. Assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,029 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,815 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,418 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,815 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods ended September 30, 2021 and December 31, 2020.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth by level within the fair value hierarchy our assets that are measured on a recurring basis and reported at fair value as of September 30, 2021 and December 31, 2020. Assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,355 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,339 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements as of</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,389 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,844 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,029 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,815 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,418 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,815 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 189355000 189355000 0 0 189355000 189355000 0 0 9984000 9984000 0 0 9984000 9984000 0 0 199339000 199339000 0 0 179389000 179389000 0 0 179389000 179389000 0 0 13275000 0 13275000 0 6540000 0 6540000 0 24029000 24029000 0 0 43844000 24029000 19815000 0 223233000 203418000 19815000 0 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of September 30, 2021 and December 31, 2020, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Expected Credit Losses</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the general standard being net 30 days. Collateral or any other security to support payment of these receivables generally is not required. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize expected credit losses on accounts receivable in accordance with Accounting Standards Update ("ASU"), ASU 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2016-13"), which we adopted effective January 1, 2020 using the modified retrospective approach through a cumulative-effect adjustment to retained earnings. The adoption of ASU 2016-13 did not have a material impact on the amount and timing of credit losses recognized in our financial statements.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each reporting period, we estimate the credit loss related to accounts receivable based on a migration analysis of accounts grouped by individual receivables delinquency status, and apply our historic loss rate adjusted for management's assumption of future market conditions. Any change in the allowance subsequent to the effective date of January 1, 2020 from new receivables acquired, or changes due to credit deterioration on previously existing receivables, is recorded in selling, general and administrative expenses. Write-offs of receivables considered uncollectible are deducted from the allowance. Specific accounts receivable are written-off once a determination is made that the amount is uncollectible. The write-off is recorded in the period in which the account receivable is deemed uncollectible. Recoveries are recognized when received and as a direct credit to earnings or as a reduction to the allowance for credit losses (which would indirectly reduce the loss by decreasing bad debt expense).</span></div> <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost or net realizable value, computed on a first-in, first-out basis and consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,865 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,709 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,587 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net of reserves</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,574 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,479 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1865000 892000 13709000 7587000 15574000 8479000 We regularly review inventory quantities on-hand for excess and obsolete inventory and, when circumstances indicate, incur charges to write down inventories to their net realizable value. The determination of a reserve for excess and obsolete inventory involves management exercising judgment to determine the required reserve, considering future demand, product life cycles, introduction of new products and current market conditions. 300000 100000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation and amortization and consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,285 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,380 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,623 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,156 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,845)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,915 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,311 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1391000 1305000 4322000 2285000 249000 249000 281000 192000 4380000 3125000 10623000 7156000 2708000 1845000 7915000 5311000 Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgwMGEyZmY2ZDgxMzQ3ZDdhMTkzMDllNzBkNDRlMDEwL3NlYzo4MDBhMmZmNmQ4MTM0N2Q3YTE5MzA5ZTcwZDQ0ZTAxMF8zNy9mcmFnOmEwZTYzYjhjN2NjNTQxNGU4Y2I3OWM4ZDRjOGVkMWU5L3RleHRyZWdpb246YTBlNjNiOGM3Y2M1NDE0ZThjYjc5YzhkNGM4ZWQxZTlfMTE1ODU_3e9d8a07-df91-49c3-bae9-e7b8723ccad4">three</span> to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. P5Y 300000 200000 900000 600000 Impairment of Long-lived AssetsLong-lived assets consist primarily of property and equipment and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require that an asset be tested for possible impairment, we compare the undiscounted cash flows expected to be generated by the asset to the carrying amount of the asset. If the carrying amount of the asset is not recoverable on an undiscounted cash flow basis, we determine the fair value of the asset and recognize an impairment loss to the extent the carrying amount of the asset exceeds its fair value. We determine fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. Our cash flow assumptions consider historical and forecasted revenue and operating costs and other relevant factors. <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of the following: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,876 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,965 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,419 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,391 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,477 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,516 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 14876000 11965000 155000 160000 27000 0 2419000 1391000 17477000 13516000 <div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue in accordance with Accounting Standards Codification ("ASC") Topic 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 606"). Revenues from product sales are recognized when the customer obtains control of the product, which occurs at a point in time, either upon shipment of the product or receipt of the product, </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">depending on shipment terms. Our standard shipping terms are free on board shipping point, unless the customer requests that control of the inventory transfer upon delivery. In those cases where shipping and handling costs are billed to customers, we classify the amounts billed as a component of cost of goods sold.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. The majority of our contracts have a single performance obligation and are short term in nature.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable consideration related to certain customer sales incentives is estimated based on the amounts expected to be paid based on the agreement with the customer using probability assessments. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer customers a limited right of return for our product in case of non-conformity or performance issues. We estimate the amount of our product sales that may be returned by our customers based on historical sales and returns. As our historical product returns to date have been immaterial, we have not recorded a reduction in revenue related to variable consideration for product returns.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold consists primarily of acquisition costs for the components of the Inspire system, overhead costs, scrap and inventory obsolescence, warranty replacement costs, as well as distribution-related expenses such as logistics and shipping costs, net of shipping costs charged to customers. The overhead costs include the cost of material procurement, depreciation expense for production equipment, and operations supervision and management personnel, including employee compensation, stock-based compensation, supplies, and travel.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of product development, clinical and regulatory affairs, quality assurance, consulting services, and other costs associated with products and technologies in development. These expenses include employee compensation, including stock-based compensation, supplies, materials, consulting, and travel expenses related to research and development programs. Clinical expenses include clinical trial design, clinical site reimbursement, data management, travel expenses, and the cost of manufacturing products for clinical trials.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an equity incentive plan to provide lon</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g-term incentives for eligible employees, consultants, and members of the board of directors. The plan allows for the issuance of restricted stock units ("RSUs") and non-statutory and incentive stock options to employees and RSUs and non-statutory stock options to consultants and directors. We also offer an employee stock purchase plan which</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> allows participating employees to purchase shares of our common stock at a discount through payroll deductions. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize equity-based compensation expense for awards of equity instruments to employees and directors based on the grant date fair value of those awards in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Compensation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASC 718"). ASC 718 requires all equity-based compensation awards to employees and directors, including grants of RSUs and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the fair value of stock options using the Black-Scholes option </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pricing model and the fair value of RSUs is equal to the closing price of our common stock on the grant date. The fair value of each purchase under the employee stock purchase plan is estimated at the beginning of the offering period using the Black-Scholes option pricing model. We have not granted any stock-based awards to our consultants.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i) the expected share price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) the expected dividend yield. Due to our limited operating history and a lack of company specific historical and implied volatility data, we have incorporated our historical stock trading volatility with those of a peer group of public companies for the calculation of volatility. The group of peer companies have characteristics similar to us, including stage of product development and focus on the life science industry. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. We use the simplified method, which is the average of the final vesting tranche date and the contractual term, to calculate the expected term for options granted to employees and directors as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is based on a U.S. government Treasury instrument whose term is consistent with the expected term of the stock options. We use an assumed dividend yield of zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense the fair value of our equity-based compensation awards granted to employees and directors on a straight-line basis over the associated service period, which is generally the period in which the related services are received. We account for award forfeitures as they occur.</span></div> 0 Advertising ExpensesWe expense the costs of advertising, including promotional expenses, as incurred. 13400000 6800000 34000000 18200000 <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in operating lease right-of-use ("ROU") asset, accrued expenses, and operating lease liability – non-current portion in our balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of our incremental borrowing rate requires management judgment based on information available at lease commencement. The operating lease ROU assets also include adjustments for prepayments, accrued lease payments and exclude lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise such options. Operating lease cost is recognized on a straight-line basis over the expected lease term. Lease agreements entered into after the adoption of ASC 842 that include lease and non-lease components are accounted for as a single lease component. Lease agreements with a noncancelable term of less than 12 months are not recorded on our balance sheets.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances against deferred tax assets are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized. As we have historically incurred operating losses, we have recorded a full valuation allowance against our net deferred tax assets, and there is no provision for income taxes other than </span></div>minimal state taxes and an accrual for uncertain tax benefits. Our policy is to record interest and penalties expense related to uncertain tax positions as other expense in the statements of operations and comprehensive loss. <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss consists of net loss and changes in unrealized gains and losses due to interest rate fluctuations and other external factors on investments classified as available-for-sale. Accumulated other comprehensive (loss) income is presented in the accompanying balance sheets as a component of stockholders' equity.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Because we have reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share as all potentially dilutive shares consisting of outstanding stock options, unvested RSUs, and shares issuable under our employee stock purchase plan were antidilutive in those periods.</span></div> <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed and considered all recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on our business practices, financial condition, results of operations, or disclosures.</span></div> Investments<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are classified as available-for-sale and consist of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:50.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-Term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,993 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:50.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-Term:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,815 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,844 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and December 31, 2020, we had no investments with a contractual maturity of greater than two years. Currently, we do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. We do not consider those investments to be other-than-temporarily impaired as of September 30, 2021. At the end of each reporting period, we evaluate potential credit impairment on available-for-sale securities in an unrealized loss </span></div>position, based on the expected cash flows to be collected and the yield-to-maturity on those securities. Securities with a valuation allowance for expected credit losses and deemed uncollectible are permanently written-down, and a reversal out of the valuation allowance occurs. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are classified as available-for-sale and consist of the following:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:50.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-Term:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,993 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,984 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:50.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-Term:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,275 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,540 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,997 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,815 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,844 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 9993000 0 9000 9984000 9993000 0 9000 9984000 13275000 0 0 13275000 6543000 0 3000 6540000 23997000 32000 0 24029000 43815000 32000 3000 43844000 0 0 Leases<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, we entered into a non-cancelable operating lease agreement to sublease approximately 45,000 square feet of office space for our corporate headquarters, which included real estate taxes and operating expenses in the base rent. This lease commenced January 15, 2019 and expired November 30, 2020. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, we entered into a new, non-cancelable operating lease agreement for the same space directly with the landlord. The initial lease term commenced on December 1, 2020 and expires May 31, 2028 with an option to renew for one additional period of five years at the then-prevailing market rate. The exercise of the lease renewal option is at our sole discretion and was not included in the lease term for the calculation of the ROU asset and lease liability when the lease commenced on December 1, 2020 as it is not reasonably certain of exercise.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning December 1, 2020, in addition to base rent, we also pay our proportionate share of the operating expenses, as defined in the lease. These payments are made monthly and adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance. In conjunction with this lease, the landlord agreed to provide a $0.6 million rent abatement and a refurbishment allowance in the amount of the cost of any leasehold improvements, not to exceed approximately $1.1 million upon Inspire providing the necessary documentation evidencing the costs of the leasehold improvements that are completed by May 31, 2022. However, the lease allows us to allocate the refurbishment allowance against base rent instead of taking a tenant improvement reimbursement. At this time, we intend to allocate the full amount of the refurbishment allowance against base rent.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into a new, non-cancelable operating lease agreement for approximately 25,000 square feet of additional corporate office space with our existing landlord. The initial lease term commences on October 1, 2021 and expires May 31, 2028 with an option to renew for one additional period of 5 years at the then-prevailing market rate. The exercise of the lease renewal option is at our sole discretion and will not be included in the lease term for the calculation of the ROU asset and lease liability when the lease commences on October 1, 2021 as it is not reasonably certain of exercise. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning October 1, 2021, in addition to base rent on the additional space, we will also pay our proportionate share of the operating expenses, as defined in the lease. These payments will be made monthly and will be adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance. In conjunction with this lease, the landlord agreed to provide a $0.2 million rent abatement and a refurbishment allowance in the amount of the cost of any leasehold improvements, not to exceed $0.4 million upon Inspire providing the necessary documentation evidencing the costs of the leasehold improvements that are completed by May 31, 2022. However, the lease allows us to allocate the refurbishment allowance against base rent instead of taking a tenant improvement reimbursement. At this time, we intend to allocate the full amount of the refurbishment allowance against base rent. The total minimum lease payments related to this forward-starting lease are $3.6 million.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the lease balances within the balance sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgwMGEyZmY2ZDgxMzQ3ZDdhMTkzMDllNzBkNDRlMDEwL3NlYzo4MDBhMmZmNmQ4MTM0N2Q3YTE5MzA5ZTcwZDQ0ZTAxMF80My9mcmFnOjhhNDk3YWY3NWM2OTRjNDM4Yzk0NTZjMjhhMjlmYzFkL3RhYmxlOjhiN2FjZTA1Nzk2ZTRlMGJiNjRhZWRmMzI2ZGQ1ZmI0L3RhYmxlcmFuZ2U6OGI3YWNlMDU3OTZlNGUwYmI2NGFlZGYzMjZkZDVmYjRfNC0yLTEtMS0w_23ff343b-1b1a-4a7b-afea-c8279947b126">27</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgwMGEyZmY2ZDgxMzQ3ZDdhMTkzMDllNzBkNDRlMDEwL3NlYzo4MDBhMmZmNmQ4MTM0N2Q3YTE5MzA5ZTcwZDQ0ZTAxMF80My9mcmFnOjhhNDk3YWY3NWM2OTRjNDM4Yzk0NTZjMjhhMjlmYzFkL3RhYmxlOjhiN2FjZTA1Nzk2ZTRlMGJiNjRhZWRmMzI2ZGQ1ZmI0L3RhYmxlcmFuZ2U6OGI3YWNlMDU3OTZlNGUwYmI2NGFlZGYzMjZkZDVmYjRfNC00LTEtMS0w_0279eca1-3196-4acf-b9a5-e520ecc0d0ed">—</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,107 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the remaining lease term was 6.7 years and the discount rate was 5.2%. The operating cash outflows from our operating leases were $0.1 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively, and $0.1 million and $0.8 million for the nine months ended September 30, 2021 and 2020, respectively.</span></div> 45000 1 P5Y 600000 1100000 25000 1 P5Y 200000 400000 3600000 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the lease balances within the balance sheets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.031%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,296 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,805 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgwMGEyZmY2ZDgxMzQ3ZDdhMTkzMDllNzBkNDRlMDEwL3NlYzo4MDBhMmZmNmQ4MTM0N2Q3YTE5MzA5ZTcwZDQ0ZTAxMF80My9mcmFnOjhhNDk3YWY3NWM2OTRjNDM4Yzk0NTZjMjhhMjlmYzFkL3RhYmxlOjhiN2FjZTA1Nzk2ZTRlMGJiNjRhZWRmMzI2ZGQ1ZmI0L3RhYmxlcmFuZ2U6OGI3YWNlMDU3OTZlNGUwYmI2NGFlZGYzMjZkZDVmYjRfNC0yLTEtMS0w_23ff343b-1b1a-4a7b-afea-c8279947b126">27</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgwMGEyZmY2ZDgxMzQ3ZDdhMTkzMDllNzBkNDRlMDEwL3NlYzo4MDBhMmZmNmQ4MTM0N2Q3YTE5MzA5ZTcwZDQ0ZTAxMF80My9mcmFnOjhhNDk3YWY3NWM2OTRjNDM4Yzk0NTZjMjhhMjlmYzFkL3RhYmxlOjhiN2FjZTA1Nzk2ZTRlMGJiNjRhZWRmMzI2ZGQ1ZmI0L3RhYmxlcmFuZ2U6OGI3YWNlMDU3OTZlNGUwYmI2NGFlZGYzMjZkZDVmYjRfNC00LTEtMS0w_0279eca1-3196-4acf-b9a5-e520ecc0d0ed">—</span> </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,080 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,107 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,886 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5296000 5805000 27000 0 6080000 5886000 6107000 5886000 P6Y8M12D 0.052 100000 300000 100000 800000 Long-Term Debt<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2015, we entered into a loan and security agreement that initially provided for a term A loan facility in the amount of $15.5 million, which was fully funded on the closing date, and a term B loan facility in an amount between $3.5 million and $10.0 million, subject to our achievement of certain revenue milestones. We refer to our term A loan facility and our term loan B facility together as our credit facility. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2017, we amended the loan and security agreement to, among other things, increase borrowings under the term A loan facility by $1.0 million, for a total of $16.5 million outstanding under the credit facility, and reduced borrowings available under the term B loan facility to $9.0 million.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, we borrowed an additional $8.0 million under the term B loan facility portion of the credit facility for a total of $24.5 million outstanding under the credit facility.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2019, we amended the loan and security agreement. The amendment modified the terms of the loan and security agreement to: (1) extend the interest-only date from March 1, 2020 to April 1, 2022 and extend the maturity date from February 1, 2022 to March 1, 2024; (2) reduce the final payment percentage from 5.50% to 3.50%; (3) modify the basic rate to be a per annum rate of interest (based on a year of 360 days) equal to the sum of (i) the greater of (A) the 30 day U.S. LIBOR rate reported in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wall Street Journal</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the last business day of the month that immediately precedes the month in which the interest will accrue or (B) 2.50%, plus (ii) 5.10%; provided, however, under no circumstances will the basic rate be less than 7.60%; (4) provide a mechanism for determining an alternative interest rate to replace the U.S. LIBOR rate upon the occurrence of certain circumstances; and (5) revise the prepayment fee to be between 1.00% and 3.00% of the principal amount, depending on the timing of any prepayment. Upon closing the amendment to the loan and security agreement, payment of the previously accrued final payment under the credit facility was required.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the principal and interest payments, under the credit facility, we are required to pay a final payment fee of 3.50% on all amounts outstanding, which is being accreted using the effective interest rate method over the term of the loan and security agreement and shall be due at the earlier of maturity or prepayment. Borrowings are prepayable at our option in whole, but not in part, together with all accrued and unpaid interest thereon and, if not previously made, the final payment, subject to a prepayment fee of 1.00%.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The credit facility includes affirmative and restrictive covenants and events of default, including the following events of default: payment defaults, breaches of covenants, judgment defaults, cross defaults to certain other contracts, certain events with respect to governmental approvals if such events could cause a material adverse change, a material impairment in the perfection or priority of the lender's security interest or in the value of the collateral, a </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material adverse change in the business, operations, or condition of us or any of our subsidiaries, and a material impairment of the prospect of repayment of the loans. Upon the occurrence of an event of default, a default increase in the interest rate of an additional 5.00% could be applied to the outstanding loan balance and the lender could declare all outstanding obligations immediately due and payable and take such other actions as set forth in the loan and security agreement.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the credit facility are secured by a first priority security interest in substantially all of our assets, other than our intellectual property. There are no financial covenants contained in the loan and security agreement. We were in compliance with the affirmative and restrictive covenants as of September 30, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future principal payments for the credit facility are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expected future principal payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 15500000 3500000 10000000 1000000 16500000 9000000 8000000 24500000 0.0550 0.0350 0.0250 0.0510 0.0760 0.0100 0.0300 0.0350 0.0100 0.0500 <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future principal payments for the credit facility are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 (remaining)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,062 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expected future principal payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,500 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 0 9188000 12250000 3062000 24500000 Employee Retirement PlanWe sponsor an employee retirement plan covering all of our full-time employees. The plan allows for eligible employees to defer a portion of their eligible compensation up to the maximum allowed by IRS Regulations. We may elect to make a voluntary contribution to the plan. We have not made contributions since inception. Stockholders' Equity<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adopted the 2007 Stock Incentive Plan (the "2007 Plan") in November 2007, which terminated in accordance with its terms on November 28, 2017; however, the outstanding stock options may continue to be exercised in accordance with their terms. Immediately following the termination of the 2007 Plan, we adopted the 2017 Stock Incentive Plan (the "2017 Plan"), which contains substantially similar terms and conditions as the 2007 Plan. Upon the IPO, no further grants were made under the 2017 Plan and we adopted the 2018 Stock Incentive Plan (the "2018 Plan"). </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the 2018 Plan is to promote the interest of our company and our stockholders by aiding in attracting and retaining employees, officers, consultants, independent contractors, and directors capable of assuring the future success of our business and to afford such persons an opportunity to acquire a proprietary interest in our company. The board of directors may amend, alter, suspend, discontinue, or terminate the 2018 Plan at any time with the approval of our stockholders. A total of 1,386,809 shares of common stock were initially reserved for issuance under the 2018 Plan, and this share reserve will automatically be supplemented each January 1, commencing on January 1, 2019 and ending on and including January 1, 2028, by an amount of shares equal to the lesser of: a) 739,631 shares, b) 4% of the shares outstanding on the final day of the immediately preceding fiscal year and c) such smaller number of shares as determined by the board of directors. As of September 30, 2021, there were 3,284,769 shares reserved for issuance under the 2018 Plan, of which 1,293,557 shares were available for issuance. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of stock-based compensation expense recognized for stock options and RSUs granted under the 2017 Plan, the 2018 Plan and under our Employee Stock Purchase Plan (the "ESPP"):</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,065 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,148 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,963 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,810 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,148 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,963 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the IPO, the exercise price of stock options represented fair value of the common stock at the time of issuance and was determined by the board of directors with the assistance of a third-party valuation specialist. Post-IPO, options are granted at the exercise price, which is equal to the closing price of our stock on the date of grant. The stock options granted to employees include a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgwMGEyZmY2ZDgxMzQ3ZDdhMTkzMDllNzBkNDRlMDEwL3NlYzo4MDBhMmZmNmQ4MTM0N2Q3YTE5MzA5ZTcwZDQ0ZTAxMF81Mi9mcmFnOmMxZTA5NDE2NGRkZDQwMmFhZWYyMmM3NjMyZTQ0ZGNmL3RleHRyZWdpb246YzFlMDk0MTY0ZGRkNDAyYWFlZjIyYzc2MzJlNDRkY2ZfMjM1NQ_c56a9e7b-59de-4ecf-99fa-83d907488d5a">four</span>-year service period and 25% vest after the first year of service and the remainder vest in equal installments over the next 36 months of service. The stock options granted to the board of directors vest in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgwMGEyZmY2ZDgxMzQ3ZDdhMTkzMDllNzBkNDRlMDEwL3NlYzo4MDBhMmZmNmQ4MTM0N2Q3YTE5MzA5ZTcwZDQ0ZTAxMF81Mi9mcmFnOmMxZTA5NDE2NGRkZDQwMmFhZWYyMmM3NjMyZTQ0ZGNmL3RleHRyZWdpb246YzFlMDk0MTY0ZGRkNDAyYWFlZjIyYzc2MzJlNDRkY2ZfMjU1Ng_0755cff5-331d-4ae3-9203-aac70ba83469">one</span> or <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgwMGEyZmY2ZDgxMzQ3ZDdhMTkzMDllNzBkNDRlMDEwL3NlYzo4MDBhMmZmNmQ4MTM0N2Q3YTE5MzA5ZTcwZDQ0ZTAxMF81Mi9mcmFnOmMxZTA5NDE2NGRkZDQwMmFhZWYyMmM3NjMyZTQ0ZGNmL3RleHRyZWdpb246YzFlMDk0MTY0ZGRkNDAyYWFlZjIyYzc2MzJlNDRkY2ZfMjU2Mg_c574746a-d1ca-4ce3-8e63-4d22ce760cb5">three</span> equal annual installments, in each case, subject to the director's continuous service through the applicable vesting date. The stock options have a contractual life of ten years.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and related information is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual Term<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic<br/>Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,857,564 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.09 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$351,626</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$47,176</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,790)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$416,515</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$276,959</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised is the difference between the estimated fair market value of our common stock at the date of exercise and the exercise price for those options. The aggregate intrinsic value of outstanding options is the difference between the closing price as of the date outstanding and the exercise price of the underlying stock options.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the amount of unearned stock-based compensation to be expensed from now through the year 2025 related to unvested employee and non-employee director stock options is $70.0 million, which we expect to recognize over a weighted average period of 2.5 years. If there are any modifications or cancellations of the underlying unvested securities, we may be required to accelerate, increase, or cancel any remaining unearned stock compensation expense. Future stock-based compensation expense and unearned stock-based compensation will increase to the extent that we grant additional stock-based awards.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model using the fair market value of our common stock on the date of grant and a number of other assumptions. These </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions include estimates regarding the expected term of the awards, estimates of the stock volatility over a duration that approximates the expected term of the awards, estimates of the risk-free rate, and estimates of expected dividend rates.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options granted to employees and non-employee directors was estimated as of the grant date using the Black-Scholes option pricing model using the following assumptions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 - 6.25</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0 - 55.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3 - 49.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79 - 1.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36 - 1.42%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$109.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$38.33</span></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Due to our limited amount of historical exercise, forfeiture, and expiration activity, we have opted to use the "simplified method" for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting terms and the original contractual term of the option. We will continue to analyze our expected term assumption as more historical data becomes available.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Due to our limited operating history and a lack of company specific historical and implied volatility data, we have incorporated our historical stock trading volatility with those of a group of similar companies that are publicly traded for the calculation of volatility. When selecting this peer group of public companies on which we have based our expected stock price volatility, we generally selected companies with comparable characteristics to it, including enterprise value, stages of clinical development, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. We will continue to analyze the historical stock price volatility assumption as more historical data for our common stock becomes available.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The risk-free rate assumption is based on the U.S. government Treasury instruments with maturities similar to the expected term of our stock options.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The expected dividend assumption is based on our history of not paying dividends and our expectation that we will not declare dividends for the foreseeable future.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of stock-based compensation expense is recognized on a straight-line basis over the vesting term and is reduced by actual forfeitures as they occur.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs are share awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs include a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgwMGEyZmY2ZDgxMzQ3ZDdhMTkzMDllNzBkNDRlMDEwL3NlYzo4MDBhMmZmNmQ4MTM0N2Q3YTE5MzA5ZTcwZDQ0ZTAxMF81Mi9mcmFnOmMxZTA5NDE2NGRkZDQwMmFhZWYyMmM3NjMyZTQ0ZGNmL3RleHRyZWdpb246YzFlMDk0MTY0ZGRkNDAyYWFlZjIyYzc2MzJlNDRkY2ZfNjUzMw_7f0fdd9d-0860-4b79-8962-bae2e6639ad5">four</span>-year service period and vest in equal installments on each of the first <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgwMGEyZmY2ZDgxMzQ3ZDdhMTkzMDllNzBkNDRlMDEwL3NlYzo4MDBhMmZmNmQ4MTM0N2Q3YTE5MzA5ZTcwZDQ0ZTAxMF81Mi9mcmFnOmMxZTA5NDE2NGRkZDQwMmFhZWYyMmM3NjMyZTQ0ZGNmL3RleHRyZWdpb246YzFlMDk0MTY0ZGRkNDAyYWFlZjIyYzc2MzJlNDRkY2ZfNjYwOA_a6bf9a79-a852-48bd-b7dc-31e781673efd">four</span> anniversaries of the date of grant, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of our common stock on the grant date.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSUs and related information is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no RSUs granted prior to 2021. The aggregate intrinsic value of RSUs outstanding was based on our closing stock price on the last trading day of the period. As of September 30, 2021, there was $0.4 million of unrecognized stock-based compensation expense related to RSUs to be recognized over a period of 3.3 years.</span></div><div style="margin-bottom:12pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ESPP allows participating employees to purchase shares of our common stock at a discount through payroll deductions. The plan is available to all of our U.S.-based full-time employees. Participating employees may purchase common stock, on a voluntary after-tax basis, at a price equal to 85% of the lower of the closing market price per share of our common stock on the first or last trading day of each stock purchase period. The plan provides for six-month purchase periods, beginning on January 1 and July 1 of each calendar year. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A total of 277,362 shares of common stock were initially reserved for issuance under the ESPP, and this share reserve will automatically be supplemented each January 1, commencing on January 1, 2019 and ending on and including January 1, 2028, by an amount of shares equal to the lesser of: a) 184,908 shares, b) 1% of the shares outstanding on the final day of the immediately preceding calendar year and c) such smaller number of shares as the board of directors may determine. On June 30, 2021, 11,351 shares were purchased under the ESPP, utilizing $1.8 million of employee contributions. As of September 30, 2021, 754,752 shares were available for future issuance under the ESPP. The current purchase period under the ESPP began on July 1, 2021 and ends December 31, 2021.</span></div> 1386809 739631 0.04 3284769 1293557 The following table presents the components and classification of stock-based compensation expense recognized for stock options and RSUs granted under the 2017 Plan, the 2018 Plan and under our Employee Stock Purchase Plan (the "ESPP"):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,065 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,303 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,810 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,148 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,963 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,153 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,229 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,252 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,569 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,810 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,311 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,148 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,963 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 6405000 2984000 18065000 8303000 29000 0 77000 0 376000 327000 1006000 660000 6810000 3311000 19148000 8963000 88000 36000 250000 122000 1153000 535000 3229000 1252000 5569000 2740000 15669000 7589000 6810000 3311000 19148000 8963000 0.25 P36M P10Y <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and related information is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual Term<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic<br/>Value <br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,857,564 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.09 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$351,626</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184,845 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208.12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269,212)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.92 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$47,176</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/expired</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93,790)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$416,515</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,413 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$276,959</span></td></tr></table></div> 2857564 66.09 P7Y10M24D 351626000 184845 208.12 269212 33.92 47176000 93790 113.37 2679407 77.47 P7Y3M18D 416515000 1355413 28.54 P6Y1M6D 276959000 70000000 P2Y6M <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of options granted to employees and non-employee directors was estimated as of the grant date using the Black-Scholes option pricing model using the following assumptions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50 - 6.25</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0 - 55.9%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.3 - 49.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.79 - 1.40%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36 - 1.42%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$109.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$38.33</span></td></tr></table> P5Y6M P6Y3M P5Y6M P6Y3M 0.550 0.559 0.423 0.493 0.0079 0.0140 0.0036 0.0142 0.000 0.000 109.81 38.33 <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSUs and related information is as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Grant Date Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 0 2275 201.51 2275 201.51 530000 400000 P3Y3M18D 0.85 277362 184908 0.01 11351 1800000 754752 Income Taxes<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At both September 30, 2021 and 2020, a valuation allowance was recorded against all deferred tax assets due to our cumulative net loss position. We recorded income tax expense of $0 and $0.1 million in the three months ended September 30, 2021 and 2020, respectively, and $0.1 million for both of the nine months ended September 30, 2021 and 2020. The nominal Income tax expense in those periods reflects minimal state income tax expense and an accrual for uncertain tax benefits. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed our 2020 U.S. federal income tax return during the third quarter of 2021. Considering provision to return true-ups, our gross federal net operating loss carryforward as of December 31, 2020 was $234.8 million, which will expire at various dates beginning in 2028. In addition, net operating loss carryforwards for state income tax purposes of $145.6 million that include net operating losses will begin to expire in 2028. We also have gross research and development credit carryforwards of $4.4 million as of December 31, 2020, which will expire at various dates beginning in 2033.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the net operating loss carryforwards may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986 and similar state provisions. We have not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit our utilization of the net operating losses and could be triggered by subsequent sales of securities by us or our stockholders.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realization of the deferred tax assets is dependent upon the generation of future taxable income, if any, the amount and timing of which are uncertain. Based on available objective evidence and cumulative losses, we believe it is more likely than not that the deferred tax assets are not recognizable and will not be recognizable until we have sufficient taxable income. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $0.1 million of gross unrecognized tax benefits as of each of September 30, 2021 and December 31, 2020. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the applicable jurisdictions. The 2018 to 2020 tax years remain open to examination by the major taxing authorities to which we are subject. We do not expect a significant change to our unrecognized tax benefits over the next 12 months.</span></div> 0 100000 100000 100000 234800000 145600000 4400000 100000 100000 0 Segment Reporting and Revenue Disaggregation<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate our business as one reporting segment. An operating segment is defined as a component of an enterprise for which separate discrete financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell our Inspire system to hospitals and ambulatory surgery centers in the U.S. and in select countries in Europe through a direct sales organization. Revenue by geographic region is as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,420 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,721 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,576 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,685 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,842 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,996 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,372 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S.</span></div> 1 Revenue by geographic region is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,420 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,379 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,387 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,721 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,576 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,993 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,685 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,842 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,996 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,372 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 58298000 33121000 145420000 63379000 3387000 2721000 9576000 5993000 61685000 35842000 154996000 69372000 Loss Per Share<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Because we have reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share as all of the following potentially dilutive shares were antidilutive in those periods:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514,801 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,687,806 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514,801 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> Because we have reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share as all of the following potentially dilutive shares were antidilutive in those periods:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514,801 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,687,806 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,514,801 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2679407 2514801 2275 0 6124 0 2687806 2514801 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
9 Months Ended
Sep. 30, 2021
Oct. 26, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 001-38468  
Entity Registrant Name Inspire Medical Systems, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 26-1377674  
Entity Address, Address Line One 5500 Wayzata Blvd.  
Entity Address, Address Line Two Suite 1600  
Entity Address, City or Town Golden Valley  
Entity Address, State or Province MN  
Entity Address, Postal Zip Code 55416  
City Area Code 844  
Local Phone Number 672-4357  
Title of 12(b) Security Common Stock, $0.001 par value per share  
Trading Symbol INSP  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding (in shares)   27,358,099
Entity Central Index Key 0001609550  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.2
BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 210,200 $ 190,518
Investments, short-term 0 43,844
Accounts receivable, net of allowance for credit losses of $95 and $42, respectively 26,675 25,063
Inventories 15,574 8,479
Prepaid expenses and other current assets 3,046 1,965
Total current assets 255,495 269,869
Investments, long-term 9,984 0
Property and equipment, net 7,915 5,311
Operating lease right-of-use asset 5,296 5,805
Other non-current assets 204 204
Total assets 278,894 281,189
Current liabilities:    
Accounts payable 9,989 7,209
Accrued expenses 17,477 13,516
Current portion of notes payable 6,125 0
Total current liabilities 33,591 20,725
Notes payable, non-current portion 18,799 24,746
Operating lease liability, non-current portion 6,080 5,886
Other non-current liability 124 85
Total liabilities 58,594 51,442
Stockholders' equity:    
Preferred Stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding 0 0
Common Stock, $0.001 par value per share; 200,000,000 shares authorized; 27,350,959 and 27,069,276 issued and outstanding at September 30, 2021 and December 31, 2020, respectively 27 27
Additional paid-in capital 497,280 467,038
Accumulated other comprehensive (loss) income (9) 29
Accumulated deficit (276,998) (237,347)
Total stockholders' equity 220,300 229,747
Total liabilities and stockholders' equity $ 278,894 $ 281,189
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.2
BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Allowance for credit loss $ 95 $ 42
Preferred shares, par value (in dollars per share) $ 0.001 $ 0.001
Preferred shares, authorized (in shares) 10,000,000 10,000,000
Preferred shares, issued (in shares) 0 0
Preferred stock, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized (in shares) 200,000,000 200,000,000
Common stock, issued (in shares) 27,350,959 27,069,276
Common stock, outstanding (in shares) 27,350,959 27,069,276
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.2
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]        
Revenue $ 61,685 $ 35,842 $ 154,996 $ 69,372
Cost of goods sold 8,624 5,211 22,123 10,462
Gross profit 53,061 30,631 132,873 58,910
Operating expenses:        
Research and development 9,614 7,307 27,056 18,807
Selling, general and administrative 53,243 33,216 143,846 89,249
Total operating expenses 62,857 40,523 170,902 108,056
Operating loss (9,796) (9,892) (38,029) (49,146)
Other expense (income):        
Interest income (22) (125) (110) (1,015)
Interest expense 537 533 1,590 1,584
Other expense (income), net 33 (2) 90 (83)
Total other expense 548 406 1,570 486
Loss before income taxes (10,344) (10,298) (39,599) (49,632)
Income taxes 3 87 52 87
Net loss (10,347) (10,385) (39,651) (49,719)
Other comprehensive loss:        
Unrealized gain (loss) on investments 3 (81) (38) (29)
Total comprehensive loss $ (10,344) $ (10,466) $ (39,689) $ (49,748)
Net loss per share, basic (in dollars per share) $ (0.38) $ (0.39) $ (1.46) $ (1.93)
Net loss per share, diluted (in dollars per share) $ (0.38) $ (0.39) $ (1.46) $ (1.93)
Weighted average common shares used to compute net loss per share, basic (in shares) 27,300,377 26,835,603 27,225,499 25,767,497
Weighted average common shares used to compute net loss per share, diluted (in shares) 27,300,377 26,835,603 27,225,499 25,767,497
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.2
STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Thousands
Total
Follow-on Offering
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Common Stock
Follow-on Offering
Additional Paid-In Capital
Additional Paid-In Capital
Follow-on Offering
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2019       24,107,350            
Beginning balance at Dec. 31, 2019 $ 139,835   $ 12 $ 24   $ 319,865   $ 102 $ (180,156) $ 12
Stockholders' Equity [Roll Forward]                    
Stock options exercised (in shares)       254,142            
Stock options exercised 787         787        
Issuance and sale of common stock (in shares)       897            
Issuance and sale of common stock 72         72        
Stock-based compensation expense 2,749         2,749        
Other comprehensive income (loss) 193             193    
Net loss (16,245)               (16,245)  
Ending balance (in shares) at Mar. 31, 2020       24,362,389            
Ending balance at Mar. 31, 2020 $ 127,403     $ 24   323,473   295 (196,389)  
Stockholders' Equity [Roll Forward]                    
Accounting Standards Update [Extensible List] Accounting Standards Update 2016-13 [Member]                  
Stock options exercised (in shares)       70,853            
Stock options exercised $ 732         732        
Issuance and sale of common stock (in shares)       1,119 2,300,000          
Issuance and sale of common stock 73 $ 124,654     $ 3 73 $ 124,651      
Issuance of common stock for employee stock purchase plan (in shares)       16,730            
Issuance of common stock for employee stock purchase plan 1,059         1,059        
Stock-based compensation expense 2,903         2,903        
Other comprehensive income (loss) (141)             (141)    
Net loss (23,089)               (23,089)  
Ending balance (in shares) at Jun. 30, 2020       26,751,091            
Ending balance at Jun. 30, 2020 233,594     $ 27   452,891   154 (219,478)  
Stockholders' Equity [Roll Forward]                    
Stock options exercised (in shares)       168,970            
Stock options exercised 2,312         2,312        
Issuance and sale of common stock (in shares)       784            
Issuance and sale of common stock 72         72        
Stock-based compensation expense 3,311         3,311        
Other comprehensive income (loss) (81)             (81)    
Net loss (10,385)               (10,385)  
Ending balance (in shares) at Sep. 30, 2020       26,920,845            
Ending balance at Sep. 30, 2020 $ 228,823     $ 27   458,586   73 (229,863)  
Beginning balance (in shares) at Dec. 31, 2020 27,069,276     27,069,276            
Beginning balance at Dec. 31, 2020 $ 229,747     $ 27   467,038   29 (237,347)  
Stockholders' Equity [Roll Forward]                    
Stock options exercised (in shares)       133,421            
Stock options exercised 3,550         3,550        
Issuance and sale of common stock (in shares)       376            
Issuance and sale of common stock 73         73        
Stock-based compensation expense 5,997         5,997        
Other comprehensive income (loss) (20)             (20)    
Net loss (16,216)               (16,216)  
Ending balance (in shares) at Mar. 31, 2021       27,203,073            
Ending balance at Mar. 31, 2021 $ 223,131     $ 27   476,658   9 (253,563)  
Beginning balance (in shares) at Dec. 31, 2020 27,069,276     27,069,276            
Beginning balance at Dec. 31, 2020 $ 229,747     $ 27   467,038   29 (237,347)  
Stockholders' Equity [Roll Forward]                    
Stock options exercised (in shares) 269,212                  
Ending balance (in shares) at Sep. 30, 2021 27,350,959     27,350,959            
Ending balance at Sep. 30, 2021 $ 220,300     $ 27   497,280   (9) (276,998)  
Beginning balance (in shares) at Mar. 31, 2021       27,203,073            
Beginning balance at Mar. 31, 2021 223,131     $ 27   476,658   9 (253,563)  
Stockholders' Equity [Roll Forward]                    
Stock options exercised (in shares)       49,318            
Stock options exercised 1,719         1,719        
Issuance and sale of common stock (in shares)       329            
Issuance and sale of common stock 72         72        
Issuance of common stock for employee stock purchase plan (in shares)       11,351            
Issuance of common stock for employee stock purchase plan 1,760         1,760        
Stock-based compensation expense 6,341         6,341        
Other comprehensive income (loss) (21)             (21)    
Net loss (13,088)               (13,088)  
Ending balance (in shares) at Jun. 30, 2021       27,264,071            
Ending balance at Jun. 30, 2021 219,914     $ 27   486,550   (12) (266,651)  
Stockholders' Equity [Roll Forward]                    
Stock options exercised (in shares)       86,473            
Stock options exercised 3,843         3,843        
Issuance and sale of common stock (in shares)       415            
Issuance and sale of common stock 77         77        
Stock-based compensation expense 6,810         6,810        
Other comprehensive income (loss) 3             3    
Net loss $ (10,347)               (10,347)  
Ending balance (in shares) at Sep. 30, 2021 27,350,959     27,350,959            
Ending balance at Sep. 30, 2021 $ 220,300     $ 27   $ 497,280   $ (9) $ (276,998)  
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.2
STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Operating activities    
Net loss $ (39,651) $ (49,719)
Adjustments to reconcile net loss:    
Depreciation and amortization 874 587
Amortization (accretion) of investment premium (discount) 15  
Amortization (accretion) of investment premium (discount)   (66)
Accretion of debt discount 178 166
Non-cash lease expense 509 743
Stock-based compensation expense 19,148 8,963
Non-cash stock issuance for services rendered 222 217
Other, net 53 (89)
Changes in operating assets and liabilities:    
Accounts receivable (1,743) (7,921)
Inventories (7,095) (3,132)
Prepaid expenses and other current assets (1,081) (15)
Accounts payable 3,490 2,262
Accrued expenses and other liabilities 4,228 (931)
Net cash used in operating activities (20,853) (48,935)
Investing activities    
Purchases of property and equipment (4,135) (1,851)
Purchases of investments (9,993) (52,721)
Proceeds from sales or maturities of investments 43,800 129,803
Net cash provided by investing activities 29,672 75,231
Financing activities    
Proceeds from the exercise of stock options 9,112 3,831
Proceeds from the sale of common stock 0 124,654
Proceeds from issuance of common stock from employee stock purchase plan 1,760 1,059
Net cash provided by financing activities 10,872 129,544
Effect of exchange rate on cash (9) 5
Increase in cash and cash equivalents 19,682 155,845
Cash and cash equivalents at beginning of period 190,518 22,860
Cash and cash equivalents at end of period 210,200 178,705
Supplemental cash flow information    
Cash paid for interest 1,417 1,422
Change in property and equipment acquired but not yet paid $ 657 $ 0
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Organization
9 Months Ended
Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
Description of Business
Inspire Medical Systems, Inc. is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first and only United States ("U.S.") Food and Drug Administration ("FDA") approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. Inspire therapy received premarket approval ("PMA") from the FDA in April 2014 and has been commercially available in certain European markets since November 2011. Japan's Ministry of Health, Labour and Welfare ("MLHW") approved Inspire therapy to treat moderate to severe OSA in June 2018 and was formally added to the Japan National Health Insurance Payment Listing in June 2021. In August 2020, the Australian Therapeutic Goods Administration approved Inspire therapy to treat moderate to severe OSA, and we are currently seeking reimbursement coverage in Australia.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Basis of Presentation
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, the results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods. For a complete discussion of our significant accounting policies and other information, the unaudited financial statements and notes thereto should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
Follow-On Public Offering
On April 16, 2020, we completed a follow-on offering that included our offer and sale of 2,300,000 shares of common stock at a public offering price of $58.00 per share. We received net proceeds of approximately $124.7 million after deducting underwriting discounts and commissions and offering expenses.
Cash and Cash Equivalents
We consider all highly liquid securities, readily convertible to cash, that mature within 90 days or less from the date of purchase to be cash equivalents. The carrying amount reported in the balance sheets for cash is cost, which approximates fair value.
Foreign Currency
Sales and expenses denominated in foreign currencies are translated at average exchange rates in effect throughout the year. Foreign currency transaction gains and losses are included in other expense (income), net, in the statements of operations and comprehensive loss. Assets and liabilities of foreign operations are remeasured at period-end exchange rates with the impacts of foreign currency remeasurement recognized in other expense (income), net in the statements of operations and comprehensive loss.
Investments
At December 31, 2020, our short-term investments consisted of commercial paper, corporate bonds, and U.S. government securities, which are classified as available-for-sale and had maturities less than one year. Our long-term investments at September 30, 2021 consisted of U.S. government securities. Investments are reported at their estimated fair market values which are based on quoted, active or inactive market prices when available. Any unrealized gains and losses due to interest rate fluctuations and other external factors are reported as a separate component of accumulated other comprehensive (loss) income. We had less than $0.1 million of unrecognized loss in accumulated other comprehensive (loss) income at September 30, 2021 and less than $0.1 million of unrecognized gain in accumulated other comprehensive (loss) income at December 31, 2020. Any realized gains and losses are calculated on the specific identification method and reported net in other expense (income), net in the statements of operations and comprehensive loss. For both of the three months ended September 30, 2021 and 2020, we recognized $0 of realized gains, net. For the nine months ended September 30, 2021 and 2020, we recognized $0 and $0.1 million of realized gains, net, respectively.
We recognize expected credit losses on investments in accordance with Accounting Standards Update ("ASU"), ASU 2016-13, Financial Instruments - Credit Losses ("ASU 2016-13"), which we adopted effective January 1, 2020 using the modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on the amount and timing of credit losses recognized in our financial statements.
We reassess our estimated credit losses on investments each reporting period. U.S. government securities and cash equivalents are under a "zero-loss exception" for credit losses, meaning no credit loss risk calculation is necessary on those instruments due to the exceptionally low rate of default, which continues to decrease as the securities approach maturity, which for us is no longer than two years. For non-U.S. government securities, we use a discounted cash flow approach to calculate expected credit losses using estimated default rates based upon historical loss data, current conditions, as well as expectations of future economic conditions. We record changes in the allowance for credit losses for available-for-sale debt securities with a corresponding adjustment in credit loss expense on the statement of operations and comprehensive loss. No reversal of a previously recorded allowance for credit losses may be made to an amount below zero. The total allowance for credit losses was $0 at both September 30, 2021 and December 31, 2020.
Fair Value of Financial Instruments
We measure certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and investments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:
Level 1—Observable inputs, such as quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2—Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability.
Level 3—Unobservable inputs that are supported by little or no market activities, which would require us to develop our own assumptions.
We use the methods and assumptions described below in determining the fair value of our financial instruments.
Money market funds: Fair values of money market funds are based on quoted market prices in active markets. These are included as Level 1 measurements in the tables below.
Commercial paper: Short-term, highly liquid investments are included as a Level 2 measurement in the table below.
Corporate bonds: Consists of short-term notes and bonds with various yields. These are included as a Level 2 measurement in the table below.
U.S. government securities: Consists of U.S. government Treasury bills and notes with original maturities of less than one year to two years. These are included as a Level 1 measurement in the tables below.
The following tables set forth by level within the fair value hierarchy our assets that are measured on a recurring basis and reported at fair value as of September 30, 2021 and December 31, 2020. Assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Fair Value Measurements as of
September 30, 2021
Estimated
Fair Value
Level 1Level 2Level 3
Cash equivalents:
Money market funds$189,355 $189,355 $— $— 
Total cash equivalents189,355 189,355 — — 
Investments:
U.S. government securities$9,984 $9,984 $— $— 
Total investments9,984 9,984 — — 
Total cash equivalents and investments$199,339 $199,339 $— $— 
Fair Value Measurements as of
December 31, 2020
Estimated
Fair Value
Level 1Level 2Level 3
Cash equivalents:
Money market funds$179,389 $179,389 $— $— 
Total cash equivalents179,389 179,389 — — 
Investments:
Commercial paper$13,275 $— $13,275 $— 
Corporate bonds6,540 — 6,540 — 
U.S. government securities24,029 24,029 — — 
Total investments43,844 24,029 19,815 — 
Total cash equivalents and investments$223,233 $203,418 $19,815 $— 

There were no transfers between levels during the periods ended September 30, 2021 and December 31, 2020.
Concentration of Credit Risk
Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable.
Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration
by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of September 30, 2021 and December 31, 2020, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.
We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.
Accounts Receivable and Allowance for Expected Credit Losses
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the general standard being net 30 days. Collateral or any other security to support payment of these receivables generally is not required.
We recognize expected credit losses on accounts receivable in accordance with Accounting Standards Update ("ASU"), ASU 2016-13, Financial Instruments - Credit Losses ("ASU 2016-13"), which we adopted effective January 1, 2020 using the modified retrospective approach through a cumulative-effect adjustment to retained earnings. The adoption of ASU 2016-13 did not have a material impact on the amount and timing of credit losses recognized in our financial statements.
Each reporting period, we estimate the credit loss related to accounts receivable based on a migration analysis of accounts grouped by individual receivables delinquency status, and apply our historic loss rate adjusted for management's assumption of future market conditions. Any change in the allowance subsequent to the effective date of January 1, 2020 from new receivables acquired, or changes due to credit deterioration on previously existing receivables, is recorded in selling, general and administrative expenses. Write-offs of receivables considered uncollectible are deducted from the allowance. Specific accounts receivable are written-off once a determination is made that the amount is uncollectible. The write-off is recorded in the period in which the account receivable is deemed uncollectible. Recoveries are recognized when received and as a direct credit to earnings or as a reduction to the allowance for credit losses (which would indirectly reduce the loss by decreasing bad debt expense).
Inventories
Inventories are valued at the lower of cost or net realizable value, computed on a first-in, first-out basis and consisted of the following:
September 30, 2021December 31, 2020
Raw materials$1,865 $892 
Finished goods13,709 7,587 
Total inventories, net of reserves$15,574 $8,479 
We regularly review inventory quantities on-hand for excess and obsolete inventory and, when circumstances indicate, incur charges to write down inventories to their net realizable value. The determination of a reserve for excess and obsolete inventory involves management exercising judgment to determine the required reserve, considering future demand, product life cycles, introduction of new products and current market conditions. The reserve for excess and obsolete inventory was $0.3 million and $0.1 million as of September 30, 2021 and December 31, 2020, respectively.
Property and Equipment
Property and equipment are stated at cost, less accumulated depreciation and amortization and consisted of the following:
September 30, 2021December 31, 2020
Computer equipment and software$1,391 $1,305 
Manufacturing equipment4,322 2,285 
Other equipment249 249 
Leasehold improvements281 192 
Construction in process4,380 3,125 
Property and equipment, cost10,623 7,156 
Less: accumulated depreciation and amortization(2,708)(1,845)
Property and equipment, net$7,915 $5,311 
Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Depreciation and amortization expense was $0.3 million and $0.2 million for the three months ended September 30, 2021 and 2020, respectively, and $0.9 million and $0.6 million for the nine months ended September 30, 2021 and 2020, respectively.
Impairment of Long-lived Assets
Long-lived assets consist primarily of property and equipment and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require that an asset be tested for possible impairment, we compare the undiscounted cash flows expected to be generated by the asset to the carrying amount of the asset. If the carrying amount of the asset is not recoverable on an undiscounted cash flow basis, we determine the fair value of the asset and recognize an impairment loss to the extent the carrying amount of the asset exceeds its fair value. We determine fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. Our cash flow assumptions consider historical and forecasted revenue and operating costs and other relevant factors. We did not record any impairment charges on long-lived assets during either of the nine months ended September 30, 2021 or 2020.
Accrued Expenses
Accrued expenses consisted of the following:
September 30, 2021December 31, 2020
Payroll related$14,876 $11,965 
Interest155 160 
Current operating lease liability27 — 
Other accrued expenses2,419 1,391 
Total accrued expenses$17,477 $13,516 
Revenue Recognition
We recognize revenue in accordance with Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"). Revenues from product sales are recognized when the customer obtains control of the product, which occurs at a point in time, either upon shipment of the product or receipt of the product,
depending on shipment terms. Our standard shipping terms are free on board shipping point, unless the customer requests that control of the inventory transfer upon delivery. In those cases where shipping and handling costs are billed to customers, we classify the amounts billed as a component of cost of goods sold.
Revenue is measured as the amount of consideration we expect to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. The majority of our contracts have a single performance obligation and are short term in nature.
Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold.
Variable consideration related to certain customer sales incentives is estimated based on the amounts expected to be paid based on the agreement with the customer using probability assessments.
We offer customers a limited right of return for our product in case of non-conformity or performance issues. We estimate the amount of our product sales that may be returned by our customers based on historical sales and returns. As our historical product returns to date have been immaterial, we have not recorded a reduction in revenue related to variable consideration for product returns.
See Note 9 for disaggregated revenue by geographic area.
Cost of Goods Sold
Cost of goods sold consists primarily of acquisition costs for the components of the Inspire system, overhead costs, scrap and inventory obsolescence, warranty replacement costs, as well as distribution-related expenses such as logistics and shipping costs, net of shipping costs charged to customers. The overhead costs include the cost of material procurement, depreciation expense for production equipment, and operations supervision and management personnel, including employee compensation, stock-based compensation, supplies, and travel.
Research and Development
Research and development expenses consist primarily of product development, clinical and regulatory affairs, quality assurance, consulting services, and other costs associated with products and technologies in development. These expenses include employee compensation, including stock-based compensation, supplies, materials, consulting, and travel expenses related to research and development programs. Clinical expenses include clinical trial design, clinical site reimbursement, data management, travel expenses, and the cost of manufacturing products for clinical trials.
Stock-Based Compensation
We maintain an equity incentive plan to provide long-term incentives for eligible employees, consultants, and members of the board of directors. The plan allows for the issuance of restricted stock units ("RSUs") and non-statutory and incentive stock options to employees and RSUs and non-statutory stock options to consultants and directors. We also offer an employee stock purchase plan which allows participating employees to purchase shares of our common stock at a discount through payroll deductions.
We recognize equity-based compensation expense for awards of equity instruments to employees and directors based on the grant date fair value of those awards in accordance with ASC Topic 718, Stock Compensation ("ASC 718"). ASC 718 requires all equity-based compensation awards to employees and directors, including grants of RSUs and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the fair value of stock options using the Black-Scholes option
pricing model and the fair value of RSUs is equal to the closing price of our common stock on the grant date. The fair value of each purchase under the employee stock purchase plan is estimated at the beginning of the offering period using the Black-Scholes option pricing model. We have not granted any stock-based awards to our consultants.
The Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i) the expected share price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) the expected dividend yield. Due to our limited operating history and a lack of company specific historical and implied volatility data, we have incorporated our historical stock trading volatility with those of a peer group of public companies for the calculation of volatility. The group of peer companies have characteristics similar to us, including stage of product development and focus on the life science industry. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. We use the simplified method, which is the average of the final vesting tranche date and the contractual term, to calculate the expected term for options granted to employees and directors as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is based on a U.S. government Treasury instrument whose term is consistent with the expected term of the stock options. We use an assumed dividend yield of zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.
We expense the fair value of our equity-based compensation awards granted to employees and directors on a straight-line basis over the associated service period, which is generally the period in which the related services are received. We account for award forfeitures as they occur.
Advertising Expenses
We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $13.4 million and $6.8 million during the three months ended September 30, 2021 and 2020, respectively, and $34.0 million and $18.2 million during the nine months ended September 30, 2021 and 2020, respectively.
Leases
Operating leases are included in operating lease right-of-use ("ROU") asset, accrued expenses, and operating lease liability – non-current portion in our balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of our incremental borrowing rate requires management judgment based on information available at lease commencement. The operating lease ROU assets also include adjustments for prepayments, accrued lease payments and exclude lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise such options. Operating lease cost is recognized on a straight-line basis over the expected lease term. Lease agreements entered into after the adoption of ASC 842 that include lease and non-lease components are accounted for as a single lease component. Lease agreements with a noncancelable term of less than 12 months are not recorded on our balance sheets.
Income Taxes
We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances against deferred tax assets are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized. As we have historically incurred operating losses, we have recorded a full valuation allowance against our net deferred tax assets, and there is no provision for income taxes other than
minimal state taxes and an accrual for uncertain tax benefits. Our policy is to record interest and penalties expense related to uncertain tax positions as other expense in the statements of operations and comprehensive loss.
Comprehensive Loss
Comprehensive loss consists of net loss and changes in unrealized gains and losses due to interest rate fluctuations and other external factors on investments classified as available-for-sale. Accumulated other comprehensive (loss) income is presented in the accompanying balance sheets as a component of stockholders' equity.
Loss Per Share
Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Because we have reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share as all potentially dilutive shares consisting of outstanding stock options, unvested RSUs, and shares issuable under our employee stock purchase plan were antidilutive in those periods.
Recent Accounting Pronouncements
We have reviewed and considered all recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on our business practices, financial condition, results of operations, or disclosures.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Investments
9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Our investments are classified as available-for-sale and consist of the following:
September 30, 2021
AmortizedUnrealized GrossAggregate
CostGainsLossesFair Value
Long-Term:
U.S. government securities$9,993 $— $(9)$9,984 
Long-term investments$9,993 $— $(9)$9,984 
December 31, 2020
AmortizedUnrealized GrossAggregate
CostGainsLossesFair Value
Short-Term:
Commercial paper$13,275 $— $— $13,275 
Corporate bonds6,543 — (3)6,540 
U.S. government securities23,997 32 — 24,029 
Short-term investments$43,815 $32 $(3)$43,844 
As of September 30, 2021 and December 31, 2020, we had no investments with a contractual maturity of greater than two years. Currently, we do not intend to sell the investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. We do not consider those investments to be other-than-temporarily impaired as of September 30, 2021. At the end of each reporting period, we evaluate potential credit impairment on available-for-sale securities in an unrealized loss
position, based on the expected cash flows to be collected and the yield-to-maturity on those securities. Securities with a valuation allowance for expected credit losses and deemed uncollectible are permanently written-down, and a reversal out of the valuation allowance occurs.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Leases
9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Leases Leases
In September 2018, we entered into a non-cancelable operating lease agreement to sublease approximately 45,000 square feet of office space for our corporate headquarters, which included real estate taxes and operating expenses in the base rent. This lease commenced January 15, 2019 and expired November 30, 2020.
In May 2019, we entered into a new, non-cancelable operating lease agreement for the same space directly with the landlord. The initial lease term commenced on December 1, 2020 and expires May 31, 2028 with an option to renew for one additional period of five years at the then-prevailing market rate. The exercise of the lease renewal option is at our sole discretion and was not included in the lease term for the calculation of the ROU asset and lease liability when the lease commenced on December 1, 2020 as it is not reasonably certain of exercise.
Beginning December 1, 2020, in addition to base rent, we also pay our proportionate share of the operating expenses, as defined in the lease. These payments are made monthly and adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance. In conjunction with this lease, the landlord agreed to provide a $0.6 million rent abatement and a refurbishment allowance in the amount of the cost of any leasehold improvements, not to exceed approximately $1.1 million upon Inspire providing the necessary documentation evidencing the costs of the leasehold improvements that are completed by May 31, 2022. However, the lease allows us to allocate the refurbishment allowance against base rent instead of taking a tenant improvement reimbursement. At this time, we intend to allocate the full amount of the refurbishment allowance against base rent.
In August 2021, we entered into a new, non-cancelable operating lease agreement for approximately 25,000 square feet of additional corporate office space with our existing landlord. The initial lease term commences on October 1, 2021 and expires May 31, 2028 with an option to renew for one additional period of 5 years at the then-prevailing market rate. The exercise of the lease renewal option is at our sole discretion and will not be included in the lease term for the calculation of the ROU asset and lease liability when the lease commences on October 1, 2021 as it is not reasonably certain of exercise.
Beginning October 1, 2021, in addition to base rent on the additional space, we will also pay our proportionate share of the operating expenses, as defined in the lease. These payments will be made monthly and will be adjusted annually to reflect actual charges incurred for operating expenses, such as common area maintenance, taxes and insurance. In conjunction with this lease, the landlord agreed to provide a $0.2 million rent abatement and a refurbishment allowance in the amount of the cost of any leasehold improvements, not to exceed $0.4 million upon Inspire providing the necessary documentation evidencing the costs of the leasehold improvements that are completed by May 31, 2022. However, the lease allows us to allocate the refurbishment allowance against base rent instead of taking a tenant improvement reimbursement. At this time, we intend to allocate the full amount of the refurbishment allowance against base rent. The total minimum lease payments related to this forward-starting lease are $3.6 million.
The following table presents the lease balances within the balance sheets:
September 30, 2021December 31, 2020
Right-of-use assets:
Operating lease right-of-use asset$5,296 $5,805 
Operating lease liabilities:
Accrued expenses27  
Operating lease liability, non-current portion6,080 5,886 
Total operating lease liabilities$6,107 $5,886 

As of September 30, 2021, the remaining lease term was 6.7 years and the discount rate was 5.2%. The operating cash outflows from our operating leases were $0.1 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively, and $0.1 million and $0.8 million for the nine months ended September 30, 2021 and 2020, respectively.
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt
9 Months Ended
Sep. 30, 2021
Long-term Debt, by Current and Noncurrent [Abstract]  
Long-Term Debt Long-Term Debt
In August 2015, we entered into a loan and security agreement that initially provided for a term A loan facility in the amount of $15.5 million, which was fully funded on the closing date, and a term B loan facility in an amount between $3.5 million and $10.0 million, subject to our achievement of certain revenue milestones. We refer to our term A loan facility and our term loan B facility together as our credit facility.
In February 2017, we amended the loan and security agreement to, among other things, increase borrowings under the term A loan facility by $1.0 million, for a total of $16.5 million outstanding under the credit facility, and reduced borrowings available under the term B loan facility to $9.0 million.
In February 2018, we borrowed an additional $8.0 million under the term B loan facility portion of the credit facility for a total of $24.5 million outstanding under the credit facility.
On March 27, 2019, we amended the loan and security agreement. The amendment modified the terms of the loan and security agreement to: (1) extend the interest-only date from March 1, 2020 to April 1, 2022 and extend the maturity date from February 1, 2022 to March 1, 2024; (2) reduce the final payment percentage from 5.50% to 3.50%; (3) modify the basic rate to be a per annum rate of interest (based on a year of 360 days) equal to the sum of (i) the greater of (A) the 30 day U.S. LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue or (B) 2.50%, plus (ii) 5.10%; provided, however, under no circumstances will the basic rate be less than 7.60%; (4) provide a mechanism for determining an alternative interest rate to replace the U.S. LIBOR rate upon the occurrence of certain circumstances; and (5) revise the prepayment fee to be between 1.00% and 3.00% of the principal amount, depending on the timing of any prepayment. Upon closing the amendment to the loan and security agreement, payment of the previously accrued final payment under the credit facility was required.
In addition to the principal and interest payments, under the credit facility, we are required to pay a final payment fee of 3.50% on all amounts outstanding, which is being accreted using the effective interest rate method over the term of the loan and security agreement and shall be due at the earlier of maturity or prepayment. Borrowings are prepayable at our option in whole, but not in part, together with all accrued and unpaid interest thereon and, if not previously made, the final payment, subject to a prepayment fee of 1.00%.
The credit facility includes affirmative and restrictive covenants and events of default, including the following events of default: payment defaults, breaches of covenants, judgment defaults, cross defaults to certain other contracts, certain events with respect to governmental approvals if such events could cause a material adverse change, a material impairment in the perfection or priority of the lender's security interest or in the value of the collateral, a
material adverse change in the business, operations, or condition of us or any of our subsidiaries, and a material impairment of the prospect of repayment of the loans. Upon the occurrence of an event of default, a default increase in the interest rate of an additional 5.00% could be applied to the outstanding loan balance and the lender could declare all outstanding obligations immediately due and payable and take such other actions as set forth in the loan and security agreement.
Our obligations under the credit facility are secured by a first priority security interest in substantially all of our assets, other than our intellectual property. There are no financial covenants contained in the loan and security agreement. We were in compliance with the affirmative and restrictive covenants as of September 30, 2021.
Expected future principal payments for the credit facility are as follows:
Year ending December 31:
2021 (remaining)$— 
20229,188 
202312,250 
20243,062 
Total expected future principal payments$24,500 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Employee Retirement Plan
9 Months Ended
Sep. 30, 2021
Retirement Benefits [Abstract]  
Employee Retirement Plan Employee Retirement PlanWe sponsor an employee retirement plan covering all of our full-time employees. The plan allows for eligible employees to defer a portion of their eligible compensation up to the maximum allowed by IRS Regulations. We may elect to make a voluntary contribution to the plan. We have not made contributions since inception.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Stockholders' Equity Stockholders' Equity
Stock-Based Compensation
We adopted the 2007 Stock Incentive Plan (the "2007 Plan") in November 2007, which terminated in accordance with its terms on November 28, 2017; however, the outstanding stock options may continue to be exercised in accordance with their terms. Immediately following the termination of the 2007 Plan, we adopted the 2017 Stock Incentive Plan (the "2017 Plan"), which contains substantially similar terms and conditions as the 2007 Plan. Upon the IPO, no further grants were made under the 2017 Plan and we adopted the 2018 Stock Incentive Plan (the "2018 Plan").
The purpose of the 2018 Plan is to promote the interest of our company and our stockholders by aiding in attracting and retaining employees, officers, consultants, independent contractors, and directors capable of assuring the future success of our business and to afford such persons an opportunity to acquire a proprietary interest in our company. The board of directors may amend, alter, suspend, discontinue, or terminate the 2018 Plan at any time with the approval of our stockholders. A total of 1,386,809 shares of common stock were initially reserved for issuance under the 2018 Plan, and this share reserve will automatically be supplemented each January 1, commencing on January 1, 2019 and ending on and including January 1, 2028, by an amount of shares equal to the lesser of: a) 739,631 shares, b) 4% of the shares outstanding on the final day of the immediately preceding fiscal year and c) such smaller number of shares as determined by the board of directors. As of September 30, 2021, there were 3,284,769 shares reserved for issuance under the 2018 Plan, of which 1,293,557 shares were available for issuance.
The following table presents the components and classification of stock-based compensation expense recognized for stock options and RSUs granted under the 2017 Plan, the 2018 Plan and under our Employee Stock Purchase Plan (the "ESPP"):
Three Months EndedNine Months Ended
September 30,September 30,
2021202020212020
Stock options$6,405 $2,984 $18,065 $8,303 
Restricted stock units29 — 77 — 
Employee stock purchase plan376 327 1,006 660 
Total stock-based compensation expense$6,810 $3,311 $19,148 $8,963 
Cost of goods sold$88 $36 $250 $122 
Research and development1,153 535 3,229 1,252 
Selling, general and administrative5,569 2,740 15,669 7,589 
Total stock-based compensation expense$6,810 $3,311 $19,148 $8,963 
Stock Options
Prior to the IPO, the exercise price of stock options represented fair value of the common stock at the time of issuance and was determined by the board of directors with the assistance of a third-party valuation specialist. Post-IPO, options are granted at the exercise price, which is equal to the closing price of our stock on the date of grant. The stock options granted to employees include a four-year service period and 25% vest after the first year of service and the remainder vest in equal installments over the next 36 months of service. The stock options granted to the board of directors vest in one or three equal annual installments, in each case, subject to the director's continuous service through the applicable vesting date. The stock options have a contractual life of ten years.
A summary of stock option activity and related information is as follows:
OptionsWeighted Average
Exercise Price
Weighted Average
Remaining
Contractual Term
(years)
Aggregate Intrinsic
Value
(in thousands)
Outstanding at December 31, 20202,857,564 $66.09 7.9$351,626
Granted184,845 $208.12 
Exercised(269,212)$33.92 $47,176
Forfeited/expired(93,790)$113.37 
Outstanding at September 30, 20212,679,407 $77.47 7.3$416,515
Exercisable at September 30, 20211,355,413 $28.54 6.1$276,959
The aggregate intrinsic value of options exercised is the difference between the estimated fair market value of our common stock at the date of exercise and the exercise price for those options. The aggregate intrinsic value of outstanding options is the difference between the closing price as of the date outstanding and the exercise price of the underlying stock options.
As of September 30, 2021, the amount of unearned stock-based compensation to be expensed from now through the year 2025 related to unvested employee and non-employee director stock options is $70.0 million, which we expect to recognize over a weighted average period of 2.5 years. If there are any modifications or cancellations of the underlying unvested securities, we may be required to accelerate, increase, or cancel any remaining unearned stock compensation expense. Future stock-based compensation expense and unearned stock-based compensation will increase to the extent that we grant additional stock-based awards.
We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model using the fair market value of our common stock on the date of grant and a number of other assumptions. These
assumptions include estimates regarding the expected term of the awards, estimates of the stock volatility over a duration that approximates the expected term of the awards, estimates of the risk-free rate, and estimates of expected dividend rates.
The fair value of options granted to employees and non-employee directors was estimated as of the grant date using the Black-Scholes option pricing model using the following assumptions:
Nine Months Ended
September 30,
20212020
Expected term (years)
5.50 - 6.25
5.50 - 6.25
Expected volatility
55.0 - 55.9%
42.3 - 49.3%
Risk-free interest rate
0.79 - 1.40%
0.36 - 1.42%
Expected dividend yield0.0%0.0%
Weighted average fair value$109.81$38.33

Expected Term — Due to our limited amount of historical exercise, forfeiture, and expiration activity, we have opted to use the "simplified method" for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting terms and the original contractual term of the option. We will continue to analyze our expected term assumption as more historical data becomes available.
Expected Volatility — Due to our limited operating history and a lack of company specific historical and implied volatility data, we have incorporated our historical stock trading volatility with those of a group of similar companies that are publicly traded for the calculation of volatility. When selecting this peer group of public companies on which we have based our expected stock price volatility, we generally selected companies with comparable characteristics to it, including enterprise value, stages of clinical development, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. We will continue to analyze the historical stock price volatility assumption as more historical data for our common stock becomes available.
Risk-Free Interest Rate — The risk-free rate assumption is based on the U.S. government Treasury instruments with maturities similar to the expected term of our stock options.
Expected Dividend Yield — The expected dividend assumption is based on our history of not paying dividends and our expectation that we will not declare dividends for the foreseeable future.
The amount of stock-based compensation expense is recognized on a straight-line basis over the vesting term and is reduced by actual forfeitures as they occur.
Restricted Stock Units
RSUs are share awards that entitle the holder to receive freely tradable shares of our common stock upon vesting. The RSUs cannot be transferred and the awards are subject to forfeiture if the holder’s employment terminates prior to the release of the vesting restrictions. The RSUs include a four-year service period and vest in equal installments on each of the first four anniversaries of the date of grant, provided the employee remains continuously employed with the Company. The fair value of the RSUs is equal to the closing price of our common stock on the grant date.
A summary of RSUs and related information is as follows:
Restricted Stock UnitsWeighted Average
Grant Date Fair Value
Aggregate Intrinsic Value (in thousands)
Unvested at December 31, 2020— $— $— 
Granted2,275 $201.51 
Unvested at September 30, 20212,275 $201.51 $530 
There were no RSUs granted prior to 2021. The aggregate intrinsic value of RSUs outstanding was based on our closing stock price on the last trading day of the period. As of September 30, 2021, there was $0.4 million of unrecognized stock-based compensation expense related to RSUs to be recognized over a period of 3.3 years.
Employee Stock Purchase Plan
Our ESPP allows participating employees to purchase shares of our common stock at a discount through payroll deductions. The plan is available to all of our U.S.-based full-time employees. Participating employees may purchase common stock, on a voluntary after-tax basis, at a price equal to 85% of the lower of the closing market price per share of our common stock on the first or last trading day of each stock purchase period. The plan provides for six-month purchase periods, beginning on January 1 and July 1 of each calendar year.
A total of 277,362 shares of common stock were initially reserved for issuance under the ESPP, and this share reserve will automatically be supplemented each January 1, commencing on January 1, 2019 and ending on and including January 1, 2028, by an amount of shares equal to the lesser of: a) 184,908 shares, b) 1% of the shares outstanding on the final day of the immediately preceding calendar year and c) such smaller number of shares as the board of directors may determine. On June 30, 2021, 11,351 shares were purchased under the ESPP, utilizing $1.8 million of employee contributions. As of September 30, 2021, 754,752 shares were available for future issuance under the ESPP. The current purchase period under the ESPP began on July 1, 2021 and ends December 31, 2021.
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
9 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
At both September 30, 2021 and 2020, a valuation allowance was recorded against all deferred tax assets due to our cumulative net loss position. We recorded income tax expense of $0 and $0.1 million in the three months ended September 30, 2021 and 2020, respectively, and $0.1 million for both of the nine months ended September 30, 2021 and 2020. The nominal Income tax expense in those periods reflects minimal state income tax expense and an accrual for uncertain tax benefits.
We filed our 2020 U.S. federal income tax return during the third quarter of 2021. Considering provision to return true-ups, our gross federal net operating loss carryforward as of December 31, 2020 was $234.8 million, which will expire at various dates beginning in 2028. In addition, net operating loss carryforwards for state income tax purposes of $145.6 million that include net operating losses will begin to expire in 2028. We also have gross research and development credit carryforwards of $4.4 million as of December 31, 2020, which will expire at various dates beginning in 2033.
Utilization of the net operating loss carryforwards may be subject to an annual limitation due to the ownership change limitations provided by Section 382 of the Internal Revenue Code of 1986 and similar state provisions. We have not performed a detailed analysis to determine whether an ownership change has occurred. Such a change of ownership would limit our utilization of the net operating losses and could be triggered by subsequent sales of securities by us or our stockholders.
Realization of the deferred tax assets is dependent upon the generation of future taxable income, if any, the amount and timing of which are uncertain. Based on available objective evidence and cumulative losses, we believe it is more likely than not that the deferred tax assets are not recognizable and will not be recognizable until we have sufficient taxable income. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance.
We had $0.1 million of gross unrecognized tax benefits as of each of September 30, 2021 and December 31, 2020.
We file income tax returns in the applicable jurisdictions. The 2018 to 2020 tax years remain open to examination by the major taxing authorities to which we are subject. We do not expect a significant change to our unrecognized tax benefits over the next 12 months.
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting and Revenue Disaggregation
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Segment Reporting and Revenue Disaggregation Segment Reporting and Revenue Disaggregation
We operate our business as one reporting segment. An operating segment is defined as a component of an enterprise for which separate discrete financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance.
We sell our Inspire system to hospitals and ambulatory surgery centers in the U.S. and in select countries in Europe through a direct sales organization. Revenue by geographic region is as follows:
Three Months EndedNine Months Ended
September 30,September 30,
2021202020212020
United States$58,298 $33,121 $145,420 $63,379 
Europe3,387 2,721 9,576 5,993 
Total revenue$61,685 $35,842 $154,996 $69,372 
All of our long-lived assets are located in the U.S.
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Loss Per Share
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Loss Per Share Loss Per ShareBasic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Because we have reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share as all of the following potentially dilutive shares were antidilutive in those periods:
September 30,
20212020
Common stock options2,679,407 2,514,801 
Restricted stock units2,275 — 
Employee stock purchase plan6,124 — 
Total2,687,806 2,514,801 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and as required by the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. When preparing financial statements in conformity with GAAP, we must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements. Actual results could differ from those estimates. Additionally, the results of operations for the interim periods are not necessarily indicative of the operating results for the full fiscal year or any future periods. For a complete discussion of our significant accounting policies and other information, the unaudited financial statements and notes thereto should be read in conjunction with the audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020.
Cash and Cash Equivalents
Cash and Cash Equivalents
We consider all highly liquid securities, readily convertible to cash, that mature within 90 days or less from the date of purchase to be cash equivalents. The carrying amount reported in the balance sheets for cash is cost, which approximates fair value.
Foreign Currency Foreign CurrencySales and expenses denominated in foreign currencies are translated at average exchange rates in effect throughout the year. Foreign currency transaction gains and losses are included in other expense (income), net, in the statements of operations and comprehensive loss. Assets and liabilities of foreign operations are remeasured at period-end exchange rates with the impacts of foreign currency remeasurement recognized in other expense (income), net in the statements of operations and comprehensive loss.
Investments InvestmentsAt December 31, 2020, our short-term investments consisted of commercial paper, corporate bonds, and U.S. government securities, which are classified as available-for-sale and had maturities less than one year. Our long-term investments at September 30, 2021 consisted of U.S. government securities. Investments are reported at their estimated fair market values which are based on quoted, active or inactive market prices when available. Any unrealized gains and losses due to interest rate fluctuations and other external factors are reported as a separate component of accumulated other comprehensive (loss) income.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
We measure certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and investments. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:
Level 1—Observable inputs, such as quoted prices (unadjusted) for identical assets or liabilities in active markets.
Level 2—Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability.
Level 3—Unobservable inputs that are supported by little or no market activities, which would require us to develop our own assumptions.
We use the methods and assumptions described below in determining the fair value of our financial instruments.
Money market funds: Fair values of money market funds are based on quoted market prices in active markets. These are included as Level 1 measurements in the tables below.
Commercial paper: Short-term, highly liquid investments are included as a Level 2 measurement in the table below.
Corporate bonds: Consists of short-term notes and bonds with various yields. These are included as a Level 2 measurement in the table below.
U.S. government securities: Consists of U.S. government Treasury bills and notes with original maturities of less than one year to two years. These are included as a Level 1 measurement in the tables below.
The following tables set forth by level within the fair value hierarchy our assets that are measured on a recurring basis and reported at fair value as of September 30, 2021 and December 31, 2020. Assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Fair Value Measurements as of
September 30, 2021
Estimated
Fair Value
Level 1Level 2Level 3
Cash equivalents:
Money market funds$189,355 $189,355 $— $— 
Total cash equivalents189,355 189,355 — — 
Investments:
U.S. government securities$9,984 $9,984 $— $— 
Total investments9,984 9,984 — — 
Total cash equivalents and investments$199,339 $199,339 $— $— 
Fair Value Measurements as of
December 31, 2020
Estimated
Fair Value
Level 1Level 2Level 3
Cash equivalents:
Money market funds$179,389 $179,389 $— $— 
Total cash equivalents179,389 179,389 — — 
Investments:
Commercial paper$13,275 $— $13,275 $— 
Corporate bonds6,540 — 6,540 — 
U.S. government securities24,029 24,029 — — 
Total investments43,844 24,029 19,815 — 
Total cash equivalents and investments$223,233 $203,418 $19,815 $— 

There were no transfers between levels during the periods ended September 30, 2021 and December 31, 2020.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments, which potentially subject us to concentrations of credit risk, consist principally of cash equivalents, investments, and accounts receivable.
Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration
by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of September 30, 2021 and December 31, 2020, we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy.
We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.
Accounts Receivable and Allowance for Expected Credit Losses
Accounts Receivable and Allowance for Expected Credit Losses
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. Customer credit terms are established prior to shipment with the general standard being net 30 days. Collateral or any other security to support payment of these receivables generally is not required.
We recognize expected credit losses on accounts receivable in accordance with Accounting Standards Update ("ASU"), ASU 2016-13, Financial Instruments - Credit Losses ("ASU 2016-13"), which we adopted effective January 1, 2020 using the modified retrospective approach through a cumulative-effect adjustment to retained earnings. The adoption of ASU 2016-13 did not have a material impact on the amount and timing of credit losses recognized in our financial statements.
Each reporting period, we estimate the credit loss related to accounts receivable based on a migration analysis of accounts grouped by individual receivables delinquency status, and apply our historic loss rate adjusted for management's assumption of future market conditions. Any change in the allowance subsequent to the effective date of January 1, 2020 from new receivables acquired, or changes due to credit deterioration on previously existing receivables, is recorded in selling, general and administrative expenses. Write-offs of receivables considered uncollectible are deducted from the allowance. Specific accounts receivable are written-off once a determination is made that the amount is uncollectible. The write-off is recorded in the period in which the account receivable is deemed uncollectible. Recoveries are recognized when received and as a direct credit to earnings or as a reduction to the allowance for credit losses (which would indirectly reduce the loss by decreasing bad debt expense).
Inventories We regularly review inventory quantities on-hand for excess and obsolete inventory and, when circumstances indicate, incur charges to write down inventories to their net realizable value. The determination of a reserve for excess and obsolete inventory involves management exercising judgment to determine the required reserve, considering future demand, product life cycles, introduction of new products and current market conditions.
Property and Equipment Depreciation is determined using the straight-line method over the estimated useful lives of the respective assets, generally three to five years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease.
Impairment of Long-lived Assets Impairment of Long-lived AssetsLong-lived assets consist primarily of property and equipment and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require that an asset be tested for possible impairment, we compare the undiscounted cash flows expected to be generated by the asset to the carrying amount of the asset. If the carrying amount of the asset is not recoverable on an undiscounted cash flow basis, we determine the fair value of the asset and recognize an impairment loss to the extent the carrying amount of the asset exceeds its fair value. We determine fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. Our cash flow assumptions consider historical and forecasted revenue and operating costs and other relevant factors.
Revenue Recognition
Revenue Recognition
We recognize revenue in accordance with Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606"). Revenues from product sales are recognized when the customer obtains control of the product, which occurs at a point in time, either upon shipment of the product or receipt of the product,
depending on shipment terms. Our standard shipping terms are free on board shipping point, unless the customer requests that control of the inventory transfer upon delivery. In those cases where shipping and handling costs are billed to customers, we classify the amounts billed as a component of cost of goods sold.
Revenue is measured as the amount of consideration we expect to receive, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, which is based on the invoiced price, in exchange for transferring products. All revenue is recognized when we satisfy our performance obligations under the contract. The majority of our contracts have a single performance obligation and are short term in nature.
Sales taxes and value added taxes in foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of goods sold.
Variable consideration related to certain customer sales incentives is estimated based on the amounts expected to be paid based on the agreement with the customer using probability assessments.
We offer customers a limited right of return for our product in case of non-conformity or performance issues. We estimate the amount of our product sales that may be returned by our customers based on historical sales and returns. As our historical product returns to date have been immaterial, we have not recorded a reduction in revenue related to variable consideration for product returns.
Cost of Goods Sold
Cost of Goods Sold
Cost of goods sold consists primarily of acquisition costs for the components of the Inspire system, overhead costs, scrap and inventory obsolescence, warranty replacement costs, as well as distribution-related expenses such as logistics and shipping costs, net of shipping costs charged to customers. The overhead costs include the cost of material procurement, depreciation expense for production equipment, and operations supervision and management personnel, including employee compensation, stock-based compensation, supplies, and travel.
Research and Development
Research and Development
Research and development expenses consist primarily of product development, clinical and regulatory affairs, quality assurance, consulting services, and other costs associated with products and technologies in development. These expenses include employee compensation, including stock-based compensation, supplies, materials, consulting, and travel expenses related to research and development programs. Clinical expenses include clinical trial design, clinical site reimbursement, data management, travel expenses, and the cost of manufacturing products for clinical trials.
Stock-Based Compensation
Stock-Based Compensation
We maintain an equity incentive plan to provide long-term incentives for eligible employees, consultants, and members of the board of directors. The plan allows for the issuance of restricted stock units ("RSUs") and non-statutory and incentive stock options to employees and RSUs and non-statutory stock options to consultants and directors. We also offer an employee stock purchase plan which allows participating employees to purchase shares of our common stock at a discount through payroll deductions.
We recognize equity-based compensation expense for awards of equity instruments to employees and directors based on the grant date fair value of those awards in accordance with ASC Topic 718, Stock Compensation ("ASC 718"). ASC 718 requires all equity-based compensation awards to employees and directors, including grants of RSUs and stock options, to be recognized as expense in the statements of operations and comprehensive loss based on their grant date fair values. We estimate the fair value of stock options using the Black-Scholes option
pricing model and the fair value of RSUs is equal to the closing price of our common stock on the grant date. The fair value of each purchase under the employee stock purchase plan is estimated at the beginning of the offering period using the Black-Scholes option pricing model. We have not granted any stock-based awards to our consultants.
The Black-Scholes option pricing model requires the input of certain subjective assumptions, including (i) the expected share price volatility, (ii) the expected term of the award, (iii) the risk-free interest rate and (iv) the expected dividend yield. Due to our limited operating history and a lack of company specific historical and implied volatility data, we have incorporated our historical stock trading volatility with those of a peer group of public companies for the calculation of volatility. The group of peer companies have characteristics similar to us, including stage of product development and focus on the life science industry. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. We use the simplified method, which is the average of the final vesting tranche date and the contractual term, to calculate the expected term for options granted to employees and directors as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is based on a U.S. government Treasury instrument whose term is consistent with the expected term of the stock options. We use an assumed dividend yield of zero as we have never paid dividends and have no current plans to pay any dividends on our common stock.
We expense the fair value of our equity-based compensation awards granted to employees and directors on a straight-line basis over the associated service period, which is generally the period in which the related services are received. We account for award forfeitures as they occur.
Advertising Expenses Advertising ExpensesWe expense the costs of advertising, including promotional expenses, as incurred.
Leases
Leases
Operating leases are included in operating lease right-of-use ("ROU") asset, accrued expenses, and operating lease liability – non-current portion in our balance sheets. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. In determining the present value of lease payments, we use our incremental borrowing rate based on the information available at the lease commencement date as the rate implicit in the lease is not readily determinable. The determination of our incremental borrowing rate requires management judgment based on information available at lease commencement. The operating lease ROU assets also include adjustments for prepayments, accrued lease payments and exclude lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise such options. Operating lease cost is recognized on a straight-line basis over the expected lease term. Lease agreements entered into after the adoption of ASC 842 that include lease and non-lease components are accounted for as a single lease component. Lease agreements with a noncancelable term of less than 12 months are not recorded on our balance sheets.
Income Taxes
Income Taxes
We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances against deferred tax assets are established, when necessary, to reduce deferred tax assets to the amounts expected to be realized. As we have historically incurred operating losses, we have recorded a full valuation allowance against our net deferred tax assets, and there is no provision for income taxes other than
minimal state taxes and an accrual for uncertain tax benefits. Our policy is to record interest and penalties expense related to uncertain tax positions as other expense in the statements of operations and comprehensive loss.
Comprehensive Loss
Comprehensive Loss
Comprehensive loss consists of net loss and changes in unrealized gains and losses due to interest rate fluctuations and other external factors on investments classified as available-for-sale. Accumulated other comprehensive (loss) income is presented in the accompanying balance sheets as a component of stockholders' equity.
Loss Per Share
Loss Per Share
Basic net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive potential shares of common stock outstanding during the period. Because we have reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share as all potentially dilutive shares consisting of outstanding stock options, unvested RSUs, and shares issuable under our employee stock purchase plan were antidilutive in those periods.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
We have reviewed and considered all recent accounting pronouncements that have not yet been adopted and believe there are none that could potentially have a material impact on our business practices, financial condition, results of operations, or disclosures.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Schedule of assets and liabilities measured at fair value on a recurring basis
The following tables set forth by level within the fair value hierarchy our assets that are measured on a recurring basis and reported at fair value as of September 30, 2021 and December 31, 2020. Assets are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.
Fair Value Measurements as of
September 30, 2021
Estimated
Fair Value
Level 1Level 2Level 3
Cash equivalents:
Money market funds$189,355 $189,355 $— $— 
Total cash equivalents189,355 189,355 — — 
Investments:
U.S. government securities$9,984 $9,984 $— $— 
Total investments9,984 9,984 — — 
Total cash equivalents and investments$199,339 $199,339 $— $— 
Fair Value Measurements as of
December 31, 2020
Estimated
Fair Value
Level 1Level 2Level 3
Cash equivalents:
Money market funds$179,389 $179,389 $— $— 
Total cash equivalents179,389 179,389 — — 
Investments:
Commercial paper$13,275 $— $13,275 $— 
Corporate bonds6,540 — 6,540 — 
U.S. government securities24,029 24,029 — — 
Total investments43,844 24,029 19,815 — 
Total cash equivalents and investments$223,233 $203,418 $19,815 $— 
Schedule of inventory Inventories are valued at the lower of cost or net realizable value, computed on a first-in, first-out basis and consisted of the following:
September 30, 2021December 31, 2020
Raw materials$1,865 $892 
Finished goods13,709 7,587 
Total inventories, net of reserves$15,574 $8,479 
Schedule of property and equipment Property and equipment are stated at cost, less accumulated depreciation and amortization and consisted of the following:
September 30, 2021December 31, 2020
Computer equipment and software$1,391 $1,305 
Manufacturing equipment4,322 2,285 
Other equipment249 249 
Leasehold improvements281 192 
Construction in process4,380 3,125 
Property and equipment, cost10,623 7,156 
Less: accumulated depreciation and amortization(2,708)(1,845)
Property and equipment, net$7,915 $5,311 
Schedule of accrued expenses Accrued expenses consisted of the following:
September 30, 2021December 31, 2020
Payroll related$14,876 $11,965 
Interest155 160 
Current operating lease liability27 — 
Other accrued expenses2,419 1,391 
Total accrued expenses$17,477 $13,516 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Investments (Tables)
9 Months Ended
Sep. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Short-term investments available-for-sale
Our investments are classified as available-for-sale and consist of the following:
September 30, 2021
AmortizedUnrealized GrossAggregate
CostGainsLossesFair Value
Long-Term:
U.S. government securities$9,993 $— $(9)$9,984 
Long-term investments$9,993 $— $(9)$9,984 
December 31, 2020
AmortizedUnrealized GrossAggregate
CostGainsLossesFair Value
Short-Term:
Commercial paper$13,275 $— $— $13,275 
Corporate bonds6,543 — (3)6,540 
U.S. government securities23,997 32 — 24,029 
Short-term investments$43,815 $32 $(3)$43,844 
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Leases (Tables)
9 Months Ended
Sep. 30, 2021
Leases [Abstract]  
Lease Balances within the Balance Sheets The following table presents the lease balances within the balance sheets:
September 30, 2021December 31, 2020
Right-of-use assets:
Operating lease right-of-use asset$5,296 $5,805 
Operating lease liabilities:
Accrued expenses27  
Operating lease liability, non-current portion6,080 5,886 
Total operating lease liabilities$6,107 $5,886 
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt (Tables)
9 Months Ended
Sep. 30, 2021
Long-term Debt, by Current and Noncurrent [Abstract]  
Schedule of expected future principal payments for the credit facility Expected future principal payments for the credit facility are as follows:
Year ending December 31:
2021 (remaining)$— 
20229,188 
202312,250 
20243,062 
Total expected future principal payments$24,500 
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of stock-based compensation expense recognized The following table presents the components and classification of stock-based compensation expense recognized for stock options and RSUs granted under the 2017 Plan, the 2018 Plan and under our Employee Stock Purchase Plan (the "ESPP"):
Three Months EndedNine Months Ended
September 30,September 30,
2021202020212020
Stock options$6,405 $2,984 $18,065 $8,303 
Restricted stock units29 — 77 — 
Employee stock purchase plan376 327 1,006 660 
Total stock-based compensation expense$6,810 $3,311 $19,148 $8,963 
Cost of goods sold$88 $36 $250 $122 
Research and development1,153 535 3,229 1,252 
Selling, general and administrative5,569 2,740 15,669 7,589 
Total stock-based compensation expense$6,810 $3,311 $19,148 $8,963 
Summary of the company's stock option activity and related information
A summary of stock option activity and related information is as follows:
OptionsWeighted Average
Exercise Price
Weighted Average
Remaining
Contractual Term
(years)
Aggregate Intrinsic
Value
(in thousands)
Outstanding at December 31, 20202,857,564 $66.09 7.9$351,626
Granted184,845 $208.12 
Exercised(269,212)$33.92 $47,176
Forfeited/expired(93,790)$113.37 
Outstanding at September 30, 20212,679,407 $77.47 7.3$416,515
Exercisable at September 30, 20211,355,413 $28.54 6.1$276,959
Summary of weighted average assumptions for fair value of options granted The fair value of options granted to employees and non-employee directors was estimated as of the grant date using the Black-Scholes option pricing model using the following assumptions:
Nine Months Ended
September 30,
20212020
Expected term (years)
5.50 - 6.25
5.50 - 6.25
Expected volatility
55.0 - 55.9%
42.3 - 49.3%
Risk-free interest rate
0.79 - 1.40%
0.36 - 1.42%
Expected dividend yield0.0%0.0%
Weighted average fair value$109.81$38.33
Schedule of restricted stock units activity
A summary of RSUs and related information is as follows:
Restricted Stock UnitsWeighted Average
Grant Date Fair Value
Aggregate Intrinsic Value (in thousands)
Unvested at December 31, 2020— $— $— 
Granted2,275 $201.51 
Unvested at September 30, 20212,275 $201.51 $530 
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting and Revenue Disaggregation (Tables)
9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Schedule of revenue by geographic region Revenue by geographic region is as follows:
Three Months EndedNine Months Ended
September 30,September 30,
2021202020212020
United States$58,298 $33,121 $145,420 $63,379 
Europe3,387 2,721 9,576 5,993 
Total revenue$61,685 $35,842 $154,996 $69,372 
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of dilutive securities excluded from computations of diluted weighted average shares outstanding Because we have reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share as all of the following potentially dilutive shares were antidilutive in those periods:
September 30,
20212020
Common stock options2,679,407 2,514,801 
Restricted stock units2,275 — 
Employee stock purchase plan6,124 — 
Total2,687,806 2,514,801 
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Follow-On Public Offering (Details) - Follow-on Offering
$ / shares in Units, $ in Millions
Apr. 16, 2020
USD ($)
$ / shares
shares
Subsidiary, Sale of Stock [Line Items]  
Shares sold (in shares) | shares 2,300,000
Sale of stock, price per share (in dollars per share) | $ / shares $ 58.00
Proceeds from sale of stock | $ $ 124.7
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Investments (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Accounting Policies [Abstract]        
Unrecognized loss (gain) in accumulated other comprehensive loss (income), less than   $ 100,000   $ 100,000
Realized gains $ 0 100,000 $ 100,000  
Allowance for credit loss $ 0 $ 0   $ 0
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) - Recurring basis - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Cash equivalents:    
Total cash equivalents $ 189,355 $ 179,389
Investments:    
Total investments 9,984 43,844
Total cash equivalents and investments 199,339 223,233
Commercial paper    
Investments:    
Total investments   13,275
Corporate bonds    
Investments:    
Total investments   6,540
U.S. government securities    
Investments:    
Total investments 9,984 24,029
Money market funds    
Cash equivalents:    
Total cash equivalents 189,355  
Level 1    
Cash equivalents:    
Total cash equivalents 189,355 179,389
Investments:    
Total investments 9,984 24,029
Total cash equivalents and investments 199,339 203,418
Level 1 | Commercial paper    
Investments:    
Total investments   0
Level 1 | Corporate bonds    
Investments:    
Total investments   0
Level 1 | U.S. government securities    
Investments:    
Total investments 9,984 24,029
Level 1 | Money market funds    
Cash equivalents:    
Total cash equivalents 189,355  
Level 2    
Cash equivalents:    
Total cash equivalents 0 0
Investments:    
Total investments 0 19,815
Total cash equivalents and investments 0 19,815
Level 2 | Commercial paper    
Investments:    
Total investments   13,275
Level 2 | Corporate bonds    
Investments:    
Total investments   6,540
Level 2 | U.S. government securities    
Investments:    
Total investments 0 0
Level 2 | Money market funds    
Cash equivalents:    
Total cash equivalents 0  
Level 3    
Cash equivalents:    
Total cash equivalents 0 0
Investments:    
Total investments 0 0
Total cash equivalents and investments 0 0
Level 3 | Commercial paper    
Investments:    
Total investments   0
Level 3 | Corporate bonds    
Investments:    
Total investments   0
Level 3 | U.S. government securities    
Investments:    
Total investments 0 $ 0
Level 3 | Money market funds    
Cash equivalents:    
Total cash equivalents $ 0  
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Inventories (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Raw materials $ 1,865 $ 892
Finished goods 13,709 7,587
Total inventories, net of reserves 15,574 8,479
Reserve for excess and obsolete inventory $ 300 $ 100
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Property and Equipment (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Property and Equipment          
Property and equipment, cost $ 10,623   $ 10,623   $ 7,156
Less: accumulated depreciation and amortization (2,708)   (2,708)   (1,845)
Property and equipment, net 7,915   7,915   5,311
Depreciation and amortization expenses 300 $ 200 900 $ 600  
Computer equipment and software          
Property and Equipment          
Property and equipment, cost 1,391   1,391   1,305
Manufacturing equipment          
Property and Equipment          
Property and equipment, cost 4,322   4,322   2,285
Other equipment          
Property and Equipment          
Property and equipment, cost 249   249   249
Leasehold improvements          
Property and Equipment          
Property and equipment, cost 281   281   192
Construction in process          
Property and Equipment          
Property and equipment, cost $ 4,380   $ 4,380   $ 3,125
Minimum          
Property and Equipment          
Estimated useful lives     3 years    
Maximum          
Property and Equipment          
Estimated useful lives     5 years    
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Accrued Expenses (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Payroll related $ 14,876 $ 11,965
Interest 155 160
Current operating lease liability 27 0
Other accrued expenses 2,419 1,391
Total accrued expenses $ 17,477 $ 13,516
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Stock Based Compensation (Details)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Dividend yield 0.00%
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Advertising Expenses (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Advertising Expenses        
Advertising expenses $ 13.4 $ 6.8 $ 34.0 $ 18.2
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Investments (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]    
Investments with maturity greater than one year $ 0 $ 0
Long-term Debt    
Debt Securities, Available-for-sale [Line Items]    
Cost 9,993,000  
Unrealized Gross Gains 0  
Unrealized Gross Losses (9,000)  
Fair Value 9,984,000  
Short-term Debt    
Debt Securities, Available-for-sale [Line Items]    
Cost   43,815,000
Unrealized Gross Gains   32,000
Unrealized Gross Losses   (3,000)
Fair Value   43,844,000
Commercial paper | Short-term Debt    
Debt Securities, Available-for-sale [Line Items]    
Cost   13,275,000
Unrealized Gross Gains   0
Unrealized Gross Losses   0
Fair Value   13,275,000
Corporate bonds | Short-term Debt    
Debt Securities, Available-for-sale [Line Items]    
Cost   6,543,000
Unrealized Gross Gains   0
Unrealized Gross Losses   (3,000)
Fair Value   6,540,000
U.S. government securities | Long-term Debt    
Debt Securities, Available-for-sale [Line Items]    
Cost 9,993,000  
Unrealized Gross Gains 0  
Unrealized Gross Losses (9,000)  
Fair Value $ 9,984,000  
U.S. government securities | Short-term Debt    
Debt Securities, Available-for-sale [Line Items]    
Cost   23,997,000
Unrealized Gross Gains   32,000
Unrealized Gross Losses   0
Fair Value   $ 24,029,000
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Narrative (Details)
ft² in Thousands, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 18 Months Ended
Aug. 31, 2021
USD ($)
ft²
renewal_option
May 31, 2019
renewal_option
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
May 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2018
ft²
Lessee, Lease, Description [Line Items]                  
Operating lease sublease land agreement (square feet) | ft² 25                
Number of renewal options | renewal_option 1                
Renewal term 5 years                
Operating lease liability $ 3,600   $ 6,107   $ 6,107     $ 5,886  
Remaining lease term     6 years 8 months 12 days   6 years 8 months 12 days        
Discount rate     5.20%   5.20%        
Operating lease payments     $ 100 $ 300 $ 100 $ 800      
Forecast                  
Lessee, Lease, Description [Line Items]                  
Operating lease income             $ 600    
Leasehold improvements             1,100    
Incentive from landlord, rent abatement             200    
Incentive from landlord, refurbishment allowance, maximum             $ 400    
Office Space Sublease                  
Lessee, Lease, Description [Line Items]                  
Operating lease sublease land agreement (square feet) | ft²                 45
Number of renewal options | renewal_option   1              
Renewal term   5 years              
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Leases - Assets and Liabilities (Details) - USD ($)
$ in Thousands
Sep. 30, 2021
Aug. 31, 2021
Dec. 31, 2020
Right-of-use assets:      
Operating lease right-of-use asset $ 5,296   $ 5,805
Operating lease liabilities:      
Current operating lease liability 27   0
Operating lease liability, non-current portion 6,080   5,886
Operating lease liability $ 6,107 $ 3,600 $ 5,886
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Accrued expenses   Accrued expenses
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Long-Term Debt (Details) - USD ($)
Mar. 27, 2019
Sep. 30, 2021
Mar. 26, 2019
Feb. 28, 2018
Feb. 28, 2017
Aug. 31, 2015
Expected future principal payments            
2021 (remaining)   $ 0        
2022   9,188,000        
2023   12,250,000        
2024   3,062,000        
Total expected future principal payments   $ 24,500,000        
Term loan facility            
Credit Facility            
Final payment percentage     5.50%      
Increase in interest rate in default   5.00%        
Term loan facility | February 2017 Amendment to Loan and Security Agreement            
Credit Facility            
Outstanding credit facility amount         $ 16,500,000  
Term loan facility | March 2019 Amendment to Loan and Security Agreement            
Credit Facility            
Final payment percentage 3.50%          
Variable interest rate 2.50%          
Variable interest rate on credit facility 5.10%          
Term loan facility | Minimum | March 2019 Amendment to Loan and Security Agreement            
Credit Facility            
Basic interest rate 7.60%          
Prepayment fee 1.00%          
Term loan facility | Maximum | March 2019 Amendment to Loan and Security Agreement            
Credit Facility            
Prepayment fee 3.00%          
Term A loan facility            
Credit Facility            
Maximum borrowing amount under credit facility           $ 15,500,000
Term A loan facility | February 2017 Amendment to Loan and Security Agreement            
Credit Facility            
Additional borrowing amount under credit facility         1,000,000  
Term B loan facility            
Credit Facility            
Outstanding credit facility amount       $ 24,500,000    
Additional borrowing amount under credit facility       $ 8,000,000    
Term B loan facility | February 2017 Amendment to Loan and Security Agreement            
Credit Facility            
Outstanding credit facility amount         $ 9,000,000  
Term B loan facility | Minimum            
Credit Facility            
Outstanding credit facility amount           3,500,000
Term B loan facility | Maximum            
Credit Facility            
Outstanding credit facility amount           $ 10,000,000
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Stock-Based Compensation (Details) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2021
Jan. 01, 2019
Dec. 31, 2018
Stock Options      
Unearned stock-based compensation $ 70.0    
Weighted average recognition period 2 years 6 months    
Options      
Stock Options      
Contractual life of stock options 10 years    
Options | Directors | Minimum      
Stock Options      
Service period 1 year    
Options | Directors | Maximum      
Stock Options      
Service period 3 years    
Options | Vesting after first year of service      
Stock Options      
Service period 4 years    
Percentage of shares to vest 25.00%    
Options | Vesting in years two through four      
Stock Options      
Vesting period 36 months    
Stock Incentive Plan 2018      
Stock Options      
Number of shares reserved for issuance (in shares) 3,284,769   1,386,809
Number of additional shares reserved for issuance, maximum (in shares)   739,631  
Number of additional shares reserved for issuance, percentage, maximum   4.00%  
Number of shares available for issuance (in shares) 1,293,557    
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Stock-Based Compensation Expense Recognized (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Stock Options        
Total stock-based compensation expense $ 6,810 $ 3,311 $ 19,148 $ 8,963
Cost of goods sold        
Stock Options        
Total stock-based compensation expense 88 36 250 122
Research and development        
Stock Options        
Total stock-based compensation expense 1,153 535 3,229 1,252
Selling, general and administrative        
Stock Options        
Total stock-based compensation expense 5,569 2,740 15,669 7,589
Stock options        
Stock Options        
Total stock-based compensation expense 6,405 2,984 18,065 8,303
Restricted stock units        
Stock Options        
Total stock-based compensation expense 29 0 77 0
Employee stock purchase plan        
Stock Options        
Total stock-based compensation expense $ 376 $ 327 $ 1,006 $ 660
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Stock Option Activity (Details)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2021
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Options    
Outstanding at beginning of the year (in shares) | shares 2,857,564 2,857,564
Granted (in shares) | shares   184,845
Exercised (in shares) | shares   (269,212)
Forfeited /expired (in shares) | shares   (93,790)
Outstanding at ending of the year (in shares) | shares   2,679,407
Exercisable (in shares) | shares   1,355,413
Weighted Average Exercise Price    
Outstanding, beginning of the period (in dollars per share) | $ / shares $ 66.09 $ 66.09
Granted (in dollars per share) | $ / shares   208.12
Exercised (in dollars per share) | $ / shares   33.92
Forfeited/expired (in dollars per share) | $ / shares   113.37
Outstanding, end of the period (in dollars per share) | $ / shares   77.47
Exercisable (in dollars per share) | $ / shares   $ 28.54
Weighted Average Remaining Contractual Term    
Outstanding 7 years 10 months 24 days 7 years 3 months 18 days
Exercisable   6 years 1 month 6 days
Aggregate Intrinsic Value    
Outstanding, beginning of period | $ $ 351,626 $ 351,626
Exercised | $   47,176
Outstanding, end of period | $   416,515
Exercisable | $   $ 276,959
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Assumptions Used to Calculate Fair Value of Options (Details) - $ / shares
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Weighted average assumptions    
Expected dividend yield 0.00%  
Options    
Weighted average assumptions    
Expected dividend yield 0.00% 0.00%
Weighted average fair value (in dollars per share) $ 109.81 $ 38.33
Options | Minimum    
Weighted average assumptions    
Expected term (years) 5 years 6 months 5 years 6 months
Expected volatility 55.00% 42.30%
Risk-free interest rate 0.79% 0.36%
Options | Maximum    
Weighted average assumptions    
Expected term (years) 6 years 3 months 6 years 3 months
Expected volatility 55.90% 49.30%
Risk-free interest rate 1.40% 1.42%
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Restricted Stock Units (Details)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2021
USD ($)
$ / shares
shares
Aggregate Intrinsic Value  
Unearned stock-based compensation $ 70,000
Weighted average recognition period 2 years 6 months
Restricted stock units  
Stock Options  
Service period 4 years
Vesting period 4 years
Restricted Stock Units  
Unvested at December 31, 2020 (in shares) | shares 0
Granted (in shares) | shares 2,275
Unvested at June 30, 2021 (in shares) | shares 2,275
Weighted Average Grant Date Fair Value  
Unvested at December 31, 2020 (in dollars per share) | $ / shares $ 0
Granted (in dollars per share) | $ / shares 201.51
Unvested at March 31, 2021 (in dollars per share) | $ / shares $ 201.51
Aggregate Intrinsic Value  
Unvested at December 31, 2020 $ 0
Unvested at June 30, 2021 530
Unearned stock-based compensation $ 400
Weighted average recognition period 3 years 3 months 18 days
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Stockholders' Equity - Employee Stock Purchase Plan (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Sep. 30, 2021
Jan. 01, 2019
Stock Options            
Issuance of common stock for employee stock purchase plan     $ 1,760 $ 1,059    
Employee Stock Purchase Plan            
Stock Options            
Employee stock purchase plan, percent         85.00%  
Number of shares reserved for issuance (in shares)         754,752 277,362
Number of additional shares reserved for issuance, maximum (in shares)           184,908
Number of additional shares reserved for issuance, percentage, maximum           1.00%
Issuance of common stock for employee stock purchase plan (in shares) 11,351          
Issuance of common stock for employee stock purchase plan   $ 1,800        
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Operating Loss Carryforwards [Line Items]          
Income tax expense $ 3,000 $ 87,000 $ 52,000 $ 87,000  
Unrecognized tax benefits 100,000   100,000   $ 100,000
Significant change to unrecognized tax benefits over the next 12 months $ 0   $ 0    
Federal          
Operating Loss Carryforwards [Line Items]          
Net operating loss carryforwards         234,800,000
State          
Operating Loss Carryforwards [Line Items]          
Net operating loss carryforwards         145,600,000
R&D credit          
Operating Loss Carryforwards [Line Items]          
Credit carryforwards         $ 4,400,000
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting and Revenue Disaggregation (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
segment
Sep. 30, 2020
USD ($)
Segment Reporting [Abstract]        
Number of reporting segments | segment     1  
Segment Reporting and Significant Customers        
Revenue $ 61,685 $ 35,842 $ 154,996 $ 69,372
United States        
Segment Reporting and Significant Customers        
Revenue 58,298 33,121 145,420 63,379
Europe        
Segment Reporting and Significant Customers        
Revenue $ 3,387 $ 2,721 $ 9,576 $ 5,993
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Loss Per Share (Details) - shares
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Loss Per Share    
Antidilutive securities excluded from computation of diluted weighted average shares outstanding (in shares) 2,687,806 2,514,801
Common stock options    
Loss Per Share    
Antidilutive securities excluded from computation of diluted weighted average shares outstanding (in shares) 2,679,407 2,514,801
Restricted stock units    
Loss Per Share    
Antidilutive securities excluded from computation of diluted weighted average shares outstanding (in shares) 2,275 0
Employee stock purchase plan    
Loss Per Share    
Antidilutive securities excluded from computation of diluted weighted average shares outstanding (in shares) 6,124 0
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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벿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�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end

&PO=V]R:W-H965T&UL4$L! A0#% @ &H)B4V%4"6!K @ MJP8 !D ("!\M4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ &H)B4VBVU5S< @ D @ !D M ("![.$ 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ &H)B4^#LT(X-! Q1 !D ("!E>X 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ &H)B M4\FOY##3 P & X !D ("!(_L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ &H)B4_=9*6 O P [0H M !D ("!$ 8! 'AL+W=O&PO=V]R:W-H965T 4 0!X;"]?7!E&UL4$L%!@ U #4 :@X *08 0 ! $! end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 211 325 1 false 53 0 false 7 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.inspiresleep.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - BALANCE SHEETS Sheet http://www.inspiresleep.com/role/BALANCESHEETS BALANCE SHEETS Statements 2 false false R3.htm 1002003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://www.inspiresleep.com/role/BALANCESHEETSParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Sheet http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) Statements 4 false false R5.htm 1004005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 1005006 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 2101101 - Disclosure - Organization Sheet http://www.inspiresleep.com/role/Organization Organization Notes 7 false false R8.htm 2102102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.inspiresleep.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2113103 - Disclosure - Investments Sheet http://www.inspiresleep.com/role/Investments Investments Notes 9 false false R10.htm 2116104 - Disclosure - Leases Sheet http://www.inspiresleep.com/role/Leases Leases Notes 10 false false R11.htm 2120105 - Disclosure - Long-Term Debt Sheet http://www.inspiresleep.com/role/LongTermDebt Long-Term Debt Notes 11 false false R12.htm 2123106 - Disclosure - Employee Retirement Plan Sheet http://www.inspiresleep.com/role/EmployeeRetirementPlan Employee Retirement Plan Notes 12 false false R13.htm 2124107 - Disclosure - Stockholders' Equity Sheet http://www.inspiresleep.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 2132108 - Disclosure - Income Taxes Sheet http://www.inspiresleep.com/role/IncomeTaxes Income Taxes Notes 14 false false R15.htm 2134109 - Disclosure - Segment Reporting and Revenue Disaggregation Sheet http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregation Segment Reporting and Revenue Disaggregation Notes 15 false false R16.htm 2137110 - Disclosure - Loss Per Share Sheet http://www.inspiresleep.com/role/LossPerShare Loss Per Share Notes 16 false false R17.htm 2203201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.inspiresleep.com/role/SummaryofSignificantAccountingPolicies 17 false false R18.htm 2304301 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.inspiresleep.com/role/SummaryofSignificantAccountingPolicies 18 false false R19.htm 2314302 - Disclosure - Investments (Tables) Sheet http://www.inspiresleep.com/role/InvestmentsTables Investments (Tables) Tables http://www.inspiresleep.com/role/Investments 19 false false R20.htm 2317303 - Disclosure - Leases (Tables) Sheet http://www.inspiresleep.com/role/LeasesTables Leases (Tables) Tables http://www.inspiresleep.com/role/Leases 20 false false R21.htm 2321304 - Disclosure - Long-Term Debt (Tables) Sheet http://www.inspiresleep.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.inspiresleep.com/role/LongTermDebt 21 false false R22.htm 2325305 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.inspiresleep.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.inspiresleep.com/role/StockholdersEquity 22 false false R23.htm 2335306 - Disclosure - Segment Reporting and Revenue Disaggregation (Tables) Sheet http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationTables Segment Reporting and Revenue Disaggregation (Tables) Tables http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregation 23 false false R24.htm 2338307 - Disclosure - Loss Per Share (Tables) Sheet http://www.inspiresleep.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.inspiresleep.com/role/LossPerShare 24 false false R25.htm 2405401 - Disclosure - Summary of Significant Accounting Policies - Follow-On Public Offering (Details) Sheet http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFollowOnPublicOfferingDetails Summary of Significant Accounting Policies - Follow-On Public Offering (Details) Details 25 false false R26.htm 2406402 - Disclosure - Summary of Significant Accounting Policies - Investments (Details) Sheet http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails Summary of Significant Accounting Policies - Investments (Details) Details 26 false false R27.htm 2407403 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) Sheet http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details) Details 27 false false R28.htm 2408404 - Disclosure - Summary of Significant Accounting Policies - Inventories (Details) Sheet http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInventoriesDetails Summary of Significant Accounting Policies - Inventories (Details) Details 28 false false R29.htm 2409405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details) Sheet http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails Summary of Significant Accounting Policies - Property and Equipment (Details) Details 29 false false R30.htm 2410406 - Disclosure - Summary of Significant Accounting Policies - Accrued Expenses (Details) Sheet http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails Summary of Significant Accounting Policies - Accrued Expenses (Details) Details 30 false false R31.htm 2411407 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details) Sheet http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails Summary of Significant Accounting Policies - Stock Based Compensation (Details) Details 31 false false R32.htm 2412408 - Disclosure - Summary of Significant Accounting Policies - Advertising Expenses (Details) Sheet http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpensesDetails Summary of Significant Accounting Policies - Advertising Expenses (Details) Details 32 false false R33.htm 2415409 - Disclosure - Investments (Details) Sheet http://www.inspiresleep.com/role/InvestmentsDetails Investments (Details) Details http://www.inspiresleep.com/role/InvestmentsTables 33 false false R34.htm 2418410 - Disclosure - Leases - Narrative (Details) Sheet http://www.inspiresleep.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 34 false false R35.htm 2419411 - Disclosure - Leases - Assets and Liabilities (Details) Sheet http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails Leases - Assets and Liabilities (Details) Details 35 false false R36.htm 2422412 - Disclosure - Long-Term Debt (Details) Sheet http://www.inspiresleep.com/role/LongTermDebtDetails Long-Term Debt (Details) Details http://www.inspiresleep.com/role/LongTermDebtTables 36 false false R37.htm 2426413 - Disclosure - Stockholders' Equity - Stock-Based Compensation (Details) Sheet http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails Stockholders' Equity - Stock-Based Compensation (Details) Details 37 false false R38.htm 2427414 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense Recognized (Details) Sheet http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails Stockholders' Equity - Stock-Based Compensation Expense Recognized (Details) Details 38 false false R39.htm 2428415 - Disclosure - Stockholders' Equity - Stock Option Activity (Details) Sheet http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails Stockholders' Equity - Stock Option Activity (Details) Details 39 false false R40.htm 2429416 - Disclosure - Stockholders' Equity - Assumptions Used to Calculate Fair Value of Options (Details) Sheet http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails Stockholders' Equity - Assumptions Used to Calculate Fair Value of Options (Details) Details 40 false false R41.htm 2430417 - Disclosure - Stockholders' Equity - Restricted Stock Units (Details) Sheet http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails Stockholders' Equity - Restricted Stock Units (Details) Details 41 false false R42.htm 2431418 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details) Sheet http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails Stockholders' Equity - Employee Stock Purchase Plan (Details) Details 42 false false R43.htm 2433419 - Disclosure - Income Taxes (Details) Sheet http://www.inspiresleep.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.inspiresleep.com/role/IncomeTaxes 43 false false R44.htm 2436420 - Disclosure - Segment Reporting and Revenue Disaggregation (Details) Sheet http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationDetails Segment Reporting and Revenue Disaggregation (Details) Details http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationTables 44 false false R45.htm 2439421 - Disclosure - Loss Per Share (Details) Sheet http://www.inspiresleep.com/role/LossPerShareDetails Loss Per Share (Details) Details http://www.inspiresleep.com/role/LossPerShareTables 45 false false All Reports Book All Reports insp-20210930.htm a2021-q3ex31x1.htm a2021-q3ex31x2.htm a2021-q3ex32x1.htm a2021-q3ex32x2.htm insp-20210930.xsd insp-20210930_cal.xml insp-20210930_def.xml insp-20210930_lab.xml insp-20210930_pre.xml insp-20210930_g1.jpg http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/country/2021 http://xbrl.sec.gov/dei/2021 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "insp-20210930.htm": { "axisCustom": 0, "axisStandard": 22, "contextCount": 211, "dts": { "calculationLink": { "local": [ "insp-20210930_cal.xml" ] }, "definitionLink": { "local": [ "insp-20210930_def.xml" ] }, "inline": { "local": [ "insp-20210930.htm" ] }, "labelLink": { "local": [ "insp-20210930_lab.xml" ] }, "presentationLink": { "local": [ "insp-20210930_pre.xml" ] }, "schema": { "local": [ "insp-20210930.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 419, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 9, "http://xbrl.sec.gov/dei/2021": 5, "total": 14 }, "keyCustom": 15, "keyStandard": 310, "memberCustom": 10, "memberStandard": 40, "nsprefix": "insp", "nsuri": "http://www.inspiresleep.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.inspiresleep.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116104 - Disclosure - Leases", "role": "http://www.inspiresleep.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120105 - Disclosure - Long-Term Debt", "role": "http://www.inspiresleep.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123106 - Disclosure - Employee Retirement Plan", "role": "http://www.inspiresleep.com/role/EmployeeRetirementPlan", "shortName": "Employee Retirement Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124107 - Disclosure - Stockholders' Equity", "role": "http://www.inspiresleep.com/role/StockholdersEquity", "shortName": "Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132108 - Disclosure - Income Taxes", "role": "http://www.inspiresleep.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134109 - Disclosure - Segment Reporting and Revenue Disaggregation", "role": "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregation", "shortName": "Segment Reporting and Revenue Disaggregation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137110 - Disclosure - Loss Per Share", "role": "http://www.inspiresleep.com/role/LossPerShare", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314302 - Disclosure - Investments (Tables)", "role": "http://www.inspiresleep.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - BALANCE SHEETS", "role": "http://www.inspiresleep.com/role/BALANCESHEETS", "shortName": "BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "insp:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317303 - Disclosure - Leases (Tables)", "role": "http://www.inspiresleep.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "insp:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321304 - Disclosure - Long-Term Debt (Tables)", "role": "http://www.inspiresleep.com/role/LongTermDebtTables", "shortName": "Long-Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325305 - Disclosure - Stockholders' Equity (Tables)", "role": "http://www.inspiresleep.com/role/StockholdersEquityTables", "shortName": "Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2335306 - Disclosure - Segment Reporting and Revenue Disaggregation (Tables)", "role": "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationTables", "shortName": "Segment Reporting and Revenue Disaggregation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2338307 - Disclosure - Loss Per Share (Tables)", "role": "http://www.inspiresleep.com/role/LossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i077a487f19014de5a9c69c00076120d8_D20200416-20200416", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - Summary of Significant Accounting Policies - Follow-On Public Offering (Details)", "role": "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFollowOnPublicOfferingDetails", "shortName": "Summary of Significant Accounting Policies - Follow-On Public Offering (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i077a487f19014de5a9c69c00076120d8_D20200416-20200416", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)", "role": "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails", "shortName": "Summary of Significant Accounting Policies - Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i7799ed056c9c4b8791964ffc68b5d0fe_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details)", "role": "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails", "shortName": "Summary of Significant Accounting Policies - Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i7799ed056c9c4b8791964ffc68b5d0fe_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408404 - Disclosure - Summary of Significant Accounting Policies - Inventories (Details)", "role": "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInventoriesDetails", "shortName": "Summary of Significant Accounting Policies - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409405 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment (Details)", "role": "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails", "shortName": "Summary of Significant Accounting Policies - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i09338644d523435ea7e797b86774129c_I20201231", "decimals": "-3", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - BALANCE SHEETS (Parenthetical)", "role": "http://www.inspiresleep.com/role/BALANCESHEETSParenthetical", "shortName": "BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410406 - Disclosure - Summary of Significant Accounting Policies - Accrued Expenses (Details)", "role": "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails", "shortName": "Summary of Significant Accounting Policies - Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411407 - Disclosure - Summary of Significant Accounting Policies - Stock Based Compensation (Details)", "role": "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails", "shortName": "Summary of Significant Accounting Policies - Stock Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i2efcad5bc6b34d4f8ee835b05a128626_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412408 - Disclosure - Summary of Significant Accounting Policies - Advertising Expenses (Details)", "role": "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpensesDetails", "shortName": "Summary of Significant Accounting Policies - Advertising Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i2efcad5bc6b34d4f8ee835b05a128626_D20210701-20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415409 - Disclosure - Investments (Details)", "role": "http://www.inspiresleep.com/role/InvestmentsDetails", "shortName": "Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i95f47aef365b49ef897c4ea75889119e_I20210831", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418410 - Disclosure - Leases - Narrative (Details)", "role": "http://www.inspiresleep.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i95f47aef365b49ef897c4ea75889119e_I20210831", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419411 - Disclosure - Leases - Assets and Liabilities (Details)", "role": "http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails", "shortName": "Leases - Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - Long-Term Debt (Details)", "role": "http://www.inspiresleep.com/role/LongTermDebtDetails", "shortName": "Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426413 - Disclosure - Stockholders' Equity - Stock-Based Compensation (Details)", "role": "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails", "shortName": "Stockholders' Equity - Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "if92f4998b12449dca6df4d2be1247006_D20210101-20210930", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i2efcad5bc6b34d4f8ee835b05a128626_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427414 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense Recognized (Details)", "role": "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails", "shortName": "Stockholders' Equity - Stock-Based Compensation Expense Recognized (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i2efcad5bc6b34d4f8ee835b05a128626_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i09338644d523435ea7e797b86774129c_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428415 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)", "role": "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails", "shortName": "Stockholders' Equity - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i2efcad5bc6b34d4f8ee835b05a128626_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "role": "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "shortName": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i2efcad5bc6b34d4f8ee835b05a128626_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429416 - Disclosure - Stockholders' Equity - Assumptions Used to Calculate Fair Value of Options (Details)", "role": "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails", "shortName": "Stockholders' Equity - Assumptions Used to Calculate Fair Value of Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "if92f4998b12449dca6df4d2be1247006_D20210101-20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "iee52ec5e242f4eab85f168e6d6130473_I20210930", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430417 - Disclosure - Stockholders' Equity - Restricted Stock Units (Details)", "role": "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails", "shortName": "Stockholders' Equity - Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "ib0b4bb58038f494ba38433f4fc3995f9_I20201231", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i6ba45fa5541243638f60f70370acdcf3_D20210401-20210630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431418 - Disclosure - Stockholders' Equity - Employee Stock Purchase Plan (Details)", "role": "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails", "shortName": "Stockholders' Equity - Employee Stock Purchase Plan (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i29e688baa03c4426b6930141efaba1ff_D20210101-20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i2efcad5bc6b34d4f8ee835b05a128626_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433419 - Disclosure - Income Taxes (Details)", "role": "http://www.inspiresleep.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i09338644d523435ea7e797b86774129c_I20201231", "decimals": "-5", "lang": "en-US", "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436420 - Disclosure - Segment Reporting and Revenue Disaggregation (Details)", "role": "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationDetails", "shortName": "Segment Reporting and Revenue Disaggregation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439421 - Disclosure - Loss Per Share (Details)", "role": "http://www.inspiresleep.com/role/LossPerShareDetails", "shortName": "Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i67f96c3007be4b7ebc12fc14b8151a6b_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "role": "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i67f96c3007be4b7ebc12fc14b8151a6b_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - STATEMENTS OF CASH FLOWS (Unaudited)", "role": "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited", "shortName": "STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization", "role": "http://www.inspiresleep.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113103 - Disclosure - Investments", "role": "http://www.inspiresleep.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "insp-20210930.htm", "contextRef": "i749d18419be24700a1ba64b885b54935_D20210101-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r572" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r573" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r574" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r570" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.inspiresleep.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "insp_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Lease Balances within the Balance Sheets" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "insp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Additional Shares Reserved, Maximum", "label": "Common Stock, Capital Shares Reserved for Future Issuance, Additional Shares Reserved, Maximum", "terseLabel": "Number of additional shares reserved for issuance, maximum (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedMaximum", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "insp_CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedPercentageMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Capital Shares Reserved for Future Issuance, Additional Shares Reserved, Percentage, Maximum", "label": "Common Stock, Capital Shares Reserved for Future Issuance, Additional Shares Reserved, Percentage, Maximum", "terseLabel": "Number of additional shares reserved for issuance, percentage, maximum" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuanceAdditionalSharesReservedPercentageMaximum", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "insp_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and Purchased software applications for licensing or long-term internal use.", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "insp_DebtInstrumentInterestRateVariableRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Interest Rate, Variable Rate", "label": "Debt Instrument, Interest Rate, Variable Rate", "terseLabel": "Variable interest rate" } } }, "localname": "DebtInstrumentInterestRateVariableRate", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "insp_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid, Percentage", "terseLabel": "Final payment percentage" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaidPercentage", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "insp_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails" ], "xbrltype": "domainItemType" }, "insp_February2017AmendmentToLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "February 2017 Amendment To Loan And Security Agreement", "label": "February 2017 Amendment To Loan And Security Agreement [Member]", "terseLabel": "February 2017 Amendment to Loan and Security Agreement" } } }, "localname": "February2017AmendmentToLoanAndSecurityAgreementMember", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "insp_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow-on Offering", "label": "Follow-on Offering [Member]", "terseLabel": "Follow-on Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFollowOnPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "insp_IncentiveFromLessorRefurbishmentAllowanceMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Incentive from Lessor, Refurbishment Allowance, Maximum", "label": "Incentive from Lessor, Refurbishment Allowance, Maximum", "terseLabel": "Incentive from landlord, refurbishment allowance, maximum" } } }, "localname": "IncentiveFromLessorRefurbishmentAllowanceMaximum", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "insp_IncentiveFromLessorRentAbatement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Incentive from Lessor, Rent Abatement", "label": "Incentive from Lessor, Rent Abatement", "terseLabel": "Incentive from landlord, rent abatement" } } }, "localname": "IncentiveFromLessorRentAbatement", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "insp_InvestmentsAllowanceForCreditLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investments, Allowance for Credit Loss", "label": "Investments, Allowance for Credit Loss", "terseLabel": "Allowance for credit loss" } } }, "localname": "InvestmentsAllowanceForCreditLoss", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "insp_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "terseLabel": "Number of renewal options" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "insp_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of additional borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Additional Borrowing Capacity", "terseLabel": "Additional borrowing amount under credit facility" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "insp_March2019AmendmentToLoanAndSecurityAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "March 2019 Amendment To Loan And Security Agreement", "label": "March 2019 Amendment To Loan And Security Agreement [Member]", "terseLabel": "March 2019 Amendment to Loan and Security Agreement" } } }, "localname": "March2019AmendmentToLoanAndSecurityAgreementMember", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "insp_OfficeSpaceSubleaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office Space Sublease [Member]", "label": "Office Space Sublease [Member]", "terseLabel": "Office Space Sublease" } } }, "localname": "OfficeSpaceSubleaseMember", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "insp_PercentageOfIncreaseInInterestRateInEventOfDefault": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of increase in interest rate, upon the occurrence of an event of default.", "label": "Percentage of Increase in Interest Rate In Event of Default", "terseLabel": "Increase in interest rate in default" } } }, "localname": "PercentageOfIncreaseInInterestRateInEventOfDefault", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "insp_PercentageOfPrepaymentFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of prepayment on borrowings.", "label": "Percentage of Prepayment Fee", "terseLabel": "Prepayment fee" } } }, "localname": "PercentageOfPrepaymentFee", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "insp_ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan": { "auth_ref": [], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from Issuance of Common Stock from Employee Stock Purchase Plan", "label": "Proceeds from Issuance of Common Stock from Employee Stock Purchase Plan", "terseLabel": "Proceeds from issuance of common stock from employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "insp_RightOfUseAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right-of-Use Assets", "label": "Right-of-Use Assets [Abstract]", "terseLabel": "Right-of-use assets:" } } }, "localname": "RightOfUseAssetsAbstract", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "insp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercisable", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Exercisable", "terseLabel": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercisable", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "insp_SharebasedCompensationNoncashServices": { "auth_ref": [], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation, Noncash, Services", "label": "Share-based Compensation, Noncash, Services", "terseLabel": "Non-cash stock issuance for services rendered" } } }, "localname": "SharebasedCompensationNoncashServices", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "insp_StockIncentivePlan2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the 2018 Stock Incentive Plan (\"the 2018 Plan\").", "label": "Stock Incentive Plan2018 [Member]", "terseLabel": "Stock Incentive Plan 2018" } } }, "localname": "StockIncentivePlan2018Member", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "insp_TermALoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term A Loan Facility", "label": "Term A Loan Facility [Member]", "terseLabel": "Term A loan facility" } } }, "localname": "TermALoanFacilityMember", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "insp_TermBLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to term B loan facility.", "label": "Term B Loan Facility [Member]", "terseLabel": "Term B loan facility" } } }, "localname": "TermBLoanFacilityMember", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "insp_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to term A loan facility.", "label": "Term Loan Facility [Member]", "terseLabel": "Term loan facility" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://www.inspiresleep.com/20210930", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r2", "r124", "r131", "r137", "r212", "r346", "r347", "r348", "r371", "r372", "r400", "r403", "r405", "r406", "r586" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r2", "r124", "r131", "r137", "r212", "r346", "r347", "r348", "r371", "r372", "r400", "r403", "r405", "r406", "r586" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r2", "r124", "r131", "r137", "r212", "r346", "r347", "r348", "r371", "r372", "r400", "r403", "r405", "r406", "r586" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Directors" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r259", "r281", "r309", "r311", "r462", "r463", "r464", "r465", "r466", "r467", "r486", "r523", "r525", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails", "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r259", "r281", "r309", "r311", "r462", "r463", "r464", "r465", "r466", "r467", "r486", "r523", "r525", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails", "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r259", "r281", "r300", "r309", "r311", "r462", "r463", "r464", "r465", "r466", "r467", "r486", "r523", "r525", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails", "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r259", "r281", "r300", "r309", "r311", "r462", "r463", "r464", "r465", "r466", "r467", "r486", "r523", "r525", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails", "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r132", "r310" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r132", "r137", "r310" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r181", "r182", "r294", "r295", "r524", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r181", "r182", "r294", "r295", "r524", "r555", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r132", "r137", "r241", "r310", "r455" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r187", "r451" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r125", "r126", "r127", "r128", "r193", "r194", "r209", "r210", "r211", "r212", "r213", "r214", "r244", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r371", "r372", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r450", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r584", "r585", "r586", "r587", "r588" ], "lang": { "en-us": { "role": { "documentation": "Indicates amendment to accounting standards.", "label": "Accounting Standards Update [Extensible Enumeration]", "terseLabel": "Accounting Standards Update [Extensible List]" } } }, "localname": "AccountingStandardsUpdateExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r16", "r48" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r9", "r28", "r188", "r189" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net of allowance for credit losses of $95 and $42, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r15", "r16", "r52" ], "calculation": { "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Payroll related" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r46", "r236" ], "calculation": { "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r31", "r65", "r66", "r67", "r514", "r533", "r537" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r64", "r67", "r75", "r76", "r77", "r121", "r122", "r123", "r389", "r528", "r529", "r588" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r29", "r349", "r454" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r121", "r122", "r123", "r346", "r347", "r348", "r405" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising Expenses" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expenses" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r314", "r338", "r351" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r35", "r190", "r215" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for credit loss" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r85", "r103", "r272", "r435" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Accretion of debt discount" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive securities excluded from computation of diluted weighted average shares outstanding (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "verboseLabel": "Loss Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Operating lease sublease land agreement (square feet)" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_Assets": { "auth_ref": [ "r116", "r166", "r170", "r176", "r208", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r384", "r390", "r416", "r452", "r454", "r492", "r512" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r11", "r13", "r61", "r116", "r208", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r384", "r390", "r416", "r452", "r454" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r408" ], "calculation": { "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total cash equivalents and investments" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r199" ], "calculation": { "http://www.inspiresleep.com/role/InvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gross Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r200" ], "calculation": { "http://www.inspiresleep.com/role/InvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized Gross Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r197", "r221" ], "calculation": { "http://www.inspiresleep.com/role/InvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r195", "r198", "r221", "r498" ], "calculation": { "http://www.inspiresleep.com/role/InvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair Value", "verboseLabel": "Total investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r196", "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-sale, Noncurrent", "terseLabel": "Investments with maturity greater than one year" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r315", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails", "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r108", "r109", "r110" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Change in property and equipment acquired but not yet paid" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r7", "r42", "r105" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Total cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r19", "r106" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r99", "r105", "r111" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r99", "r425" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Equivalents, at Carrying Value [Abstract]", "terseLabel": "Cash equivalents:" } } }, "localname": "CashEquivalentsAtCarryingValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r301", "r413" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Number of shares reserved for issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r121", "r122", "r405" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r27", "r283" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETSParenthetical", "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r27", "r454" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common Stock, $0.001 par value per share; 200,000,000 shares authorized; 27,350,959 and 27,069,276 issued and outstanding at September 30, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock": { "auth_ref": [ "r298", "r299", "r312" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]", "terseLabel": "Employee Retirement Plan" } } }, "localname": "CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/EmployeeRetirementPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r70", "r72", "r73", "r82", "r501", "r519" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r154", "r509" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in process" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r301", "r308", "r538" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r87", "r489" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.", "label": "Cost of Goods and Service Benchmark [Member]", "terseLabel": "Cost of goods sold" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Goods Sold" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r22", "r24", "r25", "r115", "r119", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r275", "r276", "r277", "r278", "r436", "r493", "r494", "r510" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Variable interest rate on credit facility" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r54", "r269", "r434" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Basic interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r55", "r115", "r119", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r275", "r276", "r277", "r278", "r436" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r203" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Realized Gain", "terseLabel": "Realized gains" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r103", "r234" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization expenses" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r103", "r164" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stockholders' Equity" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r83", "r129", "r130", "r131", "r132", "r133", "r138", "r140", "r142", "r143", "r144", "r148", "r149", "r406", "r407", "r502", "r520" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r83", "r129", "r130", "r131", "r132", "r133", "r140", "r142", "r143", "r144", "r148", "r149", "r406", "r407", "r502", "r520" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r145", "r146", "r147", "r150" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "verboseLabel": "Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r425" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r339" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average recognition period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unearned stock-based compensation" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee stock purchase plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LossPerShareDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Manufacturing equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r75", "r76", "r77", "r121", "r122", "r123", "r126", "r134", "r136", "r153", "r212", "r283", "r284", "r346", "r347", "r348", "r371", "r372", "r405", "r426", "r427", "r428", "r429", "r430", "r431", "r528", "r529", "r530", "r588" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r408", "r409", "r410", "r414" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r265", "r275", "r276", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r409", "r459", "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r408", "r409", "r411", "r412", "r415" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r265", "r301", "r302", "r307", "r308", "r409", "r459" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r265", "r275", "r276", "r301", "r302", "r307", "r308", "r409", "r460" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r265", "r275", "r276", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r409", "r461" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r265", "r275", "r276", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r459", "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r413", "r415" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring basis" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r201", "r202", "r205", "r206", "r207", "r216", "r217", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r273", "r282", "r396", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r575", "r576", "r577", "r578", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r88" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r86", "r116", "r166", "r169", "r172", "r175", "r178", "r208", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r416" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r233", "r239" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r80", "r166", "r169", "r172", "r175", "r178", "r490", "r499", "r504", "r521" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r238", "r240" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r117", "r360", "r364", "r367", "r373", "r375", "r377", "r378", "r379" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r118", "r135", "r136", "r165", "r359", "r374", "r376", "r522" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income taxes", "verboseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails", "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r74", "r357", "r358", "r364", "r365", "r366", "r370" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r102" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r102" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r102" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r102" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r102" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r78", "r163", "r433", "r435", "r503" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r97", "r100", "r107" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r16", "r17", "r52" ], "calculation": { "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Interest Payable, Current", "terseLabel": "Interest" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r37", "r229" ], "calculation": { "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r8", "r59", "r454" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Total inventories, net of reserves" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r18", "r60", "r113", "r151", "r226", "r227", "r230", "r487" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r38", "r229" ], "calculation": { "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r59", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "terseLabel": "Reserve for excess and obsolete inventory" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeAmortizationOfDiscount": { "auth_ref": [ "r91" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion of purchase discount on nonoperating securities.", "label": "Investment Income, Amortization of Discount", "negatedTerseLabel": "Amortization (accretion) of investment premium (discount)" } } }, "localname": "InvestmentIncomeAmortizationOfDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeAmortizationOfPremium": { "auth_ref": [ "r91" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization of purchase premium on nonoperating securities.", "label": "Investment Income, Amortization of Premium", "terseLabel": "Amortization (accretion) of investment premium (discount)" } } }, "localname": "InvestmentIncomeAmortizationOfPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r89", "r162" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r204", "r491", "r507", "r554", "r582" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r14", "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r51", "r116", "r171", "r208", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r385", "r390", "r391", "r416", "r452", "r453" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r34", "r116", "r208", "r416", "r454", "r495", "r516" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r53", "r116", "r208", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r385", "r390", "r391", "r416", "r452", "r453", "r454" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r25", "r494", "r510" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Outstanding credit facility amount" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Credit Facility" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing amount under credit facility" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r49", "r115" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r25", "r264", "r274", "r275", "r276", "r494", "r513" ], "calculation": { "http://www.inspiresleep.com/role/LongTermDebtDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total expected future principal payments" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByCurrentAndNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, by Current and Noncurrent [Abstract]" } } }, "localname": "LongTermDebtByCurrentAndNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Expected future principal payments" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r119", "r243", "r268" ], "calculation": { "http://www.inspiresleep.com/role/LongTermDebtDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r119", "r243", "r268" ], "calculation": { "http://www.inspiresleep.com/role/LongTermDebtDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r119", "r243", "r268" ], "calculation": { "http://www.inspiresleep.com/role/LongTermDebtDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r119" ], "calculation": { "http://www.inspiresleep.com/role/LongTermDebtDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2021 (remaining)" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt [Member]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r43" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Long-term Investments", "terseLabel": "Investments, long-term" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermNotesPayable": { "auth_ref": [ "r55" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Notes Payable, Noncurrent", "terseLabel": "Notes payable, non-current portion" } } }, "localname": "LongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketingAndAdvertisingExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketing and Advertising Expense [Abstract]", "terseLabel": "Advertising Expenses" } } }, "localname": "MarketingAndAdvertisingExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAdvertisingExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r99" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r99", "r101", "r104" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r5", "r68", "r71", "r77", "r81", "r104", "r116", "r125", "r129", "r130", "r131", "r132", "r135", "r136", "r141", "r166", "r169", "r172", "r175", "r178", "r208", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r407", "r416", "r500", "r518" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r90" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "negatedTotalLabel": "Total other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expense (income):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes Payable, Current", "terseLabel": "Current portion of notes payable" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reporting segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r166", "r169", "r172", "r175", "r178" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r440" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "auth_ref": [ "r152", "r449" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income, Lease Payments", "terseLabel": "Operating lease income" } } }, "localname": "OperatingLeaseLeaseIncomeLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r438" ], "calculation": { "http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability", "totalLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails", "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability [Abstract]", "terseLabel": "Operating lease liabilities:" } } }, "localname": "OperatingLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r438" ], "calculation": { "http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r438" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, non-current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS", "http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r441", "r447" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r437" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS", "http://www.inspiresleep.com/role/LeasesAssetsandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r6", "r395" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r15", "r16", "r17", "r52" ], "calculation": { "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r62", "r63", "r65" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "terseLabel": "Unrecognized loss (gain) in accumulated other comprehensive loss (income), less than" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r69", "r72", "r382", "r383", "r388" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liability" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherMachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.", "label": "Other Machinery and Equipment [Member]", "terseLabel": "Other equipment" } } }, "localname": "OtherMachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r104" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other, net" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r92" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other expense (income), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r95" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r94" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r315", "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r26", "r280" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred shares, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred shares, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r26", "r280" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred shares, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r26", "r454" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r10", "r12", "r231", "r232" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r96" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from the sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r93" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from sales or maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r96", "r341" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r5", "r68", "r71", "r77", "r98", "r116", "r125", "r135", "r136", "r166", "r169", "r172", "r175", "r178", "r208", "r245", "r246", "r247", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r382", "r386", "r387", "r393", "r394", "r407", "r416", "r504" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited", "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r46", "r237" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r45", "r235" ], "calculation": { "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r20", "r21", "r237", "r454", "r508", "r517" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r44", "r237", "r556", "r557" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r20", "r237" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r20", "r235" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LeasesNarrativeDetails", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r36", "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable and Allowance for Expected Credit Losses" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r355", "r488", "r569" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "R&D credit" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LossPerShareDetails", "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r30", "r284", "r349", "r454", "r515", "r532", "r537" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r121", "r122", "r123", "r126", "r134", "r136", "r212", "r346", "r347", "r348", "r371", "r372", "r405", "r528", "r530" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r160", "r161", "r168", "r173", "r174", "r180", "r181", "r185", "r293", "r294", "r489" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited", "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r114", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r296" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "terseLabel": "Schedule of revenue by geographic region" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Segment Reporting and Significant Customers" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Proceeds from sale of stock" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFollowOnPublicOfferingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFollowOnPublicOfferingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Shares sold (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFollowOnPublicOfferingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of stock, price per share (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFollowOnPublicOfferingDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "verboseLabel": "Schedule of dilutive securities excluded from computations of diluted weighted average shares outstanding" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "terseLabel": "Short-term investments available-for-sale" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r314", "r337", "r351" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of assets and liabilities measured at fair value on a recurring basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r18", "r39", "r40", "r41" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of expected future principal payments for the credit facility" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r46", "r237" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r79", "r184" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r315", "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails", "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock units activity" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r320", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of the company's stock option activity and related information" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r331" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of weighted average assumptions for fair value of options granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r156", "r158", "r159", "r166", "r167", "r172", "r176", "r177", "r178", "r179", "r180", "r184", "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting and Revenue Disaggregation" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SegmentReportingandRevenueDisaggregation" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r102" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested at June 30, 2021 (in shares)", "periodStartLabel": "Unvested at December 31, 2020 (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Restricted Stock Units" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r326" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested at March 31, 2021 (in dollars per share)", "periodStartLabel": "Unvested at December 31, 2020 (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Weighted average assumptions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r334" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "verboseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails", "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails", "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited /expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r322", "r340" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at ending of the year (in shares)", "periodStartLabel": "Outstanding at beginning of the year (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of the period (in dollars per share)", "periodStartLabel": "Outstanding, beginning of the period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r313", "r318" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails", "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited/expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "Vesting after first year of service" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Vesting in years two through four" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Weighted average fair value (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Percentage of shares to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested", "periodEndLabel": "Unvested at June 30, 2021", "periodStartLabel": "Unvested at December 31, 2020" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "periodEndLabel": "Outstanding, end of period", "periodStartLabel": "Outstanding, beginning of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Contractual life of stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r332", "r350" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityAssumptionsUsedtoCalculateFairValueofOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Employee stock purchase plan, percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer.", "label": "Short-term Debt [Member]", "terseLabel": "Short-term Debt" } } }, "localname": "ShortTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r23", "r496", "r497", "r511" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-term Investments", "terseLabel": "Investments, short-term" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Short-term Investments [Abstract]", "terseLabel": "Investments:" } } }, "localname": "ShortTermInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r112", "r120" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": { "auth_ref": [ "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.", "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit", "terseLabel": "Significant change to unrecognized tax benefits over the next 12 months" } } }, "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r58", "r75", "r76", "r77", "r121", "r122", "r123", "r126", "r134", "r136", "r153", "r212", "r283", "r284", "r346", "r347", "r348", "r371", "r372", "r405", "r426", "r427", "r428", "r429", "r430", "r431", "r528", "r529", "r530", "r588" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r121", "r122", "r123", "r153", "r489" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r26", "r27", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock for employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r26", "r27", "r283", "r284" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance and sale of common stock (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r26", "r27", "r283", "r284", "r324" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Stock options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.inspiresleep.com/role/StockholdersEquityStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r26", "r27", "r283", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock for employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.inspiresleep.com/role/StockholdersEquityEmployeeStockPurchasePlanDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r26", "r27", "r283", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance and sale of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r58", "r283", "r284" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "terseLabel": "Common stock options", "verboseLabel": "Stock options" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/LossPerShareDetails", "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationExpenseRecognizedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r27", "r32", "r33", "r116", "r192", "r208", "r416", "r454" ], "calculation": { "http://www.inspiresleep.com/role/BALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r76", "r116", "r121", "r122", "r123", "r126", "r134", "r208", "r212", "r284", "r346", "r347", "r348", "r371", "r372", "r380", "r381", "r392", "r405", "r416", "r426", "r427", "r431", "r529", "r530", "r588" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/BALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFollowOnPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFSTOCKHOLDERSEQUITYUnaudited", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFollowOnPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFollowOnPublicOfferingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental cash flow information" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFCASHFLOWSUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r368" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r201", "r202", "r205", "r206", "r207", "r273", "r282", "r396", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r575", "r576", "r577", "r578", "r579", "r580", "r581" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails", "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/SummaryofSignificantAccountingPoliciesFairValueofFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r301", "r505", "r538" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r103" ], "calculation": { "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "terseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r356", "r363" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/StockholdersEquityStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r139", "r144" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares used to compute net loss per share, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r138", "r144" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares used to compute net loss per share, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.inspiresleep.com/role/STATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSSUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r120": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r297": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r299": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r312": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r379": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r395": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r432": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r448": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r491": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r507": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r554": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r571": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r572": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r573": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r574": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r575": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r576": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r577": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r578": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r579": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r581": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r582": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r583": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" } }, "version": "2.1" } ZIP 65 0001609550-21-000048-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001609550-21-000048-xbrl.zip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